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SUMMARY 
 
Introduction: Sulforaphane (SFN), a naturally occuring isothiocyante present in 
cruciferous vegetables, is an attractive target due to its wide range of biological 
and pharmacological properties. In addition to anti-inflammatory activities, po-
tent chemopreventive effects of SFN in various carcinogenesis models are de-
scribed whereas the underlying molecular mechanisms remain partially un-
known. Previous studies could demonstrate that modulation of polyamine me-
tabolism provides a chemopreventive strategy of different phytochemicals. Inhi-
bition of the biosynthetic key enzyme ornithine decarboxylase (ODC) is associ-
ated with reduced cell growth in several human cancers. Thus, one aim of this 
work was to elucidate a possible regulation of ODC by sulforaphane and to fur-
ther specify a possible role of the transforming growth factor-β (TGF-β)-
signaling pathway.  
Chemotherapy plays an important role in the overall treatment of colorectal 
cancer but the effectiveness is often limited by tumor drug resistance and se-
vere side effects. Thus, the use of natural agents in combination with traditional 
chemotherapeutic drugs is a promising strategy for enhancing the therapeutic 
outcome. Due to their anticarcinogenic properties and their low toxicity, multiple 
phytochemicals may serve as potent agents for enhancing the therapeutic effect 
of classical chemotherapeutics. Resveratrol (Res), a natural occurring polyphe-
nol present in red wine, peanuts and grapes, has been reported to exhibit a 
wide range of biological and pharmacological properties. In addition to cardio-
protective and anti-inflammatory effects, also chemopreventive as well as 
chemosensitizing activities of Res in various carcionogenesis models are de-
scribed. Therefore, another aim of this work was to investigate whether the isi-
othiocyante sulforaphane and the polyphenol resveratrol may potentiate the 
antitumor activities of the common chemotherapeutic oxaliplatin (Ox) in a cell 
culture model of colorectal cancer.  
Methods: Caco-2 cells and human foreskin fibroblats were cultured under 
standard conditions and were treated with miscellaneous agents for different 
time intervals. For co-incubation, cells were pre-treated with SFN [10-50µM] or 
Res [50-100 µM] for 24 hours. Cell growth was determined by BrdU incorpora-
tion and crystal-violet staining. Cytotoxicity was analyzed by LDH release. Pro-
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tein levels were examined by Western blot analysis. Reverse transcriptase-PCR 
was used for measuring mRNA expression. ODC activity was assayed radio-
metrically measuring [14CO2] liberation. Acetyl-Histone H3 and H4 immunopre-
cipitation (ChIP) assay was performed followed by PCR with TGF-β-receptor II 
promoter specific primers. Apoptotic events were characterized by different 
ELISA techniques. Annexin-V- and propidium-iodide (PI)-stained cells were de-
tected by FACS analysis. Primary human macrophages were co-cultured with 
conditioned medium of treated tumor cells and cytokines were quantified by 
FACS. Drug interactions were assessed using the combination-index (CI) 
method as defined by median-effect analysis. Cl<1 indicates synergism. 
Results: SFN [1-50µmol/L] inhibites cell growth of Caco-2 cells in a dose- and 
time-dependent manner, which closely correlates with a dose-dependent reduc-
tion of ODC protein expression and activity after 24 h of incubation. This effect 
seems to be due to reduced protein levels and transactivation activity of tran-
scription factor c-myc, a direct regulator of ODC expression, as a consequence 
of SFN-induced TGF-β/Smad signaling. The coherency of these results was 
further confirmed by using TGF-β receptor kinase inhibitor SB431542, which 
largely abolished inhibitory effects of SFN on both, ODC enzyme activity and 
tumor cell growth. Moreover, SFN, Res and Ox alone inhibited cell growth of 
Caco-2-cells in a dose-dependent manner, an effect, which could be synergisti-
cally enhanced, when cells were incubated with the combination of SFN/Ox or 
Res/Ox. Co-treated cells further displayed distinctive morphological changes 
that occurred during the apoptotic process, such as cell surface exposure of 
phosphatidylserine, membrane blebbing as well as the occurence of cytoplas-
mic histone-associated DNA fragments. Further observations thereby pointed 
towards simultaneous activation of both extrinsic and intrinsic apoptotic path-
ways. With increasing concentrations and treatment duration, a shift from apop-
totic to necrotic cell death could be observed. Furthermore, cytotoxic effects of 
Res and Ox led to an altered cytokine profile of co-cultured macrophages. In 
addition, combinatorial treatment did not affect normal cells as cytotoxicity was 
not detected in human foreskin fibroblasts and in human platelets.  
Conclusion: On the basis of these findings, diet-derived sulforaphane down-
regulated ODC expression and activity in colorectal cancer cells, whereby acti-
vation of the TGFβ signaling pathway seemed to play a pivotal role. Since ele-
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vated ODC enzyme activity is associated with enhanced tumor development, 
SFN thus may be a dietary phytochemical with potential to prevent carcinogen-
esis.  
Moreover, sulforaphane as well as resveratrol enhanced oxaliplatin-induced cell 
growth inhibition via induction of different modes of cell death without da-
maging non-transformed cells. In addition, resveratrol also showed the peculi-
arity to abrogate immunosuppressive properties of oxaliplatin-treated cells. Due 
to these results both phytochemicals show great chemopreventive and thera-
peutic potential in the treatment of colorectal cancer.  
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ZUSAMMENFASSUNG 
 
Einleitung: Sulforaphan (SFN), ein natürlich vorkommendes Isothiocyanat, das 
vorwiegend in Kreuzblütlern zu finden ist, gilt aufgrund seiner potenten antikan-
zerogenen Wirkung als effektive, chemopräventiv wirkende Substanz. In frühe-
ren Studien konnte über eine Modulation des Polyaminstoffwechsels, insbeson-
dere über eine Hemmung der biosynthetischen Ornithin Deacarboxylase 
(ODC), eine Hemmung des Zellwachstums in kolorektalen Karzinomzellen beo-
bachtet werden. Ein Ziel unserer Arbeit war es daher, eine mögliche Sul-
foraphan-vermittelte Regulation der ODC sowie die Rolle des Transforming 
growth factor-β (TGF-β) in der SFN-induzierten Zellproliferationshemmung in 
Kolonkarzinomzellen näher zu charakterisieren.  
In der Behandlung solider Tumore limitieren sowohl die Ausbildung von Resis-
tenzen als auch die Toxizität der chemotherapeutischen Substanzen den Erfolg 
der Therapie. Ein kombinierter Einsatz sekundärer Pflanzenstoffe mit konventi-
onellen Chemotherapeutika könnte durch synergistische Effekte auf verschie-
dene Signaltransduktionswege sowohl eine Steigerung der antikarzinogenen 
Wirkungen, sowie eine Verminderung von Chemoresistenzen bewirken. Res-
veratrol ist ein natürlich vorkommendes Polyphenol, das vorwiegend in Trau-
ben, Erdnüssen und Rotwein zu finden ist. Neben kardioprotektiven und antiin-
flammatorischen Wirkungen werden Resveratrol auch verschiedene chemoprä-
ventive und chemotherapeutische Eigenschaften zugesprochen. Ein weiteres 
Ziel war es daher, mögliche synergistische Wirkungen von Sulforaphan und 
Resveratrol in Kombination mit Oxaliplatin in Kolonkarzinomzelllinien genauer 
zu charakterisieren. 
Methoden: Die kolorektale Karzinomzelllinie Caco-2 und humane Vorhaut-
Fibroblasten wurden unter Standardbedingungen kultiviert. Die Zellen wurden 
über definierte Zeiträume mit steigenden Konzentrationen verschiedener Sub-
stanzen inkubiert. Die Zellzahl wurde mittels Kristallviolett-Färbung, Zellprolife-
ration anhand des BrdU-Einbaus in die DNA bestimmt. Zytotoxische Wirkungen 
der eingesetzten Substanzen wurden mittels eines Zytotoxizitätstestes (Mes-
sung der Laktat Dehydrogenase-Freisetzung) analysiert. Verschiedene Proteine 
wurden durch Western Blot-Analyse detektiert. RT-PCR wurde zur Messung der 
mRNA verwendet. Zur Aktivitätsbestimmung der ODC wird radioaktiv markier-
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tes Substrat zum Zelllysat gegeben und die Freisetzung von [14CO2] gemessen. 
Ein Acetyl-Histon H3 und H4 Immunopräzipitations (ChIP) Assay gefolgt von 
einer PCR mit spezifischen TGF-β-Rezeptor II Promotor Primern wurde zur Er-
mittlung der HDAC-Wirkung von SFN verwendet. Zur Detektion apoptotischer 
Prozesse wurden verschiedene ELISA-Methoden angewandt. Mittels Annexin-V 
und Propidiumiodid-Anfärbung gefolgt von einer FACS-Analyse konnte zwi-
schen Apoptose und Nekrose differenziert werden. Primäre humane Makropha-
gen wurden mit konditioniertem Medium von behandelten Tumorzellen ko-
kultiviert. Anschließend wurden die Cytokine mittels FACS-Analyse quantifziert. 
Zur Identifikation synergistischer Effekte wurde der Kombinationsindex (CI) be-
rechnet. CI<1 indiziert Synergismus. 
Ergebnisse: Sulforaphan [1-50µM] hemmte konzentrationsabhängig Zell-
wachstum und –proliferation in Caco-2-Zellen. Weiterhin führte die Inkubation 
mit SFN zu einer dosisabhängigen Verminderung von ODC-Protein und –
Aktivität nach 24 h, was eng mit den antiproliferativen Wirkungen korreliert. Zu-
dem verminderte SFN sowohl die Proteinlevel als auch die Transaktivierung 
des Transkriptionsfaktors c-myc, der durch Bindung an eine spezifische DNA-
Sequenz die ODC direkt reguliert. Eine Beteiligung des TGF-β Signalweges 
konnte durch die Zugabe des TGF-β Rezeptor Kinase Inhibitors SB431542, der 
die SFN vermittelten Wirkungen auf ODC und Zellwachstum weitestgehend 
aufgehoben hat, weiter bestätigt werden. 
Des Weiteren hemmten SFN und Res in Kombination mit Ox synergistisch das 
Zellwachstum in Caco-2 Zellen. Nach kombinierter Behandlung mit SFN/Ox 
oder Res/Ox konnten zudem ausgeprägte morphologische Veränderungen, u.a. 
reduzierte ATP-Level, Caspase-3-Aktivierung und DNA Fragmentierung, die 
typischerweise im Zusammenhang mit Apoptose auftreten, beobachtet werden. 
Weiterhin konnte neben einer apoptotischen auch eine gesteigerte nekrotische 
Zellpopulation nachgewiesen werden, die im Falle von Resveratrol mit einer 
signifikant reduzierten Ausschüttung des anti-inflammatorischen Interleukin-10 
einhergeht aus humanen Makrophagen. Ergänzend zeigten weder Sulforaphan 
noch Resveratrol in Kombination mit Oxaliplatin zytotoxische Effekte in nicht-
transformiertem Zellen.  
Schlussfolgerung: Die vorliegenden Daten zeigen erstmals, dass SFN seine 
antikanzerogenen Effekte, zumindest teilweise, über die Hemmung der ODC 
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vermittelt. Dabei scheint die TGF-β-Signalkaskade eine regulatorische Schlüs-
selrolle einzunehmen. Weitere Daten lassen darauf schließen, dass SFN und 
Res in Kombination mit Oxaliplatin synergistisch das Zellwachstum von Kolon-
karzinomzellen durch Apoptose-Induktion hemmen. Diese in vitro Daten weisen 
auf potente chemopräventive und –therapeutische Eigenschaften der sekundä-
ren Pflanzeninhaltsstoffe Sulforaphan und Resveratrol hin, wodurch diese viel-
versprechende Substanzen in der Entwicklung neuer Therapiekonzepte in der 
Behandlung des kolorektalen Karzinoms darstellen.  
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1 INTRODUCTION 
1.1 Colorectal cancer 
 
Figure 1:  Adenoma-Carcinoma-Sequence 
Colorectal cancer results from a series of pathologic changes that transform 
normal colonic epithelium into invasive carcinoma. Specific genetic events ac-
company this multistep process [modified from Terzic et al. [1]] 
 
More than one million new cases of colorectal cancer (CRC) are diagnosed 
worldwide each year [2]. CRC is the second most common cause of cancer 
deaths in industrialized countries with 142.570 estimated new cases and 51.370 
estimated deaths in 2010 in the United States [3] despite important advances in 
detection, surgery and chemotherapy [4, 5]. As with many other cancers, rela-
tive colorectal cancer risk is defined by a complex interaction between genetic 
and environmental influences. Only about 20% of CRC cases have a familial 
basis [6], which indicates the involvement of a genetic factor. There are two 
main inherited predisposition syndromes: the familial adenomatous polyposis 
(FAP) syndrome, which accounts for approximately 1% of cases of colon cancer 
annually, and the hereditary non-polyposis colorectal cancer (HNPCC); which 
accounts for 5% to 15% of cases [7-10]. The remaining 80% of colorectal tu-
mors are attributed to so-called sporadic colorectal cancer or are caused by 
environmental or lifestyle factors such as physical inactivity [11], obesity [12], 
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smoking [13], alcohol consumption [14], a diet high in red meat [15] and inade-
quate intake of fruits and vegetables [16]. According to the World Cancer Re-
search Fund 50% of colorectal cancer is avoidable through nutritional modifica-
tions [17, 18]. 
Although the timescale of appearance and the propensity for recurrence of the-
se various forms of colorectal tumors differ, they share the common random 
pathway of the adenoma to carcinoma sequence. Vogelstein and colleagues 
[19] proposed a multistep model for the genetic events in the progression of 
sporadic colorectal cancer in which cells must accumulate a combination of four 
or five defects, including mutational activation of oncogenes and inactivation of 
tumor-suppressor genes, to undergo full malignant transformation [20] (Figure 
1). The first event inactivates the tumor suppressor gene APC (adenomatous 
polyposis of the colon), which is also mutated in the case of FAP, followed by 
mutation of the oncogene K-ras and further mutations of the tumor suppressor 
genes TGF-βR and p53 [21]. Other genetic events may also play a role in car-
cinogenesis of colorectal cancer, for example modulation of DNA methylation in 
CpG sequences of the promoter regions of tumor-suppressor and DNA-repair 
genes leading to inactivation or DNA amplification as a mechanism of oncogene 
activation [22]. All of these genetic alterations are associated with the develop-
ment of preneoplastic lesions (aberrant crypt foci, polyps, adenomas) at least 
resulting in the development of carcinomas [23].  
 
1.1.1 Chemotherapeutic agents in the treatment of colorectal cancer  
 
Despite a better understanding of the dis-
ease and the advent of modern technology 
and rationally targeted drugs over the past 
years, the prognosis for colorectal cancer 
patients in the advanced stage with distant 
metastasis still is very poor [24]. In the 
treatment of colorectal cancer, chemotherapy remains the cornerstone [25]. At 
this, diaminocyclohexane platinum compounds such as cisplatin, carboplatin, 
and oxaliplatin, have been used clinically for nearly 30 years as part of the 
treatment regimens of colorectal cancer. In general, the platinum compounds 
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are thought to predominantly target DNA [26]. Since Rosenberg and colleagues 
discovered cisplatin in the late sixties [27], around 3000 cisplatin analogs have 
been synthesized aiming to retain the wide antitumor spectrum of cisplatin, 
while at the same time reducing unwanted side toxicity. The main dose-limiting 
factors for the clinical outcome of cisplatin are toxicity on the nervous system, 
nephrotoxicity, myelotoxocity, nausea and vomiting [28-31] and auditory im-
pairment. Other limitations are the mutagenic character of cisplatin as well as 
the development of resistance during clinical use [32, 33]. In the attempt to 
overcome these side-effects, carboplatin was tested and showed the best com-
promise between antitumor activity and tolerable side toxicity with respect to 
cisplatin [34, 35]. However, cardoplatin is a less efficient DNA-damaging agent 
than cisplatin, producing DNA adducts more slowly, and it is also 45 times less 
active than cisplatin [36]. Since then many cisplatin anlogs were made, and of 
these, the simple substitution of the two amino groups of cisplatin with the dia-
minocyclohexane group afforded agents with good antitumor activity and a lack 
of cross-resistance with cisplatin [37].  
The best results were achieved with the third-generation platinum compound 
oxaliplatin, based on its water solubility [38] and promising antitumor activity 
with cisplatin. Oxaliplatin was first introduced into clinical trials by Mathé and 
colleagues in 1986 [39]. Molecular biology studies showed that oxaliplatin dif-
fers in the mechanism of action and resistance from cisplatin and carboplatin 
and is thereby effective in tumors with intrinsic and acquired resistance to both 
of these drugs [40]. The action of oxaliplatin is due to the formation of in-
trastrand cross-links with either two adjacent guanine or guanine-adenine resi-
dues of DNA resulting in the blockage of replication and transcription, cell cycle 
arrest and apoptosis [41, 42].  
In addition to the approved platinum compounds, there are several substances 
with promising anticancer activity heading towards clinical use. Among these 
complexes, 5-fluorouracil (5-FU) is a fluorinated pyrimidine that acts primarily 
through inhibition of thymidylate synthetase, the rare-limiting enzyme in pyrimi-
dine nucleotide synthesis. 5-FU is considered as the reference drug for the sys-
temic treatment of metastatic CRC [43]. Its antitumor acitivity was subsequently 
shown to be enhanced when the drug was combined with leucovorin (LV), a 
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reduced folate that is thought to stabilize fluorouracil‟s interaction with thymi-
dylate synthetase [44-47].  
Remarkable and clinically relevant advances have been made in the last five 
years in the treatment of colorectal cancer, essentially because of the adoption 
of combination chemotherapy regimens containing oxaliplatin and irinotecan 
[48]. Irinotecan is a semisynthetic derivate of the natural alkaloid camptothecin 
and inhibits topoisomerase I, an enzyme that catalyzes breakage and rejoining 
of DNA strands during DNA replication [49, 50]. Both oxaliplatin combined with 
bolus and continuous infusion of 5-FU plus LV (FOLFOX) and irinotecan com-
bined with bolus and continuous infusion of 5-FU plus LV (FOLFIRI) are recog-
nized as standard first-line therapies for metastatic CRC in which FOLFOX is 
preferred in the upfront treatment option in the U.S. [51]. In particular, combina-
tion regimens that incorporate infusional schedules of FOLFOX show signifi-
cantly improved clinical efficacy as related to overall response rates, time to 
tumor progression, and median overall survival in colorectal cancer patients [52, 
53].  
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1.2 Chemoprevention 
 
 
Figure 2: Chemopreventive strategies 
 
Chemoprevention is defined as the employment of natural or synthetic agents 
that reverse, inhibit, or prevent the development of benign or malignant tumors 
[54]. In keeping the fact that more than two-third cancers could be prevented 
through appropriate lifestyle modifications, attention has recently focused on 
screening and chemoprevention as potential methods for reducing the number 
of cases of colorectal cancer [55]. Beside the five classes of mainly chemically 
synthesized chemopreventive agents like selective estrogen receptor modula-
tors (SERMs), non-steroidal anti-inflammatory drugs (NSAIDs), calcium com-
pounds, glucocorticoids and retinoids, indicated by the National Cancer Institute 
(NCI), diet-derived compounds may have significant impact on qualifying or 
changing recommendations for high-risk cancer patients and thereby increase 
their survival through simple dietary choices with easily accessible foods. This 
preventive measures are believed to target the multi-step process of carcino-
genesis involving initiation, promotion and progression [56] and therefore de-
crease the incidence and mortality of cancer. In detail, the cellular and molecu-
lar mechanisms affected by chemopreventive agents include carcinogen activa-
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tion/detoxification by xenobiotic metabolizing enzymes, DNA repair, cell cycle 
progression, cell proliferation, differentiation and apoptosis, expression and 
functional activation of oncogenes or tumor-supressor genes, angiogenesis and 
metastasis and hormonal and growth-factor activity [57] (further chemopreven-
tive strategies are reviewed in Figure 2). 
Following requirements for an effective and acceptable chemopreventive agent 
should be fulfilled [58]: 
 Little or non toxic effects in normal and healthy cells 
 High efficacy against multiple sites 
 Capability of oral consumption 
 Known mechanism of action 
 Low cost 
 History of use by the human population 
 Acceptance by the human population 
 
1.2.1 Induction of apoptosis 
 
Apoptosis, the programmed cell death, is a tightly controlled cell suicide that 
occurs under a range of physiological and pathological conditions, resulting in 
cell shrinkage, chromatin condensation and DNA fragmentation [59]. These dis-
tinctive alterations are triggered by the proteolytic activity of a family of cysteinyl 
aspartate-specific proteases, known as caspases, which dismantle the cell by 
cleaving and thus inactivating key cellular proteins including the DNA repair en-
zyme poly(-ADP-ribose) polymerase (PARP) [60]. This cellular destruction re-
sults in the formation of apoptotic bodies that are subsequently eliminated by 
phagocytosis [59, 61]. Caspases are synthesized as inactive proenzymes, 
which are activated by cleavage at specific aspartate residues to activate en-
zymes comprising large (p20) and small (p10) units [62]. A subset of caspases, 
termed initiator caspases interact with specific adapter molecules that facilitate 
their autoprocessing. 
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Figure 3:  Extrinsic (a) and intrinsic (b) apoptotic pathway 
Both pathways cause the activation of members of the caspase family which 
trigger the morphological process of cell death defined as apoptosis [adapted 
from Plati et al. [63]] 
 
Upon activation, initiator caspases process a second class of caspases, termed 
effector caspases, which act on key cellular proteins, resulting in the dissolution 
of the cell [64, 65]. At present, two major apoptosis pathways have been identi-
fied: the death receptor or extrinsic pathway and the mitochondrial or intrinsic 
pathway (summarized in Figure 3). The extrinsic pathway is activated through 
cell surface death-receptors binding their respective cytokine ligands [59], fol-
lowed by induction of the initiator caspase-8 and subsequent activation of the 
effector caspase-3. Death receptors, like tumor necrosis factor (TNF) receptor, 
TRAIL receptor and Fas belong to the TNF receptor superfamily which consists 
of more than 20 proteins with a broad range of biological functions [66]. The 
intrinsic pathway depends on mitochondrial membrane permeabilization, which 
causes the release of apoptogenic factors, such as cytochrome c and 
Smac/DIABLO from the intermembrane space to the cytoplasm [67]. Once re-
leased, cytochrome c directly activates Apaf-1 and, in the presence of dATP or 
ATP, induces the formation of a multimeric apoptosome complex, resulting in 
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the activation of the caspase-9 followed by the cleavage and activation of 
caspase-3 and -7. The mitochondrial pathway is controlled by members of the 
Bcl-2 family regulating mitochondrial membrane permeability and subsequent 
release of proapoptotic factors. They can be divided into a pro- and antiapoptot-
ic group [68]. The antiapoptotic subclass consists of Bcl-2, Bcl-xL, Bcl-w, Mcl-1, 
and A1, which act on the outer mitochondrial membrane by neutralizing the kill-
er proteins Bax and Bak. In addition to their role in executing apoptosis, caspa-
ses also play important signaling roles in nonapoptotic processes, including 
regulation of actin dynamics, innate immunity, cell proliferation, differentiation, 
and survival [69]. Under such conditions, caspase activation does not lead to 
cell death. The required regulation of caspase activity is partly mediated by 
members of the inhibitor of apoptosis (IAP) protein family. The IAPs are a family 
of caspase inhibitors that directly bind caspase-3, -7 and/or -9 and thereby im-
pair the activity of these critical effectors of apoptosis [70]. Elevated levels of 
IAPs, such as survivin, have been found in numerous types of malignant cells, 
and their over-expression is associated with chemoresistance and poor progno-
sis [70]. Apart from apoptosis, alternative forms of cell death can be activated, 
e.g. necrosis or autophagy, which might also lead to biological consequences 
differing from apoptosis [71].  
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1.3 Phytochemicals 
 
 
 
Figure 4: Dietary agents and their major biological active compounds [adopt-
ed from Ulrich S.[72]] 
 
Epidemiological studies have consistently indicated that a high dietary intake of 
fruits and vegetables is strongly associated with reduced risk of developing 
chronic diseases, such as cancer and cardiovascular disease [73-75]. Phyto-
chemicals, defined as bioactive nonnutrient plant compounds in fruits, vegeta-
bles, grains, and other plant foods, have been linked to risk reduction of major 
chronic diseases [76]. Examples of phytochemicals that show promise as can-
cer chemopreventive agents include sulforaphane, resveratrol, epigallocatechin 
gallate (EGCG), capsaicin, curcumin, 6-gingerol, and lycopene [77-79] (summa-
rized in Figure 4). Using Phytochemicals is among the most promising chemo-
preventive and treatment options for the management of cancer. In this regard, 
the isothiocyanate sulforaphane as well as the polyphenolic resveratrol repre-
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sent such ideal molecules, due to their relatively low toxicity and capacity to tar-
get multiple signaling molecules that collectively promote cancer cell survival 
and tumor growth. Both phytochemicals will be introduced in the following sec-
tion.  
1.3.1 Sulforaphane 
Increasing evidence 
suggests the im-
portance of food and 
nutrition in the modi-
fication of the cancer 
development [80]. In 
particular, in vitro 
and in vivo data re-
vealed that con-
sumption of cruciferous vegetables is supposed to lower overall cancer risk, 
including colon cancer, especially during the early stages [81]. These anticar-
cinogenic activities have been suggested to be partly due to the relatively high 
levels of isothiocyanates accumulating within these vegetables. The content can 
vary between and within members of the cruciferous family depending on culti-
vation environment and genotype [82]. Isothiocyanates are generated from glu-
cosinolates either by the action of plant thioglucosidases or, if the plant en-
zymes have been denatured by cooking, by the action of microbial enzymes in 
the colon. Sulforaphane (SFN) (1-isothiocyanato-4-methylsulfinyl butane), the 
major isothiocyanate, was firstly isolated from broccoli in the early 1990‟s and is 
also abundantly present in cauliflower, cabbage, and kale with the highest con-
centration found in broccoli sprouts [83]. It was initially identified as a potent 
phase 2 enzyme inducer, but in recent years numerous studies have implicated 
further chemopreventive effects, comprising cell growth inhibition, induction of 
apoptosis and reduction of angiogenesis [60, 84-86]. We and others provide 
several lines of evidence that sulforaphane mediates these anti-carcinogenic 
effects partly through inhibition of the protooncogenic ornithine decarboxylase 
via induction of the TGF-β pathway (MANUSCRIPT I and [87, 88]). In addition 
to the chemopreventive properties, we could demonstrate potent chemosensi-
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tizing effects of sulforaphane in colorectal cancer cells making it to a prominent 
agent for enhancing the therapeutic outcome (MANUSCRIPT II). 
 
1.3.2 Resveratrol 
Another promising die-
tary phytochemical with 
chemopreventive and 
chemotherapeutic poten-
tial is the polyphenol 
resveratrol (trans-3,5,4 
trihydroxy-stilbene) [89], 
which has first been iso-
lated from the roots of 
white hellebore (Veratrum glandiflorum) [90]. Resveratrol is also classified as a 
phytoalexin, or plant antibiotic, produced in large quantitities in varius plants in 
reponse to environmental stresses such as injury, ultraviolet (UV) irradiation 
[91] and pathogenic attacks such as infection with Botrytis cinerea [92] and acts 
as a natural inhibitor of cell proliferation. Most widely known as a constituent of 
red wine [93], resveratrol has been detected in more than 70 plants species, 
including grapes, berries, plums, peanuts, and pines [94]. Fresh grape skin con-
tains about 50 to 100 μg of resveratrol per gram wet weight [95], and the con-
centration in wine ranges from 0.2 mg/l to 7.7 mg/l. The epidemiological finding 
of an inverse relationship between consumption of red wine and incidence of 
cardiovascular disease has been called the "French paradox" [96, 97]. For a 
variety of reasons, the cardioprotective effects of red wine have been attributed 
to resveratrol [98]. These effects include suppression of lipid peroxidation [99] 
and eicosanoid synthesis [100], inhibition of platelet aggregation, and antioxi-
dant, anti-inflammatory and vasorelaxant activities [101-103]. Extensive re-
search during the last two decades has suggested that, besides cardioprotec-
tive effects, resveratrol exhibits potent chemopreventive and chemotherapeutic 
activities [92, 94, 104]. In a pioneering study, John M. Pezzuto and his col-
leagues [104] reported that resveratrol was effective in blocking all three stages 
(i.e., initiation, promotion and progression) of carcinogenesis. These properties 
of resveratrol have been explained mainly by its activities in several cell signal-
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ing pathways including cell cycle arrest, suppression of tumor cell proliferation, 
induction of apoptosis and differentiation, reduction of inflammation and angio-
genesis, and inhibition of adhesion, invasion, and metastasis [105-107]. We 
previously reported that chemopreventive properties of resveratrol are partly 
due to the inhibitory effects on polyamine metabolism [108-111]. In addtition to 
these findings, we could show that resveratrol is able to enhance the chemo-
sensitvity of cancer cells with the distinctive feature to abrogate immunosup-
pressive properties of oxaliplatin-treated cells (MANUSCRIPT III) . 
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1.4 Aim 
 
In addition to conventional therapy, preventive measures that target the multi-
step progress of carcinogenesis involving initiation, promotion and progression 
are aimed at decrease the incidence and mortality of cancer. Indeed, multiple 
natural compounds have been shown to be effective for blocking carcinogene-
sis in certain human cancers and animal models. Using non-toxic chemical sub-
stances is regarded as a promising alternative for the prevention and control of 
human cancer. Moreover, recent studies have shown that the survival outcomes 
can possibly be further improved by adding biologic agents to combination 
chemotherapy regimens in first and subsequent lines of therapy. However, the 
precise underlying molecular mechanisms remain largely unknown. Thus, the 
aim of our study was to characterize chemopreventive and chemosensitizing 
effects of the two phytochemicals sulforaphane and resveratrol in a cell culture 
model of colorectal cancer.  
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2 RESULTS 
2.1 Isothiocyanate sulforaphane inhibits protooncogenic orni-
thine decarboxylase activity in colorectal cancer cells via 
induction of the TGF-β/Smad signaling pathway (MANU-
SCRIPT I) 
 
Regarding the role of polyamines in colonic carcinogenesis, inhibiting the poly-
amine metabolism, particularly the biosynthetic key enzyme ornithine decarbox-
ylase (ODC), is considered to represent an attractive target for both cancer 
chemotherapy and cancer chemoprevention [111, 112]. Hence, the aim of this 
work was to elucidate a possible regulation of ODC by sulforaphane also with 
regard to a possible involvement of the TGF-β signaling pathway. In the present 
study, we could demonstrate that SFN [1-50µM] inhibited cell counts and prolif-
eration significantly in Caco-2 cells in a dose and time dependent manner 
(***p<0.001), which closely correlated with a dose-dependent reduction of ODC 
protein levels after 3 and 6 h and activity after 24 h of incubation (***p<0.001). 
The crucial role of polyamine depletion was further suggested since addition of 
exogenous spermidine significantly (***p<0.001) counteracted growth inhibitory 
effects of SFN after 24 h. We also demonstrated that decreased ODC activity 
and protein levels in Caco-2 cells are accompanied by decreased protein levels 
of c-myc after 6 h of incubation, implicating a direct modulation of ODC gene 
expression by SFN. We previously reported that induction of the TGF-β signal-
ing pathway in colon cancer cells is a crucial event in the anti-carcinogenic ac-
tivities of butyrate, another natural occurring HDAC inhibitor [113]. This let us 
consider whether SFN possibly shows similar modes of action in our context. 
Thus, we measured protein as well as mRNA level of TGF-β in Caco-2 cells and 
could show an obvious increase of TGF-β precursor levels after 2 h and an in-
crease of mRNA level after 1 and 3 h of incubation with SFN, indicating regula-
tory effects on the level of transcription. Not only TGF-β alone, but also the ex-
pression status of TGF-β receptors RI and II is essential for TGF-β-mediated 
actions. Therefore, protein levels of both receptors I and II were detected after 
incubation with SFN, and were found to be highly increased after 1 h 
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(***p<0.001). To further specify these regulatory mechanisms, we performed 
chromatin immunoprecipitation analysis and observed an accumulation of 
acetylated histone H3. These findings indicated histone acetylation to be in-
volved in the transcriptional induction of RII and further suggested the im-
portance of HDAC inhibitory properties of SFN in the regulation of TGF-β signal-
ing. As both TGF-β receptor I and II protein levels were regulated by SFN, we 
were interested, whether co-incubation with exogenous TGF-β [20 nM] might 
amplify SFN-mediated reduction of cell proliferation in Caco-2 cells. For this, we 
analyzed BrdU incorporation after 24 h of treatment, but could only detect signif-
icant additive effects at a concentration of 5 µM SFN (**p<0.01). This, in ac-
cordance with our above-mentioned findings on intracellular TGF-β levels, let us 
hypothesize, that higher doses of SFN might lead to intracellular TGF-β-
saturation and thus resistance to exogenous TGF-β. Upon ligand binding, re-
ceptors of the TGF-β family generally phosphorylate Smad proteins, which then 
move into the nucleus where they activate transcription of different target 
genes. For responding the question whether SFN-mediated TGF-β-signaling 
also involves an activation of Smads, we first analyzed the phosphorylation sta-
tus of Smad2 and Smad3 in Caco-2 cells after 1 h of incubation with increasing 
concentrations of SFN, which was found to be significantly induced in a dose-
dependent manner (***p<0.001). Then we performed reporter gene assays with 
SBE4luc, where 4 Smad binding elements are cloned in the pGL3-vector. Re-
porter gene activity of SBE4luc was significantly induced by SFN (**p<0.01), 
whereas the induction could be further enhanced when expression vectors 
pCGN-Smad3/pCGN-Smad4 were cotransfected (*** p<0.001). To give the di-
rect evidence that sulforaphane mediates growth inhibitory effects, at least part-
ly, via induction of the TGF-β-signaling pathway, we simultaneously treated the 
cells with SFN and the specific transforming growth factor superfamily type 1 
activin receptor like kinase inhibitor SB431542 alone and in combination and 
measured BrdU incorporation after 24 and 48 h. And actually, cell growth inhibi-
tory effects of SFN were largely abolished by SB431542 (***p<0.001). Since 
Smad proteins were able to suppress c-myc activity in human skin epithelial 
cells by directly binding to Smad-responsive elements in the c-myc promoter 
[114], we were interested whether the observed down-regulation of c-myc pro-
tein by SFN might also be due to an activation of Smad signaling. Therefore, we 
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have done reporter gene assays after 6 h of SFN-treatment on Caco-2 cells 
either transfected with wildtype c-myc-luc or with c-myc-luc bearing mutated 
Smad-binding-elements (SBEs). TGF-β was used as a positive control. While in 
Caco-2 cells transfected with the wild type construct both SFN and TGF-β sig-
nificantly decreased reporter gene activity compared to untreated cells 
(***p<0.001), no effects could be observed in cells transfected with a mutated c-
myc-promoter. So, we conclude that due to the mutation in the SBEs, Smads 
could not efficiently bind to the promoter resulting in an abolishment of the SFN- 
and TGF-β-mediated inhibition of c-myc gene activity. Since our results re-
vealed an involvement of the TGF-β signaling pathway in SFN-mediated down 
regulation of the c-myc promoter, we suggested that modulation of TGF-β sig-
naling might also affect downstream ODC expression and activity. Indeed we 
could observe that co-incubation of SFN with a specific TGF-β kinase inhibitor 
partly abolished SFN-induced reduction of ODC protein expression and activity, 
which might be due to direct TGF-β/Smad signaling-mediated transcriptional 
repression of transcription factor c-myc, upstream of the ODC gene. These data 
provide evidence for modulatory effects of SFN on intracellular polyamine levels 
by regulating gene expression of the protooncogene ODC in colorectal cancer 
cells, whereby the activation of the TGFβ/Smad signaling pathway seems to 
play a pivotal role.  
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2.2 Sulforaphane potentiates oxaliplatin-induced cell growth 
inhibition in colorectal cancer cells via induction of differ-
ent modes of cell death (Manuscript II) 
 
 
Figure 5: Descriptive meanings of CI values  
[modified from Tumber et al. [115]] 
 
Since several in vitro and in vivo studies show first promising results regarding 
the chemosensitizing capability of phytochemicals in different cancer models 
[116], we were interested, whether plant-derived SFN might be able to enhance 
Ox-induced anti-tumor activities in colorectal cancer cells. Thus, for MANU-
SCRIPT II, we first investigated possible synergistical antiproliferative effects of 
SFN and Ox in the colorectal cancer cell line Caco-2. Both substances signifi-
cantly inhibited proliferation in Caco-2 cells in a dose-dependent manner (* 
p<0.5, ** p<0.01, *** p<0.001). The IC50s for SFN and Ox in Caco-2 cells were 
26.35 µM and 5.58 µM respectively. For studying combination effects, the cells 
were exposed to both SFN and Ox simultaneously for 24 h and co-treatment of 
the cells significantly reduced the IC50 values of the single drugs. The obtained 
data were analyzed by the Combination Index (CI)-method of Chou and Talalay 
Descriptive meanings of CI values
Description
<0.1 Very strong synergism
0.1-0.3 Strong synergism
0.3-0.7 Synergism
0.7-1.0 Additive
1.0-3.3 Antagonism
3.3-10 Strong antagonism
>10 Very strong antagonsim
Combination index range
Dose of SFN
IC50 (SFN) IC50 (Ox)
Dose of Ox
+CI = 
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(Figure 5) [117]. In Caco-2 cells, we calculated a CI of 0.3, which indicates 
strong synergism. In the next experiments we investigated distinctive morpho-
logical changes that occurred during the apoptotic process. For a rapid screen-
ing of cell death we therefore treated Caco-2 cells for 1-24 h with SFN [10-20 
µM] and Ox [500 nM] alone and in combination and measured effects on the 
ATP/ADP ratio. Changes in the intracellular ATP/ADP ratio are a useful indica-
tor to distinguish between different modes of cell death and viability. Although, 
decreasing ATP and increasing ADP levels are generally found in apoptotic 
cells, cells will rather undergo necrosis when intracellular ATP levels fall below 
a critical threshold [118]. Incubation of the Caco-2 cells with SFN and Ox result-
ed in a significant time- and, at least after 6 h, also dose-dependent reduction of 
intracellular ATP which reaches a maximum after 24 h (*** p<0.001). As a posi-
tive control, we used staurosporine [0.5 µg/ml], a well-known inducer of apopto-
sis [119]. As DNA cleavage is another hallmark for apoptosis, we further quanti-
fied histone-complexed DNA fragments in Caco-2 after 24 h of treatment. SFN 
[20µM], in contrast to Ox [500 nM], thereby leads to a significant increase of 
cystoplasmic histone associated DNA fragments, an effect which could be fur-
ther enhanced, when the drugs were used in combination (*** p<0.001). The 
activity of the effector caspase-3 was significantly activated 24 h after stimula-
tion with SFN [20 µM] and Ox [500 nM], respectively, but these effects were not 
very prominent when compared to the positive control staurosporine. However, 
SFN could significantly enhance the Ox-induced effects (*** p<0.001), which is 
in agreement with the observed cleavage of PARP (*** p<0.001), a classical 
substrate for activated caspase-3. Proteolysis of PARP usually is an indicator 
for early apoptotic events. Further experiments could demonstrate that thereby 
apparently both, extrinsic and intrinsic apoptotic pathways were involved, as 
indicated by caspase-8-cleavage (*** p<0.001) and increased mitochondrial 
membrane permeabilization (*** p<0.001). For detecting mitochondrial mem-
brane permealization, cells were incubated with SFN [20 µM] and Ox [500 nM] 
alone and in combination for 6 and 24 h before being stained with JC-1. JC-1 is 
a mitochondrial-selective dye and forms aggregates in normal polarized mito-
chondria resulting in a red-green emission of 590 nm after excitation at 490 nm. 
Upon depolarization of the mitochondrial membrane, JC-1 forms monomers that 
emit only green fluorescence at 527 nm. SFN induced a depolarization of the 
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mitochondrial membrane potential, which was significant after 24 h of treatment. 
In contrast to SFN, Ox-treatment did not show any detectable effects, neither 
after 6 nor 24 h of incubation. However, combinatorial treatment resulted in a 
distinct decrease of the red-green fluorescence intensity ratio after 6 h (** 
p<0.01) and 24 h (*** p<0.001). Interestingly, we could also observe an induc-
tion of TRAIL protein levels (*** p<0.001), a member of the TNF family of cyto-
kines, which can induce apoptotic cell death in a variety of tumor cells [120-
122]. This suggests that induction of endogenously expressed TRAIL after 
SFN/Ox-treatment for 6 h may further enhance their therapeutic outcome. To 
discriminate between different modes of cell death, Caco-2 cells treated with 
SFN [20 µM], Ox [500 nM-1 µM] alone and in combination for 5 and 24 h, were 
analyzed by Annexin V-FITC/PI labelling and flow cytometry. After 5 h of incu-
bation, Annexin V-FITC positive but also PI-positive cells could be measured 
indicating direct necrotizing effects of SFN and Ox. Compared to the 5 h-
treatment, the population of apoptotic cells in untreated and SFN [20 µM]- as 
well as Ox [500 nM-1 µM]-treated Caco-2 cells seemed to decline after 24 h. 
However, the rate of apoptosis was still significantly induced in the co-treated 
cells, but again this effect could not be further increased with a higher concen-
tration of Ox [1 µM]. Rather, at this concentration, a distinct population of PI-
stained cells could be observed, whereas a mixture of cells undergoing rapid 
primary as well as secondary necrosis/late apoptosis can be assumed. Obvi-
ously, apoptotic effects seemed to reach a maximum after 5 h of treatment, 
which is replaced by a shift towards an increased population of necrotic cells 
after 24 h. These observations could also be confirmed by SYTOX Green stain-
ing which was used to analyze late apoptosis. Binding of SYTOX Green stain to 
nucleic acids of Caco-2- cells incubated with SFN [20µM] and Ox [500nM], 
clearly presented signs of apoptotic events indicated by cell shrinkage, chroma-
tin condensation and the formation of apoptotic bodies. However, again with 
increasing concentrations of Ox [1µM], necrotic alterations became more prom-
inent. To analyze a possible toxicity of SFN and Ox on normal tissue cells, hu-
man foreskin fibroblasts were treated either with SFN [10-20µM] and Ox 
[500nM-1µM] alone or in combination and cell proliferation as well as LDH-
release as a marker of direct cytotoxicity were measured after 24 h. Actually, 
SFN alone was found to significantly inhibit cell growth of HFF in a dose-
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dependent manner  (* p<0.05; ** p<0.01, *** p<0.001), but in contrast to Caco-2 
cells, this effect was not further enhanced and no signs of cytotoxicity could be 
observed when SFN was combined with oxaliplatin. Taken together, these ob-
servations clearly indicate that depending on the applied concentration and the 
treatment duration, antiproliferative effects of SFN/Ox against Caco-2 cells can 
be associated with both apoptotic as well as necrotic events. 
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2.3 Resveratrol-induced potentiation of the anti-tumor effects 
of oxaliplatin is accompanied by an altered cytokine profile 
of human-derived macrophages (MANUSCRIPT III) 
 
In MANUSCRIPT III, we explored the possible chemosensitizing capability of 
resveratrol in a cell culture model of colorectal cancer, also by analyzing possi-
ble effects on immune cells. Our first results quickly revealed Res-induced po-
tentiation of cell growth inhibition mediated by Ox (*** p<0.001), which was 
more-than-additive as indicated by combination index analysis (CI=0.51). These 
cell-growth inhibitory effects of Res/Ox were accompanied by different hall-
marks of apoptosis. First, changes in the intracellular ATP/ADP ratio, as a use-
ful indicator to distinguish between different modes of cell death and viability, 
were analyzed. We could demonstrate that incubation with Res [50-100 µM] 
and Ox [1 µM] resulted in a significant dose-, and partially time-dependent re-
duction of intracellular ATP which reaches a maximum after 24 h (*** p<0.001). 
We further quantified histone-complexed DNA fragments in Caco-2 after 24 h of 
treatment. Res [50-100 µM] in contrast to Ox [1 µM] led to an increase of cysto-
plasmic histone-associated DNA fragments, an effect which could be signifi-
cantly enhanced, when the drugs were used in combination (*** p<0.001 vs. 
Ox). Additionally, the effector caspase-3, which is one of the key proteases in 
the apoptotic pathway, was also induced by Res [100 µM]. This effect could be 
significantly enhanced by co-stimulation with Res and Ox (*** p<0.001), which is 
in agreement with the observed cleavage of PARP (*** p<0.001), a classical 
substrate for activated caspase-3. Further experiments could demonstrate that 
the intrinsic apoptotic pathway plays a major role in apoptosis-inducing effica-
cies of Res, as Res alone already significantly decreased the mitochondrial 
membrane potential (*** p<0.001). However, Res-induced depolarization of the 
mitochondrial membrane could not be further enhanced after combinatorial 
treatment. We also observed reduced protein levels of survivin after 24 h of 
drug exposure, whereas this effect was more prominent when the cells were co-
treated with Res and Ox (*** p<0.001). To discriminate between different modes 
of cell death, Caco-2 cells treated with Res [50-100 µM], Ox [1 µM] alone and in 
combination for 5 and 24 h, were analyzed by Annexin V-FITC/PI labelling and 
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flow cytometry (also described in MANUSCRIPT II). Interestingly after 5 h of 
treatment, Annexin V-FITC positive but also PI-positive cells could be measured 
indicating direct necrotizing effects of Res and Ox. Compared to the 5 h-
treatment, the population of apoptotic cells in untreated and Res [50-100 µM] as 
well as Ox [1 µM]-treated Caco-2 cells seemed to decline after 24 h. However, 
the rate of apoptosis was significantly induced in the co-treated cells (** 
p<0.01). Rather, at this time point, a distinct population of PI-stained cells could 
be observed, so that a mixture of cells undergoing rapid primary as well as sec-
ondary necrosis/late apoptosis can be suggested. Obviously, apoptotic effects 
seemed to reach a maximum after 5 h of treatment which is replaced by a shift 
towards an increased population of necrotic cells after 24 h. In the next experi-
ments, possible effects of Res and Ox on the cytokine profile as a result of the 
observed necrotic events were investigated by co-culture experiments (Figure 
6). Human primary macrophages were incubated with conditioned medium of 
treated or control tumor cells for 24 h followed by a quantification of production 
of the cytokines TNF-α, IL-10, IL-8 and IL-1β. We could show that macrophages 
that were incubated with the supernatant of Res- or Ox-treated Caco-2- cells 
released slightly elevated levels of the pro-inflammatory cytokines TNF-α, IL-8, 
and IL-1β. This effect was markedly counteracted when macrophages were in-
cubated with the supernatant of Caco-2 cells treated with Res and Ox in combi-
nation (* p<0.05 vs. Ox). Interestingly, even though co-culture of macrophages 
with Res/Ox-treated Caco-2 cells significantly counteracted the release of IL-8 
mediated by co-culture with Ox [1 µM] (* p<0.5), this combination still provoked 
a marked increase in IL-8 production as compared to control macrophages (*** 
p<0.001), similar to single drug exposure (*** p<0.001). Most importantly, re-
lease of the cytokine IL-10 by macrophages from Ox-treated co-cultures was 
increased, compared to control macrophages, an effect which could be signifi-
cantly abolished when the Caco-2 cells were stimulated with Res and Ox in 
combination (* p<0.05). Thus, although tumor cells treated with a combination 
of Res and Ox did not elicit a strong production of pro-inflammatory mediators, 
production of immunosuppressive IL-10 was completely abolished. 
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Figure 6: Co-culture experiments: Caco-2 cells were treated with Res [100 µM], Ox 
[1 µM] or their combination. After 24 h of drug exposure, supernatant (condi-
tioned medium) was collected and human monocyte-derived macrophages were 
incubated with conditioned medium for further 24 h. Quantification of the cyto-
kines TNF-α, IL-1β, IL-8 and IL-10 was done by FACS analysis with BD Cy-
tometric Bead Array Flex Sets. Effects of conditioned medium on cell death of 
Caco-2 cells after 24 h of incubation were measured by BrdU incorporation and 
LDH release.  
 
To investigate effects of conditioned medium on tumor growth in turn, we treat-
ed Caco-2 cells with the supernatant of co-cultured macrophages and meas-
ured cell proliferation as well as LDH release after 24 h of stimulation. We could 
demonstrate that cell growth inhibition (*** p<0.001) as well as lysis (*** 
p<0.001) of Caco-2 cells were significantly enhanced, especially when the cells 
were treated with the supernatant of co-cultured macrophages with Res/Ox-
treated Caco-2 cells. Responding to the question whether Res and Ox, alone 
and in combination, cause severe toxicity to normal tissue cells, we treated hu-
man foreskin fibroblasts and human platelets with Res [50-100 µM], Ox [1 µM] 
alone and in combination and quantified LDH-release as a marker of direct cyto-
toxicity after 24 h. In healthy human fibroblasts, Res was found to inhibit cell 
growth in a dose-dependent manner. However, in contrast to Caco-2 cells, 
growth inhibitory effects on fibroblasts were not further enhanced and no signs 
of cytotoxicity could be observed when Res was combined with Ox, indicating a 
selective toxicity towards the tumor cell line while inducing only growth arrest in 
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normal fibroblasts. Additionally, neither Res or Ox alone nor their combination 
caused any signs of cytotoxicity in human platelets. In summary, the polyphenol 
resveratrol enhances oxaliplatin-induced cell growth inhibition with the feature to 
abrogate immunosuppressive properties of oxaliplatin-treated cells while show-
ing no toxicity on non-transformed cells. 
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3 DISCUSSION 
3.1 Chemopreventive strategies of the isothiocyanate sul-
foraphane 
 
The plant-derived isothiocyanate sulforaphane exhibits multiple chemopreven-
tive effects comprising cell growth inhibition, induction of apoptosis, inhibition of 
histone deacetylases, modulation of inflammation and inhibition of angiogenesis 
[reviewed in [60, 123]], whereby the underlying molecular mechanisms are only 
partly understood. One of our theories is concerning the role of polyamines or 
polyamine biosynthesis respectively (MANUSCRIPT I). Intracellular polyamine 
level are strictly controlled because decreases of polyamine concentrations in-
terfere with cell growth, whereas an excess seems to be toxic [124]. Regulation 
of polyamine levels is governed primarily by activity of ornithine decarboxylase 
(ODC), the key enzyme of polyamine biosynthesis. Hence, regarding the role of 
polyamines in colonic carcinogenesis, modulation of polyamine metabolism 
and, in particular, of ODC activity has been studied as a new perspective in 
cancer prevention [111, 112]. One aim of our work was to investigate a possible 
regulation of ODC by the natural histone deacetylase inhibitor sulforaphane and 
to further identify a possible role of transforming growth factor-β (TGF-β) in this 
process. 
 
3.1.1 Inhibition of histone deacetylases  
 
In addition to genetic changes, epigenetic alterations of genes may contribute to 
cancer development [125, 126]. Among these modifications, histone acetylation 
of nuclear histones plays a central role in gene regulation resulting in transcrip-
tional regulation [127]. In general, addition of acetyl groups to histones by his-
tone acetyltransferases (HATs) results in an “open” chromatin conformation, 
thereby facilitating gene expression by allowing transcription factors access to 
DNA [128]. Removal of acetyl groups by histone deacetylases (HDACs) results 
in a “closed” conformation, which represses transcription (Figure 7).  
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Figure 7:  Modulation of chromatin conformation and transcriptional status by 
acetylation of lysine tails in histone core proteins [adopted from Ho et 
al. [129]]  
 
In vivo, a tightly regulated balance exists between HAT and HDAC activities, 
and when this balance is interrupted, cancer development may ensue.  
Currently, 18 HDACs have been identified in humans, which can be subdivided 
into four classes based on their homology to yeast HDACs, their subcellular 
expression and their enzymatic activities. All class I and II are zinc-dependent 
enzymes, whereas members of the III class, sirtuins, require NAD+ for their en-
zymatic activity. Class IV HDAC is represented by HDAC11 [130]. HDAC inhibi-
tors (HDACi), as a new class of targeted chemotherapeutic agents, show signif-
icant promise against a variety of cancers in clinical trials [131]. Most available 
HDACi inhibit all class I and II HDACs, thereby increasing acetylation of histone 
and nonhistone protein targets [132], resulting in cell cycle arrest, differentiation 
and apoptosis as well as reduced tumor volume and/or tumor number. Moreo-
ver, it has been shown that HDACi induce the expression of a small number of 
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tumor suppressive genes, such as p21WAF1 [133], growth-differentiation factor 
11, a member of the transforming growth factor-β (TGF-β) superfamily [134] as 
well as TGF-β -receptors I and II [135, 136]. Thus, the pro-tumorigenic role for 
HDACs in colon cancer, and the pre-clinical efficacy of these agents in colon 
cancer cells justify the use of HDACi in cancer prevention and therapy [137]. 
Indeed, it has been demonstrated that combinations of HDACi with well-
established chemotherapeutics can synergise with their anti-tumor effects [138-
140]. Recently, Myzak and colleagues identified SFN as a novel HDACi in colon 
and prostate cancer cells [141]. They have found that 3-15 µmol SFN already 
induces potent HDAC inhibition and G2/M arrest in PC3 cancer cells but have 
no effect on normal prostate epithelial cells (J. D. Clarke and E. Ho, un-
published data). In addition to the in vitro studies, several dietary experiments in 
mice models supported these data [142, 143]. From these studies it can be 
concluded that HDAC inhibition represents a novel chemopreventive mecha-
nism by which SFN might promote cell cycle arrest and apoptosis in vivo. In 
MANUSCRIPT I, it was also of interest whether sulforaphane-mediated effects 
on TGF-β signaling, observed in our study model, may be due to its ability to 
inhibit HDACs.  
 
3.1.2 Polyamine metabolism 
 
The intestinal mucosa is continuously renewed from the proliferative zone of 
undifferentiated stem cells within the crypts and has the most rapid turnover 
rate of any tissue in the body [144]. The cellular polyamines spermine and 
spermidine as well as their precursor putrescine are essential for cell growth by 
stabilizing DNA structure [145], influencing membrane functions [146] and cell 
cycle regulating genes [147], whereas increasing concentrations are generally 
associated with cell proliferation and cell transformation induced by growth fac-
tors [148], carcinogens [149] or oncogenes [150]. Therefore, cellular levels of 
polyamines are strictly controlled by the combined action of the novo synthesis, 
catabolism, uptake and export of polyamines.  
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Figure 8: Polyamine metabolism 
Regulation of intracellular polyamine content in mammalian cells is mediated by 
different key enzymes: the biosynthetic ornithine decarboxylase (ODC) and S-
adenosylmethionine decarboxylase (SAMDC) and the catabolic spermi-
dine/spermine acetyltransferase (SSAT) as well as the polyamine oxidase 
(PAO) [adapted from [151]]. 
 
Regulation of polyamine concentrations are governed by ornithine decarbox-
ylase (ODC) and S-adenosylmethionine decarboxylase (SAMDC), the key en-
zymes of the polyamine biosynthesis. Catabolism excretion or reconversion of 
higher polyamines is regulated by acetylation through spermine/spermine N1-
acetyltransferase (SSAT), the rare limiting enzyme in polyamine catabolism 
[152-154]. In combined action with polyamine oxidase (PAO), it converts sperm-
ine to spermidine and subsequently to putrescine (summarized in Figure 8). In 
colon cancer tissue, the activities of polyamine-synthesizing enzymes and poly-
amine content are increased 10- to 15-fold in comparison to normal colonic epi-
thelium [155, 156], and polyamines seem to be involved in almost all steps of 
colonic tumorigenesis. Hence, regarding the role of polyamines in colonic car-
cinogenesis, modulation of polyamine metabolism and, in particular, of ODC 
activity has been studied as a new potent therapeutic strategy in cancer treat-
ment and prevention [111, 112]. Pharmacological and natural inhibitors have 
been shown to decrease mucosal growth in vitro [111, 157] and in vivo [112]. 
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However, the best known synthetic inhibitor α-difluoromethylornithine (DFMO), 
a specific inhibitor of ornithine decarboxylase [158], has been less succesfull in 
cancer therapy, resulting in cytostatic rather than cytotoxic effects in vivo [159]. 
Therefore, the use of natural substances to modulate polyamine metabolism is 
possibly a more promising strategy in cancer treatment and prevention.  
Interestingly, in their most recent publication, Furniss et al. reported modulatory 
effects of broccoli extracts as well as SFN alone on polyamine metabolism in 
colorectal cancer cells. However, direct modes of action were not further speci-
fied [88]. In MANUSCRIPT I we could show that the antiproliferative effects of 
SFN closely correlate with a reduction of ODC protein expression and activity. 
Similar effects could be observed by the group of Lee et al. where SFN inhibited 
TPA-induced ODC activity in mouse epidermal ME308 cells [160]. ODC levels 
are tightly controlled either by transcriptional regulation or by rapid post-
translational degradation. The proto-oncogene c-myc is a transcription factor 
that directly regulates the expression of ODC by binding to a specific CACGTG 
sequence in the gene promoter [161]. c-myc was actually found to be activated 
in various animal and human tumors and an overexpression of the c-myc gene 
has been described in ~15% of all human tumors [162]. Since c-myc is a ubiqui-
tous promoter of cell growth and proliferation, it functions as a transcriptional 
activator or inhibitor depending on the target gene [163, 164]. We could demon-
strate (MANUSCRIPT I) that decreased ODC activity and protein levels in Ca-
co-2 cells are accompanied by decreased protein levels of c-myc after 6 h of 
incubation, implicating a direct modulation of ODC gene expression by SFN.  
 
3.1.3 Transforming growth factor-β 
 
The transforming growth factor-β (TGF-β) superfamily, comprising TGF-βs, 
bone morphogenetic proteins (BMPs), activins and related proteins, has been 
implicated in a wide variety of cellular processes, including regulation of cellular 
proliferation [165] and differentiation [166], immune modulation [167], and ex-
tracellular matrix remodelling [168]. It exhibits their antiproliferative functions by 
activating a signaling pathway that mediates cell cycle arrest and induction of 
apoptosis. TGF-β exerts its effects through heteromeric receptor complexes 
consisting of type I and type II serine/threonine kinase receptors.  
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Figure 9 : Gerneral mechanism of TGF-β receptor and Smad activation 
(adopted from Derynck et al. [169]) 
 
The signaling is initiated by ligand-binding to the TGF-βRII cell surface receptor. 
This, in turn, recruits the TGF-βRI kinase, which then phosphorylates the R-
Smad proteins, Smad2 and Smad3 [170]. Activated R-Smads form a complex 
with the Co-Smad, Smad4, which shuttles directly to the nucleus.  
Here, the complex can either act as co-activator or DNA-binding transcription 
factor, participating in the regulation of target gene expression (e.g. P15, p21, c-
myc) [170, 171]. TGF-β signaling is further controlled by a third class of Smads, 
the inhibitory Smad6 and Smad7 proteins, which negatively regulate R-Smad 
activation (Figure 9).  
We previously reported that induction of the TGF-β signaling pathway in colon 
cancer cells is a crucial event in the anti-carcinogenic activities of butyrate, an-
other natural occurring HDAC inhibitor [113]. This, together with the findings of 
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Traka et al., who could demonstrate, that TGF-β signaling also seems to play 
an important role in various SFN-mediated effects [172], let us consider, wheth-
er SFN possibly shows similar modes of action in our context. In colorectal can-
cers, the TGF-β signaling pathway plays a central but paradoxical role in the 
predisposition and progression of the disease. While on the one hand acting as 
a tumor suppressor in normal colonic epithelial cells, TGF-β on the other hand 
promotes the survival, invasion and metastasis of colorectal cancer cells, there-
by rather acting as an oncogene [173, 174]. However, in our model we could 
demonstrate that incubation with SFN caused increased protein and mRNA lev-
els of TGF-β, an enhancement of both TGF-βRI and -RII protein expression and 
an activation of Smads signaling. Furthermore, SB431542 largely abolished 
SFN-mediated effects on Caco-2-cell growth, which provides evidence that 
TGF-β seems to play a crucial role in the antiproliferative effects of SFN. In ear-
lier works, Osada et al. already demonstrated that HDAC inhibitors can increase 
the transcriptional activity of TGF-βRII in vivo and in vitro in human cancer cell 
lines [136]. In addition to these findings, Lee et al. reported [175] that MS-275, 
another HDAC inhibitor, induces the accumulation of acetylated histones in the 
chromatin of the TGF-βRII gene, which is associated with an increase of TGF-
βRII mRNA in human breast cancer cells, contributing to the restoration of TGF-
β signaling. In terms of proving that the observed effects of SFN on the TGF-β 
pathway are due to its HDAC inhibitory properties, we further performed Acetyl-
Histone H3 and H4 immunoprecipitation (ChIP) assay, followed by PCR with RII 
promoter specific primers and in fact, an accumulation of acetylated H3, but not 
acetylated H4, in chromatin associated with RII gene after incubation with SFN 
could be found.  
Controversial data exist about the effects of TGF-β on the polyamine metabo-
lism. On the one hand, TGF-β has been shown to induce ODC mRNA in H-ras-
transformed fibrosarcoma cell lines on which TGF-β acts as a growth stimulator 
[176]. On the other hand, Motyl et al. [177] could demonstrate that TGF-β sup-
presses both cell growth and the activities of ODC and S-adenosyl-L-
methionine decarboxylase in a human chronic myelogenous lymphoma cell line. 
Similar results were found in the group of Nishikawa et al. [178], showing inhibi-
tory effects of TGF-β on polyamine metabolism. In accordance with these publi-
cations, we could observe, that co-incubation of SFN with a specific TGF-β ki-
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nase inhibitor partly abolished SFN-induced reduction of ODC protein expres-
sion and activity, which might be due to direct TGF-β/Smad signaling-mediated 
transcriptional repression of transcription factor c-myc, upstream of the ODC 
gene. This effect was investigated in detail by Chen et al. who could demon-
strate, that the repression of c-myc expression by TGF-β occurs by direct inter-
action of a repressor complex consisting of Smad3, the transcription factors 
E2F4/5 and DP1 and the retinoblastoma family member p107 with a regulatory 
Smad responsive element in the c-myc-promoter [179].  
 
3.1.4 Summary and conclusion 
 
In summary, the results in MANUSCRIPT I clearly demonstrate the first direct 
evidence that SFN mediates growth inhibitory effects in colorectal cancer cell 
lines, at least partly, via a TGF-β-dependent inhibition of c-myc and thus re-
duced protein expression and activity of protooncogenic ODC (summarized in 
Figure 10). 
Noting the fact that colorectal cancer is stilll one of the most commonly occur-
ring malignancies in the world, and the prognosis for patients with advanced 
colorectal cancer with distant metastasis is usually very poor, preventive 
measures that target the various steps involved in cancer initiation and progres-
sion could significantly decrease the incidence and mortality of cancer. There-
fore, the use of non-toxic agents, e.g. phytochemicals like SFN, which inhibit 
specific molecular steps in the carcinogenic pathway, might be a promising 
strategy for cancer chemoprevention.  
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Figure 10: Possible mechanism of sulforaphane action 
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3.2 Chemosensitizing properties of phytochemicals in colorec-
tal cancer cells 
 
Even though conventional chemotherapy certainly plays an important role in the 
overall treatment of most solid tumors, successful cancer treatment is often lim-
ited due to severe side effects and the development of multi-drug resistance 
[116]. Therefore, there is a growing need for innovative anticancer therapies. In 
the last years, a new therapeutic concept of combining antitumor drugs with 
chemopreventive agents was introduced, which may lead to enhanced anti-
tumor activity through synergistic action or compensation of inverse properties. 
Beside a multitude of synthetic substances, like non-steroidal anti-inflammatory 
drugs (NDAIDs) [180] or selective estrogen receptor modulators (SERMs) [181] 
also numerous phytochemicals have been identified to exhibit potent chemo-
preventive effects in different carcinogenesis models while, at the same time 
showing low toxicity [116]. Recent studies could further demonstrate that sever-
al of these plant-derived compounds, like capsaicin [182] from chilli peppers, 
epigallocatechine gallate [183, 184] extracted from green tea, genistein [185, 
186] found in soybeans and other legume species or curcumin [187-189] the 
principal curcumoid of the popular Indian soice turmeric, are also capable of 
enhancing the efficacy of chemotherapy and radiotherapy in various in vitro and 
in vivo cancer models, predominantly by modulating intracellular cell signaling 
pathways, abrogating drug resistance and diminishing systemic toxicities [re-
viewed in MANUSCRIPT IV and [116, 190]]. Due to their wide range of biologi-
cal and pharmacological effects, especially with regard to chemoprevention and 
the lack of toxicity in animal and human models, sulforaphane as well as 
resveratrol might also be possible agents for enhancing the effects of chemo-
therapy.  
 
3.2.1 Chemosensitizing effects of sulforaphane 
 
Most chemotherapeutic agents, including oxaliplatin, and irradiation act primari-
ly by inducing apoptosis, accordingly, defects in the apoptotic pathway often 
account for chemotherapy resistance in different tumor cells, which could also 
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be demonstrated for drug resistance arising against oxaliplatin in colorectal 
cancer cells [24]. Novel targeted therapies that more potently induce cell death 
in cancer cells or sensitize them to established cytotoxic agents and radiation 
by modulating the apoptotic machinery might therefore not only enhance thera-
peutic outcome but can further help to reverse chemotherapeutic drug re-
sistance [191]. In salivary gland adenoid cystic carcinoma high (ACC-M) and 
low (ACC-2) metastatic cell lines, treatment with sulforaphane and 5-flourouracil 
(5-FU) led to synergistic inhibition of cell growth, which was accompanied by 
decreased expression of nuclear NF-κB p65 protein [192]. In epithelial ovarian 
cancer cells (EOC), combination treatment with paclitaxel resulted in, at least, 
additive growth suppression [193]. Our first results in MANUSCRIPT II quickly 
revealed SFN-induced potentiation of cell growth inhibition mediated by oxali-
platin, which was more-than-additive as indicated by combination index analy-
sis. In addition, these effects were accompanied by different hallmarks of apop-
tosis, such as reduced ATP levels, Caspase-3-activation, PARP cleavage and 
DNA Fragmentation. Further experiments could demonstrate that thereby ap-
parently both, extrinsic and intrinsic apoptotic pathways were involved, as indi-
cated by caspase-8-cleavage and increased mitochondrial membrane permea-
bilization. Interestingly, we could also observe an induction of TRAIL protein 
levels, a member of the TNF family of cytokines, which can induce apoptotic cell 
death in a variety of tumor cells by engaging the death receptors DR4 and DR5, 
while sparing most normal cells [194]. This might be due to the HDAC inhibitory 
properties of sulforaphane [141], since several other HDAC inhibitors were also 
shown to induce expression of TRAIL, DR4 or related proteins, which contribut-
ed to subsequent apoptotic events induced by these agents [195]. Since some 
drugs and radiation sensitize tumor cells to TRAIL-induced cell death, several 
studies have expectedly shown that combinations of recombinant TRAIL and 
some chemotherapeutic drugs exhibit synergistic effects in inducing tumor cell 
apoptosis in vitro and in vivo [196, 197]. Whether endogenously induced TRAIL 
possibly acts in a similar way remains to be elucidated. Another interesting as-
pect is that TRAIL, in contrast to DNA-damaging chemotherapeutic drugs or 
radiation, induces apoptosis independently of p53 [194], which might be helpful 
to circumvent resistance to conventional chemotherapy and radiotherapy. How-
ever, in contrast to known apoptosis inducers, such as staurosporin, apoptotic 
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events induced by SFN and Ox were not very prominent and may only partly 
account for the observed inhibition of cell proliferation. In fact, with increasing 
concentrations of oxaliplatin and increasing treatment duration, annexin-V and 
PI-staining revealed a shift from an apoptotic towards a distinct population of 
necrotic cells. Similar results were observed in Sytox Green-stained cells, which 
showed considerable signs of necrosis like swelling of the organelles or cell ly-
sis with loss of membrane integrity. This is consistent with the almost complete 
ATP depletion after 24 h of incubation, which may further account for the low 
apoptotic response [198]. Currently, the majority of clinical chemotherapeutic 
agents ultimately induce tumor cell apoptosis following treatment, however, not-
ing the fact that many cancers have defective apoptosis machinery or aquire 
apoptosis resistance during therapy [199], or the finding, that apoptosis may be 
reversed in cancer cells [200], it is reasonable to consider whether activating 
alternative cell death pathways, such as necrosis, may be another effective 
strategy for cancer therapy [201]. However, whether immunologic responses, 
typically associated with necrotic cell death might really be desirable in the con-
text of cancer treatment or rather lead to further tumor growth or even over-
shooting inflammation resulting in autoimmunity remains to be elucidated. Inter-
estingly, in healthy human fibroblasts, SFN was found to inhibit cell growth in a 
dose-dependent manner, an effect which was already reported for other HDAC 
inhibitors [202, 203]. But in contrast to Caco-2 cells, growth inhibitory effects on 
fibroblasts were not further enhanced and no signs of cytotoxicity could be ob-
served when SFN was combined with oxaliplatin, indicating a selective toxicity 
towards the tumor cell line while inducing only growth arrest in normal fibro-
blasts.   
 
3.2.2 Chemosensitizing effects of resveratrol 
 
Resveratrol was examined in various studies to determine possible chemosen-
sitizing properties when combined with established cancer treatments. And ac-
tually, sensitizing effects could be observed for different anticancer drugs in a 
variety of human cancer cell lines in vitro [204-210] as well as several in vivo 
tumor models [211-213], whereby some modes of resveratrol-action could al-
ready be identified. Investigations of Fulda et al. for example revealed, that pre-
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treatment of different human cancer cell lines and primary tumor cells with 
resveratrol resulted in cell cycle arrest in the S phase and apoptosis induction 
preferentially out of S phase upon subsequent treatment with various anticancer 
drugs [204]. S phase arrest induced by resveratrol was also found in hepato-
ma22 transplanted to male BALB/c mice [213] and colon cancer cells [207], 
thus enhancing the anti-tumor effects of 5-fluorouracil (5-FU), a S phase specif-
ic pyrimidin analog typically used in the treatment of colorectal-, pancreatic-and 
hepato-carcinoma patients [214]. Gill et al. reported, that pre-treatment with 
resveratrol sensitized prostate cancer cells predominantly to agents, that specif-
ically target death receptors but not agents that initiate apoptosis through other 
mechanisms [206]. In a mouse model of pancreatic cancer, resveratrol could 
potentiate the effects of gemcitabine through suppression of markers of prolifer-
ation, invasion, angiogenesis and metastasis, which seems to be mediated by 
inhibition of NF-kappa B activity [212], a transcription factor which plays a criti-
cal role in cancer development, progression and drug resistance [215]. Fur-
thermore, the combination of chemotherapeutic agents with resveratrol might 
further be useful to limit the burden of related side effects, not only due to the 
fact that, with consistent efficiency, lower doses of the cytotoxic agents could be 
used, but also due to direct protective properties of resveratrol [210, 216-225]. 
In addtion, modulatory effects of resveratrol on most pathways which are in-
volved in the development of multidrug resistances could be reported in differ-
ent cellular and animal models (reviewed in MANUSCRIPT IV). In MANU-
SCRPIT III, we explored the possible chemosensitizing capability of resveratrol 
in a cell culture model of colorectal cancer, also by analyzing possible effects on 
immune cells. Similar to sulforaphane, cell-growth inhibitory effects of Res/Ox 
were accompanied by different hallmarks of apoptosis, such as reduced ATP 
levels, Caspase-3-activation, PARP cleavage and DNA Fragmentation. Further 
experiments could demonstrate that the intrinsic apoptotic pathway seems to 
play a major role in apoptosis-inducing efficacies as mitochondrial membrane 
potential was significantly decreased after combinatorial treatment. Recently, 
the anti-apoptotic protein survivin has been described as being selectively ex-
pressed at high levels in most human cancers and is related to clinical progres-
sion [226-229]. Survivin is a structurally unique member of the IAP (inhibitors of 
apoptosis proteins) family that is potentially involved in both control of cell divi-
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sion and inhibition of apoptosis [229]. Specifically, its anti-apoptotic function 
seems to be related to an ability to directly/indirectly inhibit caspases [230], alt-
hough the precise role of survivin in the modulation of the caspase cascade has 
not been fully elucidated [231]. In addition, survivin overexpression is accompa-
nied with poor prognosis of carcinomas of the lung, breast, colon and esopha-
gus [232-235]. Since inhibition of effector caspases by IAPs occurs at the core 
of the apoptotic machinery, therapeutic modulation of IAPs could target a key 
control point in cancer resistance [228]. Interestingly, in our studies we ob-
served reduced protein levels of survivin after 24 h of drug exposure, whereas 
this effect was more prominent when the cells were co-treated with Res and Ox. 
Based on the above evidence, survivin is at present validated as a cancer ther-
apeutic target [227] and in contrast to previous studies [236], we showed that 
Ox causes a slight induction of the protein. It is notified, that several anti-cancer 
agents, such as taxol, cisplatin and doxorubicin, show an upregulation of sur-
vivin in accordance with the cytoprotective function of survivin [237, 238].  
Depending on the lethal stimulus, tumor cells can also die by necrosis which is 
characterized by swelling of the cell and the cytoplasma organells before the 
plasma membrane ruptures and the cellular content is shed into the intercellular 
space [239]. Similar to the results of sulforaphane and oxaliplatin, Res/Ox-
mediated apoptotic effects seemed to reach a maximum after 5 h of treatment, 
which is replaced by a shift towards an increased population of necrotic cells 
after 24 h. Unlike apoptosis, which is considered immunosuppressive, therapy-
induced necrotic cell death initiates an immune response [240]. This inflamma-
tory response may help to recruit cytotoxic immune cells to the tumor site, 
thereby increasing the efficacy of the chemotherapeutic drugs. However, con-
versely the pro-inflammatory conditions might also damage normal tissue or 
induce the production of mitogenic or prosurvival cytokines, which can activate 
signaling pathways that promote cell excrescence in the damaged area and 
might induce tumor cell migration and metastasis [241, 242]. Interestingly, In-
genol-3-angelate, another plant-derived compound, was recently shown to me-
diate its in vitro anticancer activities via the induction of primary necrosis [243, 
244], as displayed by plasma membrane and mitochondrial disruption leading to 
the activation of an antitumor immune response [245]. Thus, the success of In-
genol-3-angelate in phase IIa clinical trials against human skin cancer might 
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again support the importance and potential of cytotoxic agents that act through 
irreversible necrotic cell death [246]. 
 
3.2.3 Immunogenic cell death 
 
Cells undergoing apoptosis are rapidly and specifically recognized and engulfed 
by phagocytes such as macrophages or immature dendritic cells [247]. Remov-
al of apoptotic cells by macrophages seems to result in little or no production of 
inflammatory immune mediators by unstimulated macrophages [248]. On the 
contrary, necrosis is induced by external insults and is morphologically charac-
terized by an increase in cell volume leading to the early rupture of the plasma 
membrane. Consequently, cytosolic, organelle, and nuclear components are 
spilled into the surrounding tissue [240]. Unlike apoptosis, necrosis is consid-
ered to be immunologically harmful at all times, because of the sudden release 
of so-called danger signals such as ATP or high mobility group box 1 (HMGB1), 
which elicit inflammation by activating toll like receptors (TLR) or the inflam-
masome in myeloid cells [249]. Besides, necrotic cells are able to act on fibro-
blasts to activate NF-κB and induce the expression of genes that are involved in 
inflammatory responses [250]. Classical activation of human macrophages is 
characterized by the production of superoxide (O2 -), TNF-α, IL-1β and IL-6, 
also termed the M1 macrophage phenotype [251]. In contrast, the cytokines IL-
4, IL-13 or IL-10 are usually released by the M2 phenotype [251, 252]. Since 
Virchow et al. observed the presence of leukocytes in human tumors in 1863, it 
seems accepted that macrophages are a major cell component infiltrating cer-
tain tumors [252]. High numbers of tumor-associated macrophages (TAMs) of-
ten predict a poor survival prognosis for patients with solid human tumors [253, 
254]. Moreover, TAMs promote cancer metastasis through several mecha-
nisms, including promotion of angiogenesis, induction of tumor growth, and en-
hancement of tumor cell migration and invasion (summarized in Figure 11) 
[255-257] while showing a similar molecular and functional profile, that is dis-
played by a polarized M2 phenotype [252, 258]. Therefore, reprogramming a 
M2 macrophage toward a M1 type seems to be beneficial with regard to tumor 
therapy [259]. 
  DISCUSSION 
 40 
 
Figure 11: A simplified view of the role of TAMs in the immunology of tumors 
[adapted from Mantovani et al. [252]] 
 
Among the chemotherapeutic agents, only a few have the capacity to stimulate 
immunogenic cell death. Recent studies have shown that EL4 thymoma, Glas-
gow osteosarcoma, and CT26 colon cancer cells treated with oxaliplatin, as well 
as CT26 colon cancers and MCA205 fibrosarcomas treated with anthracyclins, 
respond far better to chemotherapy when they are implanted into immunocom-
petent mice rather than into immunodeficient, athymic (nu/nu) hosts [260-262]. 
Therefore, the outcome of treatment with anthracyclins, oxaliplatin and radio-
therapy depends on the active contribution of the host immune system [263, 
264]. In our studies, tumor cells treated with a combination of Res and Ox did 
not elicit a strong production of pro-inflammatory mediators, however, produc-
tion of immunosuppressive IL-10 was completely abolished. Considering the 
role of IL-10 in suppression of immunity against established tumors e.g. by in-
ducing regulatory T cells [265, 266], these findings strengthen the rationale of 
using Ox in combination with Res for tumor therapy. Additionally, in MANU-
SCRIPT III we could show that cell growth inhibition as well as lysis of Caco-2 
cells was significantly enhanced, especially when the cells were treated with the 
supernatant of co-cultured macrophages with Res/Ox-treated Caco-2 cells. 
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These findings correlate well with the observed effects of tumor cell superna-
tants on IL-10 production in macrophages, since IL-10 potently suppresses the 
cytotoxic potential of macrophages [267].  
 
3.2.4 Summary and conclusion 
 
In addition to the chemopreventive and chemosensitizing properties of SFN 
(MANUSCRIPT I+II), pharmacokinetic studies in both rats and humans also in-
dicate, that dietary absorbed SFN can be distributed in the body, reach µM lev-
els in the blood and is capable of reaching target tissues in an active form, 
which further supports the clinical relevance of the substance [268, 269]. How-
ever, further experiments focusing intramolecular mechanisms together with in 
vivo animal studies and clinical trials are needed for eventually translating the 
concept of phytochemicals in combination therapies of human colorectal cancer 
into clinical applications. As discussed in MANUSCRIPT III, the immune re-
sponse against dying tumor cells can play a major role in determining therapeu-
tic success. If tumor cell death occurs in a potentially immunogenic fashion and 
if the immune system is capable of perceiving this immunogenicity, a potent 
innate and cognate immune response raised against dying cancer cells can 
contribute to the control and elimination of residual cancer cells. Our findings 
demonstrate for the first time that the polyphenol resveratrol is capable of ampli-
fying Ox-induced cell growth inhibition in colon cancer cells supposedly via in-
duction of different modes of cell death. As a result of the apoptotic and necrotic 
effects of resveratrol and oxaliplatin, immunosuppressive potential in macro-
phages is prevented, which renders them potently tumoricidal (summarized in 
Figure 12).  
Even though our results suggests that the phytochemicals sulforaphane and 
resveratrol show promise for serving as potent agents for enhancing the thera-
peutic effect of oxaliplatin, some reports point out that this strategy might also 
negatively affect classical treatment regimens under certain circumstances (re-
viewed in MANUSCRIPT IV). This should as well provide a cautionary note for 
the uncontrolled and non-critical supplementation of these compounds in pa-
tients with established cancer who are already undergoing chemo- or radiother-
apeutic treatment. Further mechanistic studies, in vivo animal models and hu-
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man clinical trials are therefore needed to certify the safety and efficacy of die-
tary compounds in combination with cancer therapeutics.  
 
 
Figure 12: Possible effects of resveratrol and oxaliplatin in colorectal cancer 
cells 
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3.3 Bioavailability of phytochemicals 
 
The bioavailability of a nutrient depends on the degree to which it becomes 
available to the target tissue after administration. Regarding cancer therapies, a 
defect of drug accumulation in cancer cells is an important cause of failure. In-
deed, the action of chemopreventive and chemotherapeutic agents can be di-
minished by a failure of their absorption, distribution, metabolism or an increase 
in their excretion. Hence, the knowledge of absorption and metabolism of a 
compound in vivo is the precondition to analyze its bioavailability. 
The initial step of SFN absorption involves enzymatic hydrolysis of glu-
coraphanin, the glucosinolate precursor of SFN, found in plants. The enzymatic 
reaction is catalyzed by myrosinase, a β-thioglucosidase, which cleaves the 
glycone from the glucosinolate forming glucose, hydrogen sulphate and one of 
many different aglycones (e.g. thiocyanate, ITC, or a nitrile). After absorption, 
SFN is predominantly metabolized via the mercapturic acid pathway, starting 
with glutathione (GSH) conjugation by glutathione-S-transferase (GST) [270] 
followed by generation of SFN-cysteine (SFN-Cys) and SFN-N-acetylcysteine 
(SFN-NAC) [123]. The absorption and bioavailability of SFN can be affected by 
several factors. For example, the initial step can be influenced by alterations in 
the myrosinase activity which is due to the fact that plant myrosinase is heat 
labile and thus cooking procedure can inactivate the enzyme and significantly 
reduce the bioavailability of SFN up to 3-fold [271]. Another source of myrosi-
nase activity is the intestinal microbial flora. Data suggests that glucoraphanin 
can be converted by colonic microbial flora and that enterohepatic circulation is 
requisite for efficient metabolism [272]. However, it seems that the bioavailabil-
ity is more depending on plant myrosinase activity as seen by the fact that bioa-
vailability of SFN is six times less when metabolism of the glucosinolate to the 
ITC had not occurred prior to ingestion [273]. Further example for affecting SFN 
bioavailability is related to polymorphisms in Phase 2 SFN-metabolizing genes, 
such as GSTs, playing significant roles in determining the detoxifying ability of 
an organism. In general, GSTs are dimeric enzymes that catalyze the conjuga-
tion of GSH to electrophiles such as SFN, thereby facilitating their metabolism 
and excretion. Although the metabolism of SFN depends upon this GSTM1 
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genotype, approximately 50% of the population have a depletion of the GSTM1 
gene (“GSTM1 nulls”). The group of Gasper et al. showed that after 24 h, while 
GSTM1 null individuals excreted almost 100% of SFN, GSTM1-positive individ-
uals excreted only about 60% of ingested SFN [274]. Therefore, the observed 
protective effect of sulforaphane is influenced by GSTM1 genotype due to the 
fact that GSTM1-positive individuals gain greater cancer protection than 
GSTM1 Nulls [275-277].  
Several pharmacokinetic studies in both rats and humans indicate, that dietary 
absorbed sulforaphane can be widely distributed in the body, reach µM levels in 
the blood and is capable of reaching target tissues in an active form [123, 268, 
269]. Notably, the accumulation of SFN in colonic tissue corresponded with de-
creased adenoma formation in mice supplemented with 300 or 600 ppm SFN 
[278]. In clinical studies, it has been shown that 75% of SFN from broccoli is 
absorbed in the jejunum and a portion of that returns to the lumen of the jeju-
num as SFN-GSH [279]. When the metabolism of glucoraphanin efficiently oc-
curs, SFN-NAC is the primary SFN metabolite excreted in the urine [270-272, 
280]. In rats, nearly 72% of a single oral dose of SFN was recovered in the 
urine as NAC conjugates in 24 h [270], but only about 1% of the dose was de-
tected in the second 24-h urine sample [281], indicating an extremely high bioa-
vailability and a small inter-individual variation of SFN absorption and metabo-
lism. Once SFN is distributed it can accumulate in tissues, and be maintained to 
achieve the anti-tumor effects [123]. In a recent pilot study in human mammary 
tissue, a oral dose of broccoli sprout preparation containing 200 µmol sul-
foraphane 1 h prior to tissue removal showed mean accumulation of 1.45 ± 1.12 
pmol/mg tissue in the right breast and 2.00 ± 1.95 pmol/mg in the left breast 
[282].  
The consumption of isothiocyanates, such as sulforaphane is actually expected 
to rise due to the use of dietary supplements and public health initiatives pro-
moting the consumption of more fruits and vegetables. This together with its 
excellent bioavailability makes sulforaphane a potent candidate for food-drug 
interactions, whereby these interactions may result in both positive and negative 
consequences regarding cancer therapy.  
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In rats and humans, the bioavailability of resveratrol depends on its absorption 
and metabolism, which have been studied in several models, including isolated 
rat intestine [283, 284], rats and mice after oral administration [285-289], human 
colon carcinoma Caco-2 cell line [290], human hepatocytes [291] and healthy 
human subjects [292, 293]. Using radiolabelled resveratol administered by oral 
route, an considerable fraction, 50-75% of the dose, was absorbed in rats and 
radioactivity could be recovered in the stomach, liver, kidney, intestine, bile and 
urine in mice [289]. Intragastric administration of different amounts of resveratrol 
to rats revealed an absorption rate of 77-80% resveratrol in the intestine and 
reached µM levels in plasma [294]. In humans, after oral administration less 
than 2% of free resveratrol in plasma and serum was detected [294]. Obviously, 
with time, the plasma concentration diminished until a secondary peak ap-
peared and this secondary peak was due to the recirculation of resveratrol after 
release from bile. The liver and gallbladder filtered resveratrol and its metabo-
lites from the circulation and transported them back again into the intestine 
through the bile for a delayed absorption [286, 287]. According to pharmacoki-
netic studies in mice, rats, and dogs, resveratrol is rapidly absorbed and glucu-
ronated in the human liver and sulphated in both the liver and the duodenum 
[105], whereas only very minute amounts of resveratrol are distributed to all or-
gans [283]. In 2004, Walle [294] and colleagues showed that most of an intra-
venous dose of resveratrol is converted to sulphate conjugates within ~30 min 
in humans. A detailed analysis of plasma metabolites after oral dosing was not 
possible; however, both sulphate and glucuronide conjugates were detected. In 
addition, they also demonstrated that, compared to resveratrol, which has a 
plasma half-life of 8–14 min, the metabolites have a plasma half-life of about 9.2 
hours, indicating that exposure to modified forms is much higher than that for 
unchanged resveratrol [294]. However, the bioavailability and efficacy of these 
resveratrol metabolites is unknown [94]. According to above-mentioned phar-
macokinetic studies circulating resveratrol is rapidly metabolized [295], which 
cast doubts on the therapeutic relevance of resveratrol due to the discrepancy 
between the relatively low bioavailability in vivo and the biologically relevant 
concentrations used in in vitro studies [296]. However, systemic administration 
of resveratrol has been shown to inhibit the initiation and growth of tumors in a 
wide variety of rodent cancer models [297-301]. According to the literature, in-
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traluminal accumulation of resveratrol might be a hypothesis to explain this dis-
crepancy. In animals, resveratrol accumulated in the liver up to a concentration 
comparable to that which exerts biological effects in in vitro assays (micromolar 
range) [289] and several amounts are found in the colon, whereas its tissue dis-
tribution required a few hours. Thus, in the case of colorectal cancer, it might 
also be interesting, which amount of resveratrol is not absorbed and reaches 
the colon.  
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3.4  Future perspectives for the use of phytochemicals in can-
cer treatment 
 
It is obvious that phytochemicals exhibit excellent anticancer and anti-
inflammatory properties, but a majority of these studies were conducted in in 
vitro and in animal models. Due to differences in metabolism and genetics, 
there is a need to investigate these physiological effects in humans, as the ac-
tivity observed in animal models cannot be easily extrapolated.  
Several epidemiological trials recently suggested that cruciferous vegetables, 
including broccoli, may provide more protection than fruits and vegetables in 
general, against many different cancers [302]. Whereas epidemiological studies 
are excellent for hypothesis generation, a recent report even suggested that 
epidemiological studies are considerably less than 50% reproducible [303]. This 
low reproducibility might be due to our lack of knowledge of different aspects of 
the food under study, such as changes in the content of bioactive components 
with plant variety or cooking method. Hence, animal studies followed by clinical 
trials are necessary to clarify the data often based on epidemiological studies.  
 
3.4.1 Sulforaphane: preclinical and clinical studies 
 
While promising protective effects of broccoli are proposed, one frequently 
asked question is: “How many broccoli do I have to eat”? Most cultivars of broc-
coli accumulate between 2 and 10 µmol g-1 of 4-methylsulfinyl glucosinolate in 
their florets. Higher levels on a dry weight basis may sometimes be found within 
broccoli sprouts which are mostly used in animal or human trials, a few days 
after germination. A high-glucosinolate variety of broocoli has, however, been 
specially bred to accumulate about threefold higher levels of glucosinolates in 
its florets [304]. As Keum and colleagues [305] recently indicated, broccoli 
sprouts may serve as a good dietary source of SFN in vivo while showing signif-
icant inhibitory effects on prostate tumorigenesis. But it is difficult to determine 
whether such protective effects are related to isothiocyanates or other factors 
associated with cruciferous vegetables intake. As Hanlon et al. [306] recently 
demonstrated, fresh broccoli from retail sources generates very low levels of 
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SFN even when consumed raw, and that in humans, SFN is rapidly absorbed 
following consumption of liquidised broccoli, but repeated intake of vegetables 
does not lead to higher plasma levels. Nevertheless, the results of some pro-
spective cohort studies suggest that adults should aim for at least 5 weekly 
servings of cruciferous vegetables for gaining preventive properties [307-309].  
In preclinical rodent models, there is significant data supporting the chemopre-
ventive effects of SFN at several stages of carcinogenesis [reviewed in Clarke, 
2008]. As shown in suppression studies, supplementation with SFN decreased 
polyp formation in Apcmin mice [143, 278], decreased colonic aberrant crypt foci 
in azoxymethane (AOM)-induced rats [310] and also decreased tumor growth in 
prostate xengraft studies [142, 311]. To date, some clinical trials investigated 
the safety and tolerance of SFN when it was extracted from broccoli sprouts. A 
phase I clinical study, for example, examined the safety, tolerance, and metabo-
lism of orally dosed broccoli sprout extracts as glucosinolates and isothiocya-
nates in healthy human volunteers over 7-day period [312]. No significant or 
consistent subjective or objective abnormal events like potential toxicities were 
observed with 25 µmol isothiocyanate (equivalent to ~4.4 mg as sulforaphane) 
per person per day, however, there have been little systematic evaluations of 
high doses and long-term administration of isothiocyanates in human studies. In 
order to move sulforaphane into large-scale clinical trials, more research into 
metabolism, bioavailability and the impact of this compound is needed. Dash-
wood et al. recently performed a small preliminary human study in the interest 
of determining whether the HDAC inhibition effects observed in cell culture and 
mice could be translated into humans. In normal healthy volunteers, 3-6 h after 
ingestion of 68 g of broccoli sprouts, a >50% significant decrease in HDAC ac-
tivity was evident in peripheral blood mononuclear cells with a concomitant in-
crease in acetylated H3 and H4 [142], which confirmed the findings in mice, and 
in cultured cells treated with SFN [313]. The extent to which acute inhibition of 
histone deacetylase activity plays a causative role in cancer prevention remains 
to be determined.  
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Table 1: Clinical Trials with Sulforaphane 
[[http://clinicaltrials.gov/ct2/results?term=sulforaphane] date: 08.2010] 
BSE= Boccoli Sprout Extracts 
 
To date, very few clinical studies have evaluated the effects of SFN on cancer 
outcome. However, some phase I-III trials are currently underway or finished 
(summarized in Table 1). Most of these studies are under the condition of 
breast cancer, none of them investigate the influence of broccoli sprout extracts 
or even pure sulforphane on colon cancer outcome. However, a cross-over 
broccoli sprouts trial in healthy subjects (NCT01008826) investigates whether 
broccoli sprouts are effective at altering the urinary levels of metabolites of the 
hepatocarcinogen aflatoxin B1 and of the air-borne pollutant phenanthrene in 
residents of Qidong. Residents of Qidong are at high risk for development of 
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heptacellular carcinoma, in part due to consumption of aflatoxin-contaminated 
foods, and are exposed to high levels of phenanthrene. In this study, an inverse 
correlation between SFN treatment and excretion of carcinogens was detected, 
suggesting induction of one or more Phase 2 enzymes. In summary, due to all 
these properties, also in regard to above described chemosensitizing proper-
ties, sulforaphane seems to be an auspicious candidate in chemoprevention or 
in chemotherapeutic approaches and could be a potential compound in the de-
velopment of new therapeutic strategies. In future, also studies with purified sul-
foraphane are desirable and essential to verify the efficacy in humans suffering 
from cancer. 
 
3.4.2 Resveratrol: preclinical and clinical studies 
 
The initial reports of therapeutic potential to resveratrol led to the increased in-
terest in this compound from 1997 [104]. Now, it is obvious that resveratrol ex-
hibits excellent anticancer and anti-inflammatory properties including cell growth 
inhibition of a wide range of human cancer cells in culture as well as implanted 
tumors usually in mice [105, 314]. The compound inhibited experimental tumor-
igenesis in a wide range of animal models by targeting many components of 
intracellular signaling pathways including pro-inflammatory mediators, regula-
tors of cell survival and apoptosis, and tumor angiogenic and metastatic switch-
es by modulating a distinct set of upstream kinases, transcription factors, and 
their regulators [106, 315].  
The potential association between red wine consumption and risk of cardiovas-
cular disease mortality has been highlighted by the „„French Paradox‟‟ where 
protective effects are observed for consumption levels up to 300 ml wine per 
day [316, 317], in which the reductions in risk from low to moderate consump-
tion of alcoholic beverages are greater for red wine compared to white wine, 
beer, and most spirits [318]. Since concentration of trans-resveratrol in red 
wines estimate about 5 mg resveratrol per litre [319, 320], assuming a con-
sistent daily intake of 375 ml, or about two glasses of wine, a person weighing 
70 kg would receive a dose of ~27 μg per kg (body weight) each day. The prob-
lem is that at higher doses, the detrimental effects of alcohol are likely to mask 
any health benefits including the beneficial effect of alcohol consumption on 
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Alzheimer‟s disease which is maximal at 1–6 drinks per week [321] and con-
suming more than four drinks per day nullifies the beneficial effect of alcohol on 
the risk of myocardial infarction [322]. But apart from the negative effects of al-
cohol in higher concentrations, what about the safety aspect of resveratrol in-
take? As Planas et al. [323] recently reported no hematologic or histopathologic 
toxicity associated with daily oral administration of resveratrol at a high dose of 
20 mg/kg in rats exists. This dosage represents a 1000-fold higher resveratrol 
dosage than typically consumed by humans at the rate of one glass of red wine 
a day. The results of Crowell et al. [324] further support the above finding where 
they have shown no adverse effects in rats when administered resveratrol at 
300 mg/day for 4 weeks. Absence of toxicity has also been demonstrated in 
humans that received a single dosage of up to 5 g resveratrol [325]. These ex-
periments clarify that this phytochemical could be applied as a chemopreventive 
agent without causing any adverse effects. However, it must be recognized that 
all of these observations have been made with doses of resveratrol that are well 
above those achievable in humans though normal diet. A recently concluded 
10-year epidemiology study showed an inverse relationship between resveratrol 
and breast cancer risk in women with resveratrol consumption from grapes, but 
not from wine [326] which could not be explained by several potential confound-
ing factors, including alcohol intake, nor was it attributable to a nonspecific fa-
vorable effect of fruit on breast cancer risk [326]. At high doses, orders of mag-
nitude higher than would be achievable through red wine consumption by hu-
mans, orally ingested resveratrol is also able to extend lifespan greater than 
50% in a number of organisms ranging from mono-cellular yeasts, nematode, 
insect, fish and mice [327-329]. But to achieve the equivalent dose of resvera-
trol that was fed to the fish in order to achieve a >50% lifespan extension [328] 
and to mice in order to prevent the detrimental effects of a high fat diet [330], 
one would need to consume around 60 l ⁄d of high resveratrol red wine, which is 
clearly not feasible.  
Preclinical trials clearly show great promise for resveratrol in the treatment and 
prevention of cancers [297-301]. The observed efficacy of low doses, for exam-
ple 200µg/kg body weight/day, which counteracted azoxymethane-induced car-
cinogenesis in a rat model of colon cancers, suggests that even concentrations 
of resveratrol, which might be achievable from dietary sources, 
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Table 2: Clinical trials with resveratrol in the condition of cancer 
[[http://clinicaltrials.gov/ct2/results?term=resveratrol]; date: 08.2010] 
EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid 
 
such as red wine, could be therapeutic in some cases [209]. But protective ef-
fects of resveratrol are more dramatic at higher, but pharmacological achievable 
doses. Therefore, from a functional, pharmacological and clinical point of view it 
would be useful to distinguish between “pharmacological” and “dietary” chemo-
prevention. Responding to the question whether the observed effects in in vitro 
and in vivo models are also conferrable and relevant for humans, several phase 
I and II clinical trials are currently in progress. One such study is a recently 
completed phase I clinical trial, supported by the US National Cancer Institute 
and the UK Medical Research Council, demonstrates that consumption of 
resveratrol (5 g) does not cause any serious adverse effects in healthy volun-
teers, but the peak plasma level (2.4 mol/L) remains much below the minimum 
required concentration (5 mol/L) of the compound to exert the chemopreventive 
effect in cultured cells [325]. The study also indicates the presence of several 
fold higher plasma levels of resveratrol monoglucuronides and resveratrol-3-
sulfate. Several other clinical trials are in progress to demonstrate the cancer 
therapeutic effects of resveratrol in cancer patients (summarized in Table 2). 
One of these studies is a phase I trial (NCT00433576) conducted at the Univer-
sity of Michigan, investigating the bioavailability and toxicity profile of resvera-
NCT0000455416Drugs: EPA; DHA; 
Selenium; Gralic
extract; Promegranate
juice; Grape juice; 
Green Tea 
Follicular
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I5
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trol, and its effects in the expression of COX-2 and in M/G cell cycle arrest in 
individuals with colorectal cancer. Phases I and II clinical trials in patients with 
colon cancer (NCT00256334) conducted from researchers at the University of 
California, will investigate the effects of resveratrol in modulating the Wnt-
signaling pathway, a pathway that is implicated in the etiology of colon cancer. 
They also propose starting another clinical intervention study using dietary 
resveratrol in colon cancer prevention (NCT00578396). This study will investi-
gate if a grape juice-supplemented diet will reduce the risk of colon cancer in 
healthy volunteers who are 18 years of age and older. In addition to these stud-
ies, resveratrol is part of a multicomponent dietary intervention phase II clinical 
trial in progress at the University of Oslo (NCT00455416). This study proposes 
to use dietary components, including resveratrol in the form of grape juice, in 
the induction of apoptosis, inhibition of cell proliferation, and modulation of tu-
mor cell infiltrate in patients with follicular lymphoma. Results of these trials will 
address the issue of extrapolation from the results of resveratrol in animal stud-
ies to therapeutic potential for humans and also provide a basis for the prospec-
tive application of resveratrol in cancer chemoprevention. Recently, a clincal 
trial of a formulation of resveratrol has been suspended due to safety concerns. 
In this phase II trial safety and activity of a resveratrol-based drug alone or in 
combination with the proteasome inhibitor bortezomib in patients multiple mye-
loma should be assessed (NCT00920556). The trial was halted when 5 out of 
24 patients developed a kidney condition called cast nephropathy. Interestingly, 
all patients who experienced kidney failure during the trial were being treated 
with only the resveratrol-based drug when their kidney problems developed. 
However, it is still uncertain whether the kidney failures were actually related to 
the resveratrol treatment, or were simply a manifestation of the underlying mye-
loma since cast nephropathy is so commonly associated with multiple myeloma 
that it is even called “myeloma kidney” [331] 
Developing novel resveratrol derivatives is another possible approach for en-
hancing bioavailability. A series of cis-stilbenes and trans-stilbenes related to 
resveratrol with varying functional groups have been synthesized, and some of 
these compounds are more potent than resveratrol in suppressing the growth of 
human cancer cells in vitro (reviewed in [332]). Researchers have started to 
explore the anticancer effects of resveratrol derivatives in vivo [333-337] and at 
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least one study indicated that a tetramer of resveratrol (heyneanol) presented 
comparable or better anticancer efficacy than did resveratrol in a mouse lung 
cancer model [334]. The preclinical and clinical data examined in this report 
strongly suggest that resveratrol is a promising candidate in chemopreventive 
and chemotherapeutic strategies and a potential weapon in the effort to allevi-
ate the burden of human cancer, even more when also regarding the chemo-
sensitizing effects, described above. Considering its multivarious molecular tar-
gets, John Pezzuto has asserted very timely that resveratrol induces a „biologi-
cally specific tsunami‟ [338]. 
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Isothiocyanate sulforaphane inhibits protooncogenic
ornithine decarboxylase activity in colorectal cancer cells
via induction of the TGF-b/Smad signaling pathway
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Scope: The objective of this study was to elucidate molecular mechanisms behind the anti-
tumor activities of the isothiocyanate sulforaphane (SFN) in colorectal cancer cells.
Methods and results: Cell growth was determined by BrdU incorporation and crystal violet
staining. Protein levels were examined by Western blot analysis. Ornithine decarboxylase
(ODC) activity was assayed radiometrically. Reverse transcriptase-PCR was used for
measuring mRNA expression. For reporter gene assays plasmids were transfected into cells
via lipofection and luciferase activity was measured luminometrically. Acetyl-histone H3 and
H4 chromatin immunoprecipitation (ChIP) assays were performed followed by PCR with
TGF-b-receptor II promoter specific primers. We could show that SFN-mediated cell growth
inhibition closely correlates with a dose-dependent reduction of protein expression and
enzymatic activity of ODC. This effect seems to be due to reduced protein levels and trans-
activation activity of transcription factor c-myc, a direct regulator of ODC expression, as a
consequence of SFN-induced TGF-b/Smad signaling. The coherency of these results was
further confirmed by using TGF-b receptor kinase inhibitor SB431542, which largely abol-
ishes inhibitory effects of SFN on both, ODC activity and cell growth.
Conclusion: Since elevated ODC enzyme activity is associated with enhanced tumor devel-
opment, SFN may be a dietary phytochemical with potential to prevent carcinogenesis.
Keywords:
c-myc / Colorectal cancer / Ornithine decarboxylase / Sulforaphane / Transforming
growth factor-b signaling
1 Introduction
Colorectal cancer accounts for approximately 10% of all
cancers and is the second leading cause of cancer-related
death in Western countries with an estimated 146 970 new
cases and 49 900 deaths in 2009 in the United States [1].
In addition to conventional cancer therapy, preventive
measures that target the multi-step progress of carcino-
genesis involving initiation, promotion and progression [2]
are aimed at decreasing the incidence and mortality of
cancer. In this context, increasing evidence suggests the
importance of food and nutrition in the modification of the
cancer development [3]. In particular, in vitro and in vivo data
revealed that consumption of cruciferous vegetables is
supposed to lower overall cancer risk, including colon
cancer, especially during the early stages [4]. These anti-
carcinogenic activities have been suggested to be partly due
to the relatively high levels of sulforaphane (SFN), the major
biologically active compound [5]. SFN, first isolated from
broccoli in the early 1990s, was initially identified as a potent
Abbreviations: BrdU, bromodeoxyuridine; FCS, fetal calf serum;
HDAC, histone deacetylase; HDACi, histone deacetylase inhibi-
tor; ODC, ornithine decarboxylase; SBE, Smad binding element;
SFN, sulforaphane; TGF-b, transforming growth facor-b; TGF-b
RI, transforming growth factor-b receptor I; TGF-b RII, transform-
ing growth factor-b receptor II
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phase 2 enzyme inducer, but in recent years numerous
studies have implicated further chemopreventive effects,
comprising cell growth inhibition, induction of apoptosis
and reduction of angiogenesis [6–9], whereby the underlying
molecular mechanisms remain largely unclear.
Recently, Myzak and Colleagues identified SFN as a novel
histone deacetylase inhibitor (HDACi) in colon and prostate
cancer cells [10]. HDACi, as a new class of chemotherapeutic
agents, show significant promise against a variety of cancers
in clinical trials [11]. Most available HDACi inhibit all class I
and II histone deacetylases (HDACs), thereby increasing
acetylation of histone and nonhistone protein targets [12].
In vivo, histone acetylation depends on the balance between
histone acetyltransferases and HDACs, which has been
proposed to play an important role in transcriptional regula-
tion by altering chromatin structure [13]. Histone acetylation
by histone acetyltransferases is associated with an open
chromatin conformation, promoting gene transcription,
whereas HDACs maintain the chromatin in the closed, tran-
scriptional inactive state. HDAC inhibitors have been shown
to induce the expression of several tumor suppressive genes,
such as p21WAF1 [14], growth-differentiation factor 11, a
member of the transforming growth factor-b (TGF-b) super-
family [15] as well as TGF-b receptors I and II (TGF-bRI and
TGF-bRII) [16, 17]. Thus, the pro-tumorigenic role of HDACs
in colon cancer and the pre-clinical efficacy of these agents in
colon cancer cells justify the use of HDACi in cancer
prevention and therapy [18].
TGF-b has been implicated in various cellular processes,
including regulation of cellular proliferation [19] and
differentiation [20], immune modulation [21] and extra-
cellular matrix remodeling [22]. It exhibits its anti-
proliferative functions by activating a signaling pathway that
mediates cell cycle arrest and induction of apoptosis. TGF-b
exerts its effects through heteromeric receptor complexes
consisting of type I and type II serine/threonine kinase
receptors. The signaling is initiated by ligand binding to the
TGF-bRII cell surface receptor. This, in turn, recruits the
TGF-bRI kinase, which then phosphorylates the R-Smad
proteins, Smad2 and Smad3 [23]. Activated R-Smads form a
complex with the Co-Smad, Smad4, which shuttles directly
to the nucleus. Here, the complex can either act as a
co-activator or DNA-binding transcription factor, participat-
ing in the regulation of target gene expression (e.g. p15, p21,
c-myc) [23, 24]. TGF-b signaling is further controlled by a
third class of Smads, the inhibitory Smad6 and Smad7
proteins, which negatively regulate R-Smad activation.
Recently, Daniel et al. [25] could demonstrate that butyrate,
another natural occurring HDACi, mediates anti-
carcinogenic effects in colorectal cancer cells, at least partly,
through the activation of the TGF-b signaling pathway.
Furthermore, Traka et al. [26] provide evidence that SFN
enhances TGF-b signaling in cell cultures.
Previous studies could demonstrate that modulation of
polyamine metabolism provides a chemopreventive strategy
of different phytochemicals [27–31]. Although cellular
polyamines spermidine and spermine, as well as their
precursor putrescine, are essential for growth and DNA
synthesis, increasing concentrations are associated with
hyperproliferation and cell transformations [32]. Overall,
polyamines are involved in almost all steps of colonic
tumorigenesis. Regulation of polyamine levels is governed
primarily by activity of ornithine decarboxylase (ODC), the
key enzyme of polyamine biosynthesis. Hence, regarding
the role of polyamines in colonic carcinogenesis, modula-
tion of polyamine metabolism and, in particular, of ODC
activity has been studied as a potent therapeutic strategy in
cancer treatment and prevention [30, 33].
Thus, the aim of this project was to provide insight into
the molecular mechanisms of SFN-mediated anti-tumor
activities, in particular by investigating regulatory functions
of SFN on ODC activity, also with regard to a possible
involvement of the TGF-b signaling pathway.
2 Materials and methods
2.1 Cell culture and materials
Caco-2 cells were kept in DMEM, supplemented with 10%
fetal calf serum (FCS), 1% penicillin/streptomycin, 1%
sodium pyruvate and 1% nonessential amino acids and were
maintained at 371C in an atmosphere of 95% air and 5%
CO2. The cells were passaged weekly using Dulbecco’s PBS
containing 0.1% trypsin and 1% EDTA. The cells were
screened for possible contamination with mycoplasma at
monthly intervals. For experiments, the cells were seeded
onto plastic cell culture wells in serum-containing medium
and allowed to attach for 24 h. For the ODC activity assay,
the cells were synchronized in a medium containing 1%
FCS 24h before treatment. SFN (Calbiochem) was dissolved
in DMSO at a concentration of 100mM, SB431542 (Sigma-
Aldrich) was dissolved in DMSO at a concentration of
10mM and TGF-b-1 (PeproTech) was dissolved in BSA at a
concentration of 10mg/mL. DMEM, DMEM/Ham’s F-12
medium, McCoy’s 5A, FCS, DMSO, Sodium pyruvate
solution, penicillin and streptomycin stock solutions were
all obtained from PAA Laboratories GmbH.
2.2 Cell counts
Cells were suspended and cultured in 96-well dishes at a
density of 104/well (0.28 cm2). Twenty-four hours after
plating, cells were incubated for 24–72 h with substances. At
given time points, cell numbers were assessed by crystal
violet staining. Medium was removed from the plates and
cells were fixed with 5% formaldehyde for 5min. After
washing with PBS, cells were stained with 0.5% crystal
violet for 10min, washed again with PBS and destained with
33% acetic acid. Absorption, correlating linear with cell
number, was measured at 620 nm.
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2.3 Cell proliferation
The effects of SFN on DNA synthesis of cells was assessed
using a cell proliferation ELISA kit (Roche Diagnostics).
This assay is a colorimetric immunoassay for the quantifi-
cation of cell proliferation based on the measurement of
bromodeoxyuridine (BrdU) incorporation during DNA
synthesis. Cells were grown in 96well culture dishes
(104 cells/well), incubated with SFN for different time
intervals and then labeled with BrdU for a further 4 h.
Incorporated BrdU was measured colorimetrically.
2.4 Plasmids
The human pGL3-c-myc promoter (62–93) with the
sequence TTCTCAGAGGCTTGGCGGGAAAAAGAACGG
and the pGL3-c-myc-promotor (62–93) TIEm with the
sequence TTCTCAGATTAAAGGCGGGAAAAAGAACGG
(Smad binding site mutated) were kindly provided by Prof.
Ellenrieder (Marburg, Germany).
The pCGN-Smad3 and pCGN-Smad4 expression plas-
mids were obtained from Dr. X. F. Wang (Durham, USA)
and the 4 SBE (Smad binding element)-luc promoter was
generously provided by B. Vogelstein (Johns Hopkins,
Baltimore, MD, USA) [34].
2.5 Reporter assays
Caco-2 cells were transfected by using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions.
Medium was changed after 4 h of transfection and the cells
were incubated in a medium containing 10% serum for
another 16–20 h. Later, the cells were treated with SFN
(20 mM) or TGF-b (20 nM) and then subjected to luciferase
assay. pCGN and pGL3, as empty vector plasmids, were
used as a negative control for transfection and luciferase
assay. Luciferase assays were carried out by using luciferase
assay kit (Promega) and a luminometer (TECAN Spectra-
FluorPlus). A cytomegalovirus-Renilla luciferase plasmid or a
Simian Virus-40-Renilla luciferase plasmid (both from
Promega) was used as a control, to normalize the transfec-
tion efficiency, and was assayed as described [35].
2.6 SDS-polyacrylamide gel electrophoresis and
immunoblot analysis
Caco-2 cells were seeded in 80-cm2 flasks; 24 h after plating,
cells were incubated with substances for different time
intervals ranging from 1 to 48 h. After washing the cells with
ice-cold PBS, followed by an incubation step with cell lysis
buffer (Cell signalling) containing multiple protease inhi-
bitors (Complete Minis, Roche) for 20min at 41C, cells
were harvested by scraping. Protein extracts were obtained
after sonication of cell lysates (2 5 s) and centrifuged at
10 000 rpm for 10min at 41C. Samples were analyzed for
their protein content using the BioRads colorimetric assay
according to the method of Bradford (BioRad Laboratories).
After addition of sample buffer (Roti Loads, Roth) to the
total cellular extract and boiling for 5min at 951C, 30–40 mg
of total protein lysate was separated on a 10 or 12%
SDS-polyacrylamide gel. Protein was transferred onto
nitrocellulose membrane (Schleicher&Schuell) and the
membrane was blocked for 1 h at room temperature with
5% skimmed milk in Tris-buffered saline containing 0.05%
Tween-20. Next, blots were washed and incubated overnight
at 41C in Tris-buffered saline containing 0.05% Tween-20
containing either 5% BSA or 5% skimmed milk with a
1:1000 or 1:2000 dilution of primary antibodies for TGF-b1,
TGF-bRI and TGF-bRII (all from Cell Signaling), c-myc and
ODC (all from Santa Cruz Biotechnology). The secondary,
horseradish peroxidase-conjugated, antibody (Santa Cruz
Biotechnology) was diluted at 1:2000 or 1:4000 and incu-
bated with the membrane for another 60min in skimmed
milk. Following chemoluminescence reaction (ECL, Amer-
sham pharmacia biotech), bands were detected after expo-
sure to Hyperfilm-MP (Amersham International plc). Blots
were reprobed with b-actin antibody (Santa Cruz Biotech-
nology). For quantitative analysis, bands were evaluated
densitometrically by ProViDoc system (Desaga), normalized
for the density of b-actin.
2.7 Reverse transcriptase-PCR
Total cellular RNA was isolated by RNAzol BTM (Wak-
Chemie), following manufacturer’s instructions. Reverse
transcription of total cellular RNA was carried out using
Superscript II RNase H reverse transcriptase (Life Technolo-
gies) and random hexanucleotide primers (Promega). PCR
was performed (on the cDNA) using the following sense and
antisense primers, custom-synthesized by Biospring: TGF-b1:
50-CAC GAT CAT GTT GGA CAA CTG CTC C-30 and 50-CTT
CAG CTC CAC AGA GAA GAA CTG-30; GAPDH: 50-ATC
TTC CAG GAG CGA GAT CC-30 and 50-ACC ACT GAC ACG
TTG GCA GT-30. Thermal cycling was performed as follows:
denaturation for 30 s at 951C, annealing for 30 s at 551C and
extension for 90 s at 721C. Twenty-five to thirty-five cycles were
performed. Primers were used at a final concentration of
10mM each, dNTPs at 500mM (Eurogentec) and MgCl2 at
3mM. Five units of Taq DNA Polymerase were used per 50mL
reaction. Ten microliter of PCR product were separated on a
1.5% agarose gel containing ethidium bromide and visualized
by UV illumination.
2.8 ODC activity
The activity of ODC was assayed using a radiometric
technique in which the amount of 14CO2 liberated from
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DL-[l-14C]ornithine (207.2 104MBq/mol, Amersham Phar-
macia Biotech) was estimated, as described previously [36].
Briefly, after treatment, cell culture dishes were placed on
ice and monolayers were washed three times with cold PBS.
Cells were harvested by scraping in homogenizing buffer
(50mM Tris buffer, pH 7.2, 5mM DTT, 100 mM EGTA),
sonicated and centrifuged for 10min at 15 000 g at 41C.
Hundred microliter of the obtained supernatant was incu-
bated in a stoppered tube with 74 mM DL-[l-14C]ornithine in
the presence of pyridoxal-5-phophate for 1 h at 371C. 14CO2,
liberated by the decarboxylation of ornithine and trapped on
filters impregnated with benzethonium hydroxide, was
measured by liquid scintillation spectroscopy. Samples were
analyzed for their protein content using the BioRads
colorimetric assay according to the method of Bradford
(BioRad Laboratories). ODC is expressed in picomolar of
released CO2 per hour per milligram of protein. Controls
always included samples for measurement of nonenzymatic
release of 14CO2.
2.9 Chromatin immunoprecipitation Assay
Chromatin immunoprecipitation assays were performed
using Acetyl-Histone Immunoprecipitation Assay Kits
(Upstate Biotechnology) following the manufacturer’s
instructions. Briefly, approximately 1 106 cells cultured in a
75 cm2 dish were treated with different concentrations of SFN
(10–20mM). Histones were cross linked to DNA by adding 1%
formaldehyde directly to culture medium for 10min at 371C.
Each sample was lysed in SDS lysis buffer (kit component)
containing protease inhibitors (1mM PMSF, 1mg/mL aproti-
nin and 1mg/mL pepstatin A) followed by sonication on ice to
shear DNA to lengths between 200 and 1000bp and incuba-
tion with primary antibodies to acetylated histone H3 or
acetylated histone H4 overnight at 41C. Samples were incu-
bated with Salmon Sperm DNA/Protein A Agarose-Slurry (kit
component) for 1h at 41C with rotation. After washing several
times with washing buffers (kit components), the pellet
protein A agarose/antibody/histone complex was incubated
with elution buffer (1% SDS and 0.1M NaHCO3) for 15min
at room temperature. Samples were incubated with 0.2M
NaCl for 4h at 651C. After DNA was recovered by phenol/
chloroform extraction and ethanol precipitation, PCR was
performed using the following primers for TGF-bRII
promoter, sense: 50-GAG AGA GCT AGG GGC TGG-30;
antisense: 50-CTC AAC TTC AAC TCA GCG CTG C-30;
primer for b-actin gene promoter, sense: 50-CCA ACG CCA
AAA CTC TCC C-30; antisense: 50-AGC CAT AAA AGG CAA
CTT TCG-30 [17]. Results were finally normalized to b-actin.
2.10 Statistics
The data are expressed as mean7SE of at least three inde-
pendent experiments. Results were analyzed using Graph-
Pad Prism software by a two-way ANOVA. A p-value o0.05
was considered to be significant.
3 Results and discussion
3.1 Cell growth-inhibitory effects of SFN closely
correlate with the reduction of ODC protein and
activity
In colorectal cancer tissue, the activities of the polyamine-
synthesizing enzymes ODC and S-adenosylmethionine
decarboxylase as well as the content of polyamines are
increased 3- to 4-fold over that found in the equivalent
normal colonic tissue [37]. Increasing concentrations of
polyamines are generally associated with cell proliferation
and cell transformation induced by growth factors [38],
carcinogens [39] or oncogenes [32]. Several studies suggest
Figure 1. Cell counts and cell proliferation of Caco-2 cells (A, B)
24, 48, and 72 h after incubation without (control) or with SFN
(1–50 mM). Values represent mean7SE (n5 3); po0.05,
po0.01, po0.001 versus control.
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that a number of potential chemopreventive agents down-
regulate ODC expression/activity and subsequently deplete
polyamine content in colon cancer cells [40]. Hence, inhi-
biting the polyamine metabolism, particularly the biosyn-
thetic key enzyme ODC, is considered to represent an
attractive target for both cancer chemotherapy and cancer
chemoprevention. Interestingly, in their most recent publi-
cation, Furniss et al. reported modulator effects of broccoli
extracts as well as SFN alone on polyamine metabolism in
colorectal cancer cells. However, direct modes of action were
not further specified [41]. In the present study, we could
demonstrate that SFN (1–50 mM) inhibits cell counts and
proliferation significantly in Caco-2 cells in a dose- and time-
dependent manner (po0.001) (Fig. 1A and B), which
closely correlates with a dose-dependent reduction of ODC
protein levels after 3 and 6 h (Fig. 2A) and activity after 24 h
of incubation (Fig. 2B) (po0.001). The crucial role of
polyamine depletion was further suggested as addition of
exogenous spermidine significantly (po0.001) counter-
acted growth inhibitory effects of SFN after 24 h (Fig. 2C).
Similar effects could be observed by the group of Lee et al.
where SFN inhibited TPA-induced ODC activity in mouse
epidermal ME308 cells [42].
ODC levels are tightly controlled either by transcriptional
regulation or by rapid post-translational degradation. The
proto-oncogene c-myc is a transcription factor that directly
regulates the expression of ODC by binding to a specific
CACGTG sequence in the gene promoter [43]. c-myc was
subsequently found to be activated in various animal and
human tumors and an amplification of the c-myc gene has
been described in 15% of all human tumors [44]. Since
c-myc is a ubiquitous promoter of cell growth and prolif-
eration, it functions as a transcriptional activator or inhibitor
depending on the target gene [45, 46]. We could demon-
strate that decreased ODC activity and protein levels in
Caco-2 cells are accompanied by decreased protein levels of
c-myc after 6 h of incubation (Fig. 2D), implicating a direct
modulation of ODC gene expression by SFN.
3.2 Effects of SFN on TGF-b signaling
We previously reported that induction of the TGF-b signal-
ing pathway in colon cancer cells is a crucial event in the
anti-carcinogenic activities of butyrate, another natural
occurring HDAC inhibitor [25]. This, together with the
Figure 2. (A) Western blot of
ODC (53 kDa) in Caco-2 cells
after incubation with SFN
(5–50 mM) for 3 and 6 h. The
graph presents densitometric
analysis of the Western blot
images normalized to b-actin
(mean7SE (n5 3); po0.01,
po0.001 versus control). (B)
Activity of ODC in Caco-2 cells
after incubation with SFN
(20–50 mM) for 24 h. Bar graphs
represent mean7SE (n5 4);
po0.001 versus control. (C)
Add-back experiment with sper-
midine. Cell proliferation was
measured after simultaneous
treatment of Caco-2 cells with
SFN (20mM) and spermidine
(SPD) (5–10 mM) for 24 h. Bar
graphs represent mean7SE
(n5 3); po0.05, po0.001
versus control. (D) Western blot
of c-myc protein expression
(67 kDa) in Caco-2 cells after
incubation with SFN (1–10 mM)
for 6 h. The bar graph presents
densitometric analysis of the
Western blot images normalized
to b-actin (mean7SE (n5 3);
po0.05, po0.001 versus
control). Representative immu-
noblots of three independent
experiments are shown.
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findings of Traka et al., who could demonstrate that TGF-b
signaling also seems to play an important role in various
SFN-mediated effects [26] lets us consider whether SFN
possibly shows similar modes of action in our context. Thus,
we measured protein as well as mRNA level of TGF-b in
Caco-2 cells and could show an obvious increase of TGF-b
precursor levels after 2 h (Fig. 3A) and an increase of mRNA
after 1 and 3 h of incubation with SFN, indicating regulatory
effects on the level of transcription (Fig. 3B). As already
mentioned, not only TGF-b alone but also the expression
status of TGF-bRI and TGF-bRII is essential for TGF-b-
mediated actions. Therefore, protein levels of both receptors
I and II were detected after incubation with SFN, and
were found to be highly increased after 1 h (Fig. 3C)
(po0.001).
To further specify these regulatory mechanisms, we used
chromatin immunoprecipitation analysis to investigate
possible effects of SFN-mediated HDAC inhibition on the
Figure 3. (A) Western blot of TGF-b1 precursor (50 kDa) in Caco-2 cells after incubation with SFN (5–50 mM) for 2 h. A representative
immunoblot of three independent experiments is shown. The bar graph presents densitometric analysis of the Western blot images
normalized to b-actin (mean7SE (n53); po0.01, po0.001 versus control). (B) RT-PCR of TGF-b mRNA (298 bp) in Caco-2 cells after
incubation with SFN (5–20 mM) for 1 and 3 h. Representative agarose gels showing PCR products of three independent experiments for
both time-points are shown. (C) SFN-induced expression of TGF-b receptors I and II protein level after 1 h of incubation. Caco-2 cells were
treated without (control) and with SFN (5–50mM). Whole-cell lysates were prepared and TGF-b receptors I and II protein expression were
determined by Western blotting using either anti-TGF-b receptors I (52 kDa) and II (110 kDa) antibodies. Representative immunoblots of
three independent experiments are shown. po0.01, po0.001 versus control. (D) Caco-2 cells were treated with SFN (10–20 mM) or
vehicle for 1 h of incubation. DNA was cross-linked to proteins before harvesting. Chromatin immunoprecipitation (ChIP Assay) was
performed against acetylated histone H3, and after DNA isolation and reversal of cross-linking, primers specific for TGF-b receptor II
(101 bp) were used during PCR amplification. Results were normalized to b-actin (156 bp), and expressed relative to control, which was
assigned an arbitrary value of 1.0. Graph presents the densitometric analysis after 1 h (mean7SE (n5 3);  po0.05,  po0.001 versus
control). (E) Caco-2 cells were treated with SFN (10–20 mM) or vehicle for 1 h of incubation. DNA was cross-linked to proteins before
harvesting. ChIP Assay was performed against acetylated histone H4, and primers specific for TGF-b receptor II (101 bp) were used during
PCR amplification. Results were normalized to b-actin (156 bp), and expressed relative to control, which was assigned an arbitrary value of
1.0. Graph presents the densitometric analysis after 1 h. (F) Cell proliferation of Caco-2 cells after simultaneous treatment with SFN
(5–20 mM) and TGF-b (20 nM) for 24 h. Values represent mean7SE (n5 3); po0.01, po0.001 versus control.
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acetylation status of histone H3 as well as histone H4
associated with the TGF-bRII promoter (Fig. 3D and E).
After 1 h, accumulation of RII with highly acetylated histone
H3 was observed in SFN-treated Caco-2 cells in comparison
to untreated control cells (po0.001) (Fig. 3D). This SFN
effect on RII is selective because the b-actin gene was not
affected and obviously specific for acetylated H3 since
acetylated histone H4 was not associated with the TGF-bRII
gene after incubation with SFN for 1 h (Fig. 3E). The
observed accumulation of acetylated histone H3 indicated
histone acetylation to be involved in the transcriptional
induction of RII and further suggests the importance of
HDAC inhibitory properties of SFN in the regulation of
TGF-b signaling. In earlier works, Osada et al. already
demonstrated that HDAC inhibitors can increase the tran-
scriptional activity of TGF-bRII in vivo and in vitro in human
cancer cell lines [17]. In addition to these findings, Lee et al.
reported [47] that another HDAC inhibitor MS-275 induces
the accumulation of acetylated histones in the chromatin of
the TGF-bRII gene, which is associated with an increase of
TGF-bRII mRNA in human breast cancer cells, contributing
to the restoration of TGF-b signaling. As both TGF-bRI and
TGF-bII protein levels were regulated by SFN, we were
interested to know whether co-incubation with exogenous
Figure 4. (A) Western blot of pSmad2 and pSmad3 in Caco-2 cells after incubation with SFN (5–50 mM) for 1 h. One representative
immunoblot of three independent experiments for both proteins is shown. The bar graphs present densitometric analysis of the Western
blot images normalized to b-actin (mean7SE; po0.01, po0.001 versus control). (B) The pGL3-SBE4-luc reporter gene construct
(800 ng) alone and in combination with the expression vectors pCGN-Smad3/pCGN-Smad4 (100 ng each) and 20 ng SV-40-renilla were
transiently transfected into Caco-2 cells via lipofection. Cells were treated without (control) or with SFN (20 mM) for 6 h before luciferase
activity was determined. Results are presented as relative light per units (RLUs) in percentage of control, normalized to transfection
efficiency (cotransfection of SV-40-renilla) and normalized to effects of the empty vectors pCGN and pGL3basic (mean7SE (n5 3);
po0.01, po0.001 versus untreated cells). (C) Cell proliferation of Caco-2-cells treated with SB431542 (10 mM) and SFN (5–20 mM).
BrdU incorporation was measured after 24 and 48 h of incubation (mean7SE (n5 3); po0.01, po0.001 versus control).
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TGF-b (20 nM) might amplify SFN-mediated reduction of
cell proliferation in Caco-2 cells. For this, we analyzed BrdU
incorporation after 24 h of treatment, but could only detect
significant additive effects at a concentration of 5 mM SFN
(po0.01) (Fig. 3F). That, in accordance with our above-
mentioned findings on intracellular TGF-b levels, lets us
hypothesize that higher doses of SFN might lead to intra-
cellular TGF-b-saturation and thus resistance to exogenous
TGF-b.
Upon ligand binding, receptors of the TGF-b family
generally phosphorylate Smad proteins, which then move
into the nucleus where they activate transcription of differ-
ent target genes. For responding to the question whether
SFN-mediated TGF-b-signaling also involves an activation of
Figure 5. (A) Either pGL3-c-myc-luc or pGL3-c-myc-luc (DSBE) (400 ng) and 15 ng CMV-renilla were transiently transfected into Caco-2 cells
via lipofection. Cells were treated with SFN (20 mM) or TGF-b (20 ng) for 6 h before luciferase activity was determined. Each experiment
was performed in triplicates. Results are presented as mean7SE of at least three independent experiments after normalization for
transfection efficiency by cotransfection of CMV-renilla. Results are expressed with respect to pGL3-cotransfected cells (po0.01,
po0.001 versus control). (B) Western blot of ODC protein in Caco-2 cells after 6 h of incubation with SFN (20 mM) or/and SB431542
(10 mM). One representative immunoblot of three independent experiments for both proteins is shown. The bar graphs present densi-
tometric analysis of the Western blot images normalized to b-actin (mean7SE; (n5 3); po0.001 versus control; po0.01 versus SFN).
(C) Activity of ODC after simultaneous treatment with SFN (20–50 mM) and/or SB431542 (10mM) in Caco-2 after 24 h of incubation
(mean7SE; (n5 3); values not sharing a letter differ significantly, po0.05).
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Smads, we first analyzed the phosphorylation status of
Smad2 and Smad3 in Caco-2 cells after 1 h of incubation
with increasing concentrations of SFN, which was found to
be significantly induced in a dose-dependent manner
(Fig. 4A) (po0.001). Then, we performed reporter gene
assays with SBE4luc, where four SBEs are cloned in the
pGL3-vector. Reporter gene activity of SBE4luc was signifi-
cantly induced by SFN (po0.01), whereas the induction
could be further enhanced when expression vectors pCGN-
Smad3/pCGN-Smad4 were cotransfected (po0.001)
(Fig. 4B). To give the direct evidence that SFN mediates
growth inhibitory effects, at least partly via induction of the
TGF-b-signaling pathway, we simultaneously treated the
cells with SFN and the specific TGF superfamily type 1
activin receptor-like kinase inhibitor SB431542 alone and in
combination and measured the BrdU incorporation after 24
and 48 h (Fig. 4C). In fact, cell growth inhibitory effects of
SFN were largely abolished by SB431542 (po0.001).
3.3 Involvement of the TGF-b signaling pathway in
SFN-induced inhibitory effects on ODC
expression and activity in Caco-2 cells
Since Smad proteins were able to suppress c-myc activity in
human skin epithelial cells by directly binding to Smad-
responsive elements in the c-myc promoter [48], we were
interested whether the observed downregulation of c-myc
protein by SFN might also be due to an activation of Smad
signaling. Therefore, we have done reporter gene assays
after 6 h of SFN-treatment on Caco-2 cells either transfected
with wild-type c-myc-luc or with c-myc-luc bearing mutated
SBEs. TGF-b was used as a positive control. While in Caco-2
transfected with the wild-type construct, both SFN and
TGF-b significantly decreased reporter gene activity
compared to untreated cells (po0.001), no effects could
be observed in cells transfected with a mutated c-myc-
promoter (Fig. 5A). We conclude that due to the mutation in
the SBEs, Smads could not efficiently bind to the promoter
resulting in an abolishment of the SFN- and TGF-b-medi-
ated inhibition of c-myc gene activity.
Controversial data exist about the effects of TGF-b on
polyamine metabolism. On the one hand, TGF-b has been
shown to induce ODC mRNA in H-ras-transformed fibro-
sarcoma cell lines on which TGF-b acts as a growth stimu-
lator [49]. On the other hand, Motyl et al. [50] could
demonstrate that TGF-b suppresses both cell growth and the
activities of ODC and S-adenosyl-L-methionine decarboxy-
lase in a human chronic myelogenous lymphoma cell line.
Similar results were found in the group of Nishikawa et al.
[51], showing inhibitory effects of TGF-b on polyamine
metabolism. In accordance with these publications and
since our results revealed an involvement of the TGF-b
signaling pathway in SFN-mediated downregulation of the
c-myc promoter, we suggested that modulation of TGF-b
signaling might also affect downstream ODC expression
and activity. Indeed we could observe that co-incubation
of SFN with a specific TGF-b kinase inhibitor partly abol-
ished SFN-induced reduction of ODC protein expression
(Fig. 5B) and activity (Fig. 5C), which might be due to direct
TGF-b/Smad signaling-mediated transcriptional repression
of transcription factor c-myc, upstream of the ODC gene.
This effect was investigated in detail by Chen et al., who
could demonstrate that repression of c-myc expression by
TGF-b occurs by direct interaction of a repressor complex
consisting of Smad3 the transcription factors E2F4/5
and DP1 and the retinoblastoma family member p107
with a regulatory Smad responsive element in the c-myc
promoter [52].
4 Concluding remarks
In summary, the present study clearly points out that SFN
mediates growth inhibitory effects in colorectal cancer cell
lines, at least partly, via TGF-b-dependent inhibition of
c-myc and thus reduced protein expression and activity
of proto-oncogene ODC. Noting the fact that colorectal
cancer is still one of the most commonly occurring malig-
nancies worldwide, the use of nontoxic agents like SFN,
which inhibit specific molecular steps in the carcinogenic
pathway, might be a promising strategy for cancer chemo-
prevention.
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Abstract The objective of this study was to investigate,
whether the plant-derived isothiocyanate Sulforaphane
(SFN) enhances the antitumor activities of the chemo-
therapeutic agent oxaliplatin (Ox) in a cell culture model
of colorectal cancer. Caco-2 cells were cultured under
standard conditions and treated with increasing concen-
trations of SFN [1–20 lM] and/or Ox [100 nM–10 lM].
For co-incubation, cells were pre-treated with SFN for
24 h. Cell growth was determined by BrdU incorpora-
tion. Drug interactions were assessed using the combi-
nation-index method (CI) (Cl \ 1 indicates synergism).
Apoptotic events were characterized by different ELISA
techniques. Protein levels were examined by Western
blot analysis. Annexin V- and propidium iodide (PI)
staining followed by FACS analysis was used to differ-
entiate between apoptotic and necrotic events. SFN and
Ox alone inhibited cell growth of Caco-2 cells in a
dose-dependent manner, an effect, which could be
synergistically enhanced, when cells were incubated with
the combination of both agents. Co-treated cells further
displayed distinctive morphological changes that occur-
red during the apoptotic process, such as cell surface
exposure of phosphatidylserine, membrane blebbing as
well as the occurence of cytoplasmic histone-associated
DNA fragments. Further observations thereby pointed
toward simultaneous activation of both extrinsic and
intrinsic apoptotic pathways. With increasing concentra-
tions and treatment duration, a shift from apoptotic to
necrotic cell death could be observed. In conclusion, the
data suggest that the isothiocyanate SFN sensitizes colon
cancer cells to Ox-induced cell growth inhibition via
induction of different modes of cell death.
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Introduction
Despite a markedly improved understanding of the disease,
the advent of modern technology and rationally targeted
drugs over the past years, colorectal cancer (CRC) remains
a leading cause of cancer-related deaths worldwide [1].
Current treatment options involve the combination of a
variety of chemotherapeutic drugs, more recently including
the anticancer drug oxaliplatin (Ox). Ox is a third gener-
ation platinum-based drug, which has shown a broad
spectrum of antitumor activities in a wide range of cancer
cell lines by disrupting DNA replication and transcription
by forming intrastrand DNA adducts [2]. It further dem-
onstrates a better safety profile than platinum analogs of the
first-(cisplatin) and second-(carboplatin)-generation and is
typically administered in combination with different drugs
as part of specific cancer-treatment regimens, e.g. Ox plus
5-Fluorouracil and leucovorin (referred to as FOLFOX),
Ox plus capecitabine (XELOX) or Ox plus cetuximab
(CAPOX). Such oxaliplatin-based combination regimens
show improved clinical efficacy as related to overall
response rates, time to tumor progression, median overall
survival in patients with metastatic colorectal cancer and
especially offer an alternative treatment option against
cisplatin resistant tumors [3–5]. However, even though
conventional cancer therapies play a major role in cancer
treatment, successful therapeutic outcome is often limited
due to high toxicity as well as the development of multi-
drug resistance. It is therefore of particular importance to
investigate further drug combinations for the development
of new therapeutic regimens obtaining higher efficacy,
while, at the same time minimizing unwanted side effects,
which could significantly improve patients outcome.
Emerging evidence suggests that combining chemopre-
ventive agents with chemotherapy or radiotherapy may
lead to enhanced antitumor activity through synergistic
action or compensation of inverse properties. Besides a
multitude of synthetic substances, also numerous phyto-
chemicals have been identified to exhibit potent chemo-
preventive effects in different carcinogenesis models while,
at the same time showing low toxicity [6]. SFN is a natu-
rally occuring isothiocyanate derived from cruciferous
vegetables such as broccoli, cauliflower, cabbage and kale,
which targets cancer initiation and progression both in vitro
and in vivo, and further induces antiproliferative and
cytotoxic effects in cells that are already transformed [7].
Recently, SFN was identified as a novel histone deacetyl-
ase inhibitor (HDACi) in colon and prostate cancer cells
[8]. HDACi, as a new class of chemotherapeutic agents,
show significant promise against a variety of cancers in
clinical trials [9]. Most available HDACi inhibit all class I
and II HDACs, thereby increasing acetylation of histone
and nonhistone protein targets [10]. In vivo, histone acety-
lation depends on the balance between histone acetyltrans-
ferase (HAT) and histone deacetylase (HDAC), which has
been proposed to play an important role in transcriptional
regulation by altering chromatin structure [11]. Histone
acetylation by HATs is associated with an open chromatin
conformation, promoting gene transcription, whereas
HDACs maintain the chromatin in the closed, transcrip-
tionally inactive state. HDAC inhibitors have been shown to
induce the expression of several tumor suppressive genes,
which justifies its use in cancer prevention and therapy [12].
Several studies indicate that SFN causes growth inhibi-
tion of human cancer cells predominantly by inducing
apoptosis and/or blocking cell cycle progression [13, 14].
Apoptosis is defined as an active physiologic process of
cellular self-destruction, with specific morphologic and
biochemical changes characterized by DNA fragmentation,
cell shrinkage, nuclear condensation and membrane bleb-
bing [15, 16]. At present, two major apoptosis pathways
have been identified: the intrinsic or mitochondrial pathway
and the extrinsic or death receptor-related pathway. While
the extrinsic pathway is activated through cell surface death
receptors binding their respective cytokine ligands, such as
TRAIL [17], the intrinsic pathway depends on mitochon-
drial membrane permeabilization, which causes the release
of apoptogenic factors from the intermembrane space to the
cytoplasm. Prevalently, both pathways result in the activa-
tion of members of the caspase family converging at the
level of caspase-3 [18]. However, apoptotic events can also
be observed in the absence of caspase-3 activation,
depending on the cell type and the apoptosis initiating pro-
cess [19, 20]. Apart from apoptosis, alternative forms of cell
death can be activated, e.g. necrosis or autophagy, which
might also lead to biological consequences differing from
apoptosis [21]. In the present study, we addressed the ques-
tion whether plant-derived sulforaphane is able to enhance
the anticarcinogenic activities of the common chemotherapy
drug oxaliplatin in colorectal cancer cells with special regard
to regulatory effects on the cell death machinery.
Materials and methods
Cell culture
Caco-2 cells were kept in Dulbecco’s modified Eagle’s
medium (DMEM), supplemented with 10% fetal calf
serum (FCS), 1% penicillin/streptomycin, 1% sodium
pyruvate and 1% nonessential amino acids. Human fore-
skin fibroblasts (HFF) were cultured in DMEM/Ham’s
F-12 medium supplemented with 10% FCS and 1% peni-
cillin/streptomycin. Both cell lines were maintained at
Cancer Chemother Pharmacol
123
37C in an atmosphere of 95% air and 5% CO2. The cells
were passaged weekly using Dulbecco’s PBS containing
0.1% trypsin and 1% EDTA. The medium was changed
thrice weekly. Cells were screened for possible contami-
nation with mycoplasma at monthly intervals. For experi-
ments, the cells were seeded onto plastic cell culture
wells in serum-containing medium and allowed to attach
for 24 h. Sulforaphane (Merck Chemicals, Darmstadt,
Germany) was dissolved in DMSO at a concentration of
100 mM, oxaliplatin (Sigma–Aldrich, Mu¨nchen, Germany)
was dissolved in water at a concentration of 10 mM.
DMEM, DMEM/Ham’s F-12 medium, DMSO, sodium
pyruvate solution, penicillin and streptomycin stock solu-
tions were all obtained from PAA Laboratories GmbH.
When synergistic effects were analyzed, the cells were pre-
treated with SFN for 24 h.
Cell proliferation assay
The effect of SFN, Ox or their combination on cellular
DNA synthesis was assessed using a cell proliferation
ELISA kit (Roche Diagnostics, Mannheim, Germany).
This assay is a colorimetric immunoassay for quantification
of cell proliferation based on the measurement of bromo-
deoxyuridine (BrdU) incorporation during DNA synthesis
and is a nonradioactive alternative to the [3H]-thymidine
incorporation assay. Cells were grown in 96-well culture
dishes (103 cells/well), incubated with SFN and/or Ox for
different time intervals, and then labeled with BrdU for
further four hours. Incorporated BrdU was measured
colorimetrically.
Combination index (CI)
To assess the drug interactions of SFN and Ox, we used the
combination-index (CI) method defined by median-effect
analysis of Chou and Talalay [22]. The fractional inhibitory
concentration was calculated by dividing the IC50 con-
centration of the drug in the combination by the amount of
the drug that is required to reach the same degree of
inhibition (IC50) by itself.
CI =
dose of SFN
IC50 SFNð Þ þ
dose of Ox
IC50 Oxð Þ
In this equation, the sum of the dose of SFN and the
dose of Ox give 50% inhibition of cell growth. Cl \ 1
indicates a synergistic effect; Cl = 1, additive effect; and
Cl [ 1, antagonistic effect [23].
Determination of ATP level
Caco-2 cells were grown in 96-well culture dishes
(103 cells/well) and allowed to grow overnight. Cell
Viability Assay Kit (ApoSENSORTM, BioVision, CA,
USA) was used according to the manufacturer’s instruc-
tions following a 6-h exposure to SFN and Ox alone and in
combination. The assay utilizes luciferase to catalyze the
formation of light from ATP and luciferin, and the light can
be measured using a luminometer. Changes in ATP levels
were determined by comparing the results with the levels
of untreated cells (control).
Annexin V-FITC/PI double-labeled flow cytometry
To discriminate between apoptotic and necrotic cell sub-
populations, simultaneous staining with Annexin V-FITC
and propidium iodide was performed. Cells incubated with
SFN and/or Ox drugs for 5 and 24 h were harvested with
accutase for 30 min. After centrifugation, cells were
resuspended in 100 lL binding buffer mixed with 5 lL
Annexin V-FITC (ImmunoTools, Friesoythe, Germany)
and 5 ll PI and then incubated in dark for 10 min at 4C.
Fluorescence was measured with a flow cytometer.
Determination of DNA fragmentation
Nuclear fragmentation as a late marker of apoptosis was
determined by (1) DNA staining with SYTOX Green and
(2) quantification of cytoplasmic histone-associated DNA
fragments. For SYTOX Green staining, cells (1 9 106)
were seeded onto glass slides and incubated in Quadriperm
wells with the test compounds for 48 h. Thereafter, glass
slides were washed with PBS, and cells were fixed with 2%
paraformaldehyde. DNA was stained with 0.25 lM
SYTOX Green solution (Invitrogen, Karlsruhe, Germany)
and then visualized under an epifluorescence microscope
(Zeiss Axioskope 2).
Cytoplasmic histone-associated DNA fragments in
control and treated cells were quantified using a commer-
cially available ELISA kit (Roche Diagnostics). Briefly,
Caco-2 cells were grown in 96-well culture dishes
(103 cells/well) and allowed to grow overnight. The cells
were then incubated with or without (control) the test
substances. After 24 h of treatment, the cells were centri-
fuged with 2009g for 10 min and the supernatant con-
taining DNA from necrotic cells was removed. The cell
pellet was resuspended in 200 ll lysis buffer and incubated
for 30 min followed by centrifugation at 2009g for
10 min. Then 20 ll of the supernatant were transferred to
streptavidin-coated wells in a mircotiter plate. The super-
natant aliquots were incubated for 2 h at room temperature
with 80 ll of an immunoreagent containing monoclonal
antibodies against histone (biotinlabeled) and DNA (per-
oxidase-conjugated), with which the nucleosomes in the
supernatant bind. The immobilized antibody–histone
complexes were washed three times with incubation buffer
Cancer Chemother Pharmacol
123
to remove cell components that were not immunoreactive.
Then 100 ll ABTS solution was added to each well, and
the plates were incubated at room temperature on a plate
shaker at 250 rpm for 20 min. Finally, the amount of col-
ored product and thus of the immobilized antibody–histone
complexes (DNA fragments) in the plate was measured
spectrophotometrically at 405 nm on a microplate spec-
trophotometer (Fluostar Optima, BMG Labtech, Durham,
NC) using ABTS solution as a blank control.
Mitochondrial membrane potential (DWm) analysis
Cell cultures were seeded into cultivation flasks at a den-
sitiy of 1 9 105 cells/well and allowed to grow overnight.
Cells were stained with JC-1, as a component of the JC-1
Mitochondrial membrane potential Assay Kit (Cayman
Chemical Company, Ann Harbor, MI) following a 6- and
24-h exposure to SFN and Ox alone and in combination.
JC-1 is a lipophilic, cationic dye that can selectively enter
into mitochondria and reversibly change color from green
to red as the membrane potential increases. Changes in
DWm were finally assessed by microfluorimetry analysis
using TECAN SpectraFluor Plus (TECAN Austria GmbH,
Gro¨dig, Austria) and indicated as changes of red/green
ratio.
Caspase-3 activity assay
Caco-2 cells were seeded in 80-cm2 flasks, allowed to grow
overnight. Caspase-3 activity was analyzed using a fluo-
rometric immunosorbent enzyme assay (Roche Diagnos-
tics) according to the manufacturer’s instructions. Briefly,
after 24 h of incubation with the test substances, the cells
were incubated with lysis buffer for 10 min. After cell lysis
and following centrifugation, samples were removed and
transferred to the anti-caspase-3-coated wells of a micro-
plate, capturing caspase-3. After 1 h, the immobilized
antibody-caspase-3 complexes were washed three times to
remove cell components that are not immunoreactive.
Afterward, samples were incubated with caspase substrate
(Ac-DEVD-AFC) for 120 min that is proteolytically
cleaved into free fluorescent AFC. Then the AFC can be
measured fluorometrically at excitation 430 nm and emis-
sion 535 nm. Finally, protein concentrations were mea-
sured and adapted to the activity.
SDS–polyacrylamide gel electrophoresis
and immunoblot analysis
Caco-2 cells were seeded in 80 cm2 flasks; 24 h after plating,
cells were incubated with substances for 6 h. After washing
the cells for three times with ice-cold PBS, followed by an
incubation step with cell lysis buffer (Cell signalling,
Berverly, MA) containing multiple protease inhibitors
(Complete Mini, Roche) for 20 min at 4C, cells were
harvested by scraping. Protein extracts were obtained after
sonication of cell lysates (2 9 5 s) and centrifuged at
10,000 rpm for 10 min at 4C. Samples were analyzed for
their protein content using the BioRad colorimetric assay
according to the method of Bradford (BioRad Laboratories).
After addition of sample buffer (Roti Load, Roth,
Karlsruhe, Germany) to the total cellular extract and boiling
for 5 min at 95C, 30–40 lg of total protein lysate was
separated on a 10 or 12% SDS–polyacrylamide gel. Protein
was transferred onto nitrocellulose membrane (Schleicher
&Schuell, Dassel, Germany), and the membrane was
blocked for one hour at room temperature with 5% skimmed
milk in Tris–buffered saline containing 0.05% Tween 20
(TBS-T). Next, blots were washed and incubated overnight
at 4C in TBS-T containing either 5% bovine serum albu-
minate (BSA) or 5% skimmed milk with a 1:1,000 or 1:2,000
dilution of primary antibodies for PARP, full length as well
as cleaved Caspase-8 (all from Cell Signaling, Berverly,
MA) and TRAIL (from Santa Cruz Biotechnology,
Heidelberg, Germany). The secondary, horseradish peroxi-
dase-conjugated, antibody (Santa Cruz Biotechnology) was
diluted at 1:2,000 or 1:4,000 and incubated with the
membrane for another 60 min in skimmed milk. After
chemoluminescence reaction (ECL, Amersham pharmacia
biotech, Wien, Austria), bands were detected after exposure
to Hyperfilm-MP (Amersham International plc, Bucking-
hamshire, UK). Blots were reprobed with b-actin antibody
(Santa Cruz Biotechnologies).
Cytotoxicity
Cytotoxicity was analyzed by measuring lactate dehydro-
genase (LDH) release using a commercially available kit
(Cytotoxicity detection kit (LDH), Roche). For this, HFF
were incubated with SFN and/or Ox for 24 h. Triton X-100
(2%) was used as a positive control. After centrifugation at
2509g for 10 min, the supernatant was carefully removed
and transferred into corresponding wells of an optically
clear 96-well flat bottom microplate. To determine the
LDH activity in these supernatants, 100 ll reaction mixture
was added and the samples were incubated for up to
30 min. Finally, the absorbance of the samples was mea-
sured at 490 nm.
Statistics
The data are expressed as means ± SE of at least three
independent experiments. Results were analyzed using
GraphPad Prism 4.01 (San Diego, CA, USA) by a two-way
ANOVA. A P value \0.05 was considered to be
significant.
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Results
Effects of single-drug exposure on cell proliferation
of Caco-2 cells
Effects of SFN [1–50 lM] and Ox [100 nM–10 lM] on
Caco-2 cell proliferation were assessed after 24 h of drug
exposure (Fig. 1a, b). Both substances significantly inhibit
proliferation in Caco-2 cells in a dose-dependent manner
(*P \ 0.5, **P \ 0.01, ***P \ 0.001 vs. control). The
IC50s for SFN and Ox in Caco-2 cells were 26.35 and
5.58 lM, respectively.
Synergistic antiproliferative effects of SFN and Ox
For studying combination effects, the cells were exposed to
both SFN and Ox simultaneously for 24 h. As shown in
Fig. 1c, co-treatment of the cells significantly reduced the
IC50 values of the single drugs. The obtained data were
analyzed by the CI method of Chou and Talalay [22]. In
Caco-2 cells, we calculated a CI of 0.3, which indicates
synergism (see ‘‘Materials and methods’’).
Effects of SFN/Ox on different apoptotic events
ATP/ADP ratio: Changes in the intracellular ATP/ADP ratio
are a useful indicator to distinguish between different modes
of cell death and viability. Although decreasing ATP and
increasing ADP levels are generally found in apoptotic cells,
cells will rather undergo necrosis when intracellular ATP
levels fall below a critical threshold [24]. For a rapid
screening of cell death, we therefore treated Caco-2 cells for
1–24 h with SFN [10–20 lM] and Ox [500 nM] alone and in
combination and measured effects on the ATP/ADP ratio. As
can be seen from Fig. 2a, incubation with SFN and Ox
resulted in a significant time- and, at least after 6 h, also
dose-dependent reduction in intracellular ATP, which
reaches a maximum after 24 h (***P \ 0.001). As a positive
control, we used staurosporine [0.5 lg/ml], a well-known
inducer of apoptosis [25].
DNA Fragmentation: As DNA cleavage is another
hallmark for apoptosis, we further quantified histone-
complexed DNA fragments in Caco-2 after 24 h of treat-
ment. SFN [20 lM], in contrast to Ox [500 nM], thereby
leads to a significant increase of cytoplasmic histone-
associated DNA fragments, an effect which could be fur-
ther enhanced, when the drugs were used in combination
(Fig. 2b) (***P \ 0.001).
Caspase-3 Activity: The activity of the effector caspase-
3 was significantly activated 24 h after stimulation with
SFN [20 lM] and Ox [500 nM], respectively, but this
effects were not very prominent when compared to the
positive control staurosporine. However, SFN could sig-
nificantly enhance the Ox-induced effects (Fig. 2c)
(***P \ 0.001), which is in agreement with the observed
cleavage of PARP (Fig. 2d) (***P \ 0.001), a classical
substrate for activated caspase-3. Proteolysis of PARP
usually is an indicator for early apoptotic events.
Extrinsic and intrinsic apoptotic events: In the next step,
we measured protein levels of the TNF-related apoptosis-
inducing ligand (TRAIL) as well as of full length and
cleaved caspase-8, both markers of the extrinsic or death
receptor-mediated apoptotic pathway. In some tumor cell
lines, TRAIL protein expression could be induced by
chemopreventive agents resulting in TRAIL-mediated
apoptosis in an autocrine or paracrine manner [26–28].
This suggests that induction of endogenously expressed
TRAIL after SFN/Ox-treatment for 6 h (Fig. 3a) may fur-
ther enhance their therapeutic outcome. Additionally, co-
stimulation resulted in a decrease of procaspase-8 and an
increase of cleaved caspase-8 after 6 h of treatment, a
common upstream event of caspase-3 activation (Fig. 3b).
Fig. 1 a, b Inhibition of cell proliferation of Caco-2 by 24 h exposure
to SFN and Ox alone. Values represent mean ± SE (n = 8);
*P \ 0.05, **P \ 0.01, ***P \ 0.001 versus control. c The combined
effects of concurrent treatment with SFN and Ox on Caco-2 cells. Cell
proliferation was measured by BrdU incorporation after 24 h of
incubation. CI values were determined by the method of Chou and
Talalay [22] described in ‘‘Materials and methods’’. Values represent
mean ± SE (n = 3); **P \ 0.01, ***P \ 0.001 versus control
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Next, we determined whether both agents might also
increase mitochondrial membrane depolarization as a
consequence of the activation of the intrinsic apoptotic
pathway. For this, cells were incubated with SFN
[20 lM] and Ox [500 nM] alone and in combination for
6 and 24 h before being stained with JC-1 (Fig. 3c). JC-1
is a mitochondrial-selective dye and forms aggregates in
normal polarized mitochondria that result in a green
orange emission of 590 nm after excitation at 490 nm.
Upon depolarization of the mitochondrial membrane,
JC-1 forms monomers that emit only green fluorescence
at 527 nm. As shown in Fig. 3c, SFN induced a depo-
larization of the mitochondrial membrane potential,
which was significant after 24 h of treatment. In contrast
to SFN, Ox-treatment did not show any detectable
effects, neither after 6 nor 24 h of incubation. However,
combinatorial treatment resulted in a distinct decrease of
the red-green fluorescence intensity ratio after 6 h
(**P \ 0.01) and 24 h (***P \ 0.001). These observa-
tions pointed toward involvement of both extrinsic and
intrinsic apoptotic pathways in SFN/Ox-mediated induc-
tion of apoptosis.
Fig. 2 a Intracellular content of ATP in control (untreated), SFN-
and/or Ox- as well as staurosporine (0.5 lg/ml)-treated cells. Caco-2
cells were incubated with the test substances for 1–24 h. Results are
expressed as the percentage of control. Values represent mean ± SE
(n = 4); *P \ 0.05, **P \ 0.01, ***P \ 0.001 versus control.
b Quantification of cytoplasmic histone-associated DNA after 24 h
of incubation with the test compounds. Values represent mean ± SE
(n = 4); ***P \ 0.001. c Effects of SFN, Ox, their combination and
staurosporine on activation of caspase-3 in Caco-2 cells after 24 h of
exposure. Results are expressed as the percentage of control. Values
represent mean ± SE (n = 4); *P \ 0.05, ***P \ 0.001. d Western
blot analysis for PARP cleavage using whole cell extracts from Caco-
2 cells exposed to SFN and Ox, separately or in combination, for 6 h.
The bar graph presents densitometric analysis of the Western blot
images normalized to b-actin (mean ± SE; (n = 3); ***P \ 0.001.
Representative immunoblots of three independent experiments are
shown
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Switching from apoptosis to necrosis with increasing
concentrations of SFN/Ox
Even though increasing concentrations of Ox/SFN
[e.g. 1/20 lM] can further potentiate the observed effects on
cell growth inhibition shown in Fig. 1 (data not presented
here), these effects seem not to be explainable by enhanced
induction of apoptosis, as DNA fragmentation for example
could not be further amplified with increasing concentrations
of oxaliplatin (Fig. 2b), indicating other modes of action.
Thus, to discriminate between different modes of cell death,
Caco-2 cells treated with SFN [20 lM], Ox [500 nM–1 lM]
alone and in combination for 5 and 24 h were analyzed by
Annexin V-FITC/PI labeling and flow cytometry. The
degree of apoptosis thereby was quantitatively expressed as a
percentage of the Annexin V-FITC-positive but PI-negative
cells, while necrosis or late apoptosis was quantitatively
expressed as a percentage of PI-positive or Annexin V-FITC/
PI double-stained cells. Analysis after 5 h was chosen in
order to differentiate between primary and secondary
necrosis as a result of late apoptosis. Interestingly at this time
point, Annexin V-FITC-positive but also PI-positive cells
could be measured indicating direct necrotizing effects of
SFN and Ox (Fig. 4a, b). Compared to the 5-h treatment, the
population of apoptotic cells in untreated and SFN [20 lM]-
as well as Ox [500 nM–1 lM]-treated Caco-2 cells (Fig. 4c,
d) seems to decline after 24 h. However, the rate of apoptosis
was still significantly induced in the co-treated cells, but
again this effect could not be further increased with a
higher concentration of Ox [1 lM]. Rather, at this con-
centration, a distinct population of PI-stained cells could
be observed, whereas a mixture of cells undergoing rapid
primary as well as secondary necrosis/late apoptosis can
be assumed (Fig. 4b). Obviously, apoptotic effects seem
to reach a maximum after 5 h of treatment, which is
replaced by a shift toward an increased population of
necrotic cells after 24 h.
These observations could also be confirmed by SYTOX
Green staining (Fig. 5), which was used to analyze late
apoptosis. SYTOX Green nucleic acid stain is an unsym-
metrical cyanine dye with three positive charges that is
completely excluded from live eukaryotic and prokaryotic
cells. Binding of SYTOX Green stain to nucleic acids
of Caco-2 cells incubated with SFN [20 lM] and Ox
[500nM] clearly presents signs of apoptotic events indi-
cated by cell shrinkage, chromatin condensation and the
formation of apoptotic bodies (see white arrows in Fig. 5a,
c). However, again with increasing concentrations of Ox
[1 lM], necrotic alterations like osmotic swelling and cell
lysis with loss of membrane integrity became more
prominent (Fig. 5c).
Taken together, these observations clearly indicate that
depending on the applied concentration and the treatment
duration, antiproliferative effects of SFN/Ox against Caco-
2 cells can be associated with both apoptotic as well as
necrotic events.
Fig. 3 a Western blot analysis for TRAIL in Caco-2 cells after
incubation with SFN [20 lM] and/or Ox [100–500 nM] for 6 h. A
representative immunoblot of three independent experiments is shown.
The bar graph presents densitometric analysis of the Western blot
images normalized to b-actin (mean ± SE (n = 3); *P \ 0.05,
**P \ 0.01, ***P \ 0.001). b Western blot analysis for caspase-8,
full length and cleaved, using whole cell extracts from Caco-2 cells
exposed to SFN and/or Ox for 6 h. A representative immunoblot of
three independent experiments is shown. The bar graph presents
densitometric analysis of the Western blot images normalized to b-actin
(mean ± SE (n = 3); *P \ 0.05, ***P \ 0.001). c Loss of mitochon-
drial membrane potential (DWm) in Caco-2 cells exposed to SFN and
Ox, alone or in combination, after 6 and 24 h of treatment. Results
represent mean of at least three experiments, *P \ 0.05, **P \ 0.01,
***P \ 0.001
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Fig. 4 Effects of SFN and Ox,
separately and in combination,
on Annexin V-FITC and/or PI
staining of Caco-2 cells after 5
(a) and 24 h (c) of incubation.
Cells were analyzed by flow
cytometry as described in
‘‘Materials and methods’’.
The percentage of apoptotic and
necrotic (b, d) cells versus
control as a result of the FACS
analysis are presented by bar
graphs. Values represent
mean ± SE (n = 4),
quantifying a minimum of
10,000 cells per treatment
(*P \ 0.05, **P \ 0.01,
***P \ 0.001)
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Effects of SFN and Ox on cell proliferation and LDH
release of human foreskin fibroblasts (HFF)
To analyze a possible toxicity of SFN and oxaliplatin on
normal tissue cells, human foreskin fibroblasts were
treated with either SFN [10–20 lM] and Ox [500 nM–
1 lM] alone or in combination and cell proliferation as
well as LDH release as a marker of direct cytotoxicity
were measured after 24 h (Fig. 6). Actually, SFN alone
was found to significantly inhibit cell growth of HFF in
a dose dependent manner (*P \ 0.05; **P \ 0.01,
***P \ 0.001) (Fig. 6a), but in contrast to Caco-2 cells,
this effect was not further enhanced and no signs of
cytotoxicity could be observed when SFN was combined
with oxaliplatin (Fig. 6b).
Discussion
Oxaliplatin is now widely used in the treatment of advanced
colorectal cancers mostly in combination with continuous
intravenous infusions of 5-fluorouracil [3]. However,
adverse effects, e.g. acute and persistent neuropathy as well
as the development of chemotherapy resistance limit the
overall success of oxaliplatin-based treatment regimens.
Since several in vitro and in vivo studies show first promising
results regarding the chemosensitizing capability of phyto-
chemicals in different cancer models [6], we were interested,
whether plant-derived SFN might be able to enhance
Ox-induced antitumor activities in colorectal cancer cells,
also concerning modes of action that might help to overcome
drug resistance in cancer tissues.
Fig. 5 Sytox Green staining following a 48-h exposure to control or
different concentrations of the test compounds (a, c). Arrows indicate
morphological changes as a consequence of SFN/Ox-induced apop-
tosis. Experiments were repeated three times, and the results were
comparable. Data from a representative experiment are shown. The
percentage of apoptotic cells (b, d) cells versus control are presented
by bar graphs. Values represent mean ± SE (n = 3), ***P \ 0.001
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Most chemotherapeutic agents, including oxaliplatin, and
irradiation act primarily by inducing apoptosis, accordingly,
defects in the apoptotic pathway often account for chemo-
therapy resistance in different tumor cells, which could also
be demonstrated for drug resistance arising against oxalipl-
atin in colorectal cancer cells [29]. Novel targeted therapies
that more potently induce cell death in cancer cells or sen-
sitize them to established cytotoxic agents and radiation by
modulating the apoptotic machinery might therefore not
only enhance therapeutic outcome but can further help to
reverse chemotherapeutic drug resistance [30].
Our first results quickly revealed SFN-induced
potentiation of cell growth inhibition mediated by oxa-
liplatin, which was more-than-additive as indicated by
combination-index analysis. In addition, these effects were
accompanied by different hallmarks of apoptosis, such as
reduced ATP levels, Caspase-3 activation, PARP cleavage
and DNA Fragmentation. Further experiments could dem-
onstrate that thereby apparently both, extrinsic and intrinsic
apoptotic pathways were involved, as indicated by caspase-
8 cleavage and increased mitochondrial membrane per-
meabilization. Interestingly, we could also observe an
induction of TRAIL protein levels, a member of the TNF
family of cytokines, which can induce apoptotic cell death
in a variety of tumor cells by engaging the death receptors
DR4 and DR5, while sparing most normal cells [31]. This
might be due to the HDAC inhibitory properties of Sul-
foraphane [8], since several other HDAC inhibitors were
also shown to induce expression of TRAIL, DR4 or related
proteins, which contributed to subsequent apoptotic events
induced by these agents [32]. Since some drugs and radi-
ation sensitize tumor cells to TRAIL-induced cell death,
several studies have expectedly shown that combinations
of recombinant TRAIL and some chemotherapeutic drugs
exhibit synergistic effects in inducing tumor cell apoptosis
in vitro and in vivo [33, 34]. Whether endogenously
induced TRAIL possibly acts in a similar way remains to
be elucidated. Another interesting aspect is that TRAIL, in
contrast to DNA-damaging chemotherapeutic drugs or
radiation, induces apoptosis independently of p53 [31],
which might be helpful to circumvent resistance to con-
ventional chemotherapy and radiotherapy. However, in
contrast to known apoptosis inducers, such as staurosporin,
apoptotic events induced by SFN and Ox were not very
prominent and may only partly account for the observed
inhibition of cell proliferation.
In fact, with increasing concentrations of oxaliplatin and
increasing treatment duration, Annexin V and PI staining
revealed a shift from an apoptotic toward a distinct popu-
lation of necrotic cells (Fig. 4). Similar results were
observed in Sytox Green-stained cells, which showed
considerable signs for necrosis-like swelling of the organ-
elles or cell lysis with loss of membrane integrity (Fig. 5).
This is consistent with the almost complete ATP depletion
after 24 h of incubation, which may further account for the
low apoptotic response [35].
Currently, the majority of clinical chemotherapeutic
agents ultimately induce tumor cell apoptosis following
treatment, however, noting the facts that many cancers
have defective apoptosis machinery or aquire apoptosis
resistance during therapy [36], or the finding, that apoptosis
may be reversed in cancer cells [37], it is reasonable to
consider whether activating alternative cell death path-
ways, such as necrosis, may be another effective strategy
Fig. 6 a The combined effects of concurrent treatment with SFN and
Ox on HFF cells. Cell proliferation was measured by BrdU
incorporation after 24 h of incubation. Values represent mean ± SE
(n = 4); *P \ 0.05, **P \ 0.01, ***P \ 0.001 versus control.
b Effects of SFN and Ox, separately and in combination, on
cytotoxicity in HFF cells after 24 h of incubation. Results are
expressed as the percentage of control. Values represent mean ± SE
(n = 4); ***P \ 0.001
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for cancer therapy [38]. Unlike apoptosis that is largely
immune silent or immunosuppressive, therapy-induced
necrotic cell death initiates an immune response to tumor
cells [39]. This inflammatory response may help to recruit
cytotoxic immune cells to the tumor site, thereby increas-
ing the efficacy of the chemotherapeutic drugs. However,
conversely the pro-inflammatory conditions might also
damage normal tissues or induce the production of mito-
genic or prosurvival cytokines, which can activate signal-
ing pathways that promote cell excrescence in the damaged
area and might induce tumor cell migration and metastasis
[40, 41]. Further studies are therefore required to address
the question whether the inflammation associated with
necrosis might be desirable in the context of cancer treat-
ment or rather leads to further tumor growth or even
overshooting inflammation, leading to autoimmunity.
Interestingly, Ingenol-3-angelate, another plant-derived
compound, was recently shown to mediate its in vitro
anticancer activities via the induction of primary necrosis
[42, 43], as displayed by plasma membrane and
mitochondrial disruption leading to the activation of an
antitumor immune response [44]. Thus, the success of
Ingenol-3-angelate in phase IIa clinical trials against
human skin cancer might again support the importance and
potential of cytotoxic agents that act through irreversible
necrotic cell death. [45]. In healthy human fibroblasts, SFN
was found to inhibit cell growth in a dose-dependent
manner, an effect that was already reported for other
HDAC inhibitors [46, 47]. But in contrast to Caco-2 cells,
growth inhibitory effects on fibroblasts were not further
enhanced and no signs of cytotoxicity could be observed
when SFN was combined with oxaliplatin, indicating a
selective toxicity toward the tumor cell line while inducing
only growth arrest in normal fibroblasts.
Summarizing our findings, we could demonstrate for the
first time that the secondary plant-metabolite sulforaphane
is capable of amplifying Ox-induced cell growth inhibition
in colon cancer cells supposedly via induction of different
modes of cell death. Sulforaphane might thereby not only
be a promising candidate due to it’s potent chemopreven-
tive properties but also pharmacokinetic studies in both rats
and humans indicate that dietary absorbed SFN can be
distributed in the body, reach lM levels in the blood and is
capable of reaching target tissues in an active form, which
further supports the clinical relevance of the substance
[48, 49]. However, further experiments focusing intramo-
lecular mechanisms together with in vivo animal studies
and clinical trials are needed for eventually translating the
concept of phytochemicals in combination therapies of
human colorectal cancer into clinical applications.
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1 Introduction 
 
Colorectal carcinoma is one of the most 
prevalent human cancers in the world [1], 
and is frequently diagnosed at late stages 
that require chemotherapeutic treatment. 
Current treatment options involve the 
combination of a variety of 
chemotherapeutic drugs, more recently 
including the anticancer drug oxaliplatin 
(Ox). Ox is a third generation platinum-
based drug demonstrating a better safety 
profile than platinum-analogs of the first-
(cisplatin) and second-(carboplatin)-
generation [2]. It is typically administered 
in combination with other drugs as part of 
specific cancer-treatment regimens, e.g. Ox 
plus 5-Fluoruracil and leucovorin (referred 
to as FOLFOX), Ox plus capecitabine 
(XELOX) or Ox plus cetuximab 
(CAPOX). Although oxaliplatin-based 
combination regimens show improved 
clinical efficacy as related to overall 
response rates, time to tumor progression 
and median overall survival in patients 
with metastatic colorectal cancer [3, 4], 
successful therapeutic outcome is often 
limited due to high toxicity as well as the 
development of multi-drug resistance. 
Therefore, there is a growing need for the 
development of innovative anticancer 
therapies. In the last years, a new 
therapeutic concept of combining 
antitumor drugs with chemopreventive 
agents was introduced, which may lead to 
enhanced antitumor activity through 
synergistic action or compensation of 
inverse properties. Beside a multitude of 
synthetic substances, also numerous 
phytochemicals have been identified to 
exhibit potent chemopreventive effects in 
different carcinogenesis models while, at 
the same time, showing low toxicity [5]. 
Due to its wide range of biological and 
pharmacological effects, especially with 
regard to chemoprevention and the lack of 
toxicity in animal and human models, 
resveratrol might be such a promising 
agent for enhancing the effects of 
chemotherapy. The chemopreventive 
properties of resveratrol have thereby been 
explained mainly by its activities in cell 
cycle control and apoptosis induction [6].  
Apoptosis is morphologically defined by 
chromatin condensation, nuclear 
fragmentation, shrinkage of the cytoplasm, 
blebbing of the plasma membrane and 
formation of apoptotic bodies [7]. This 
physiological cell death is energy-
dependent and usually, but not exclusively, 
associated with caspase activation [8] and 
mitochondrial membrane permeabilization 
[9]. Caspases are the major proteases 
responsible for the proteolytical cleavage 
of numerous substrates during this process 
[10]. Cells undergoing apoptosis are 
rapidly and specifically recognized and 
engulfed by phagocytes such as 
macrophages or immature dendritic cells 
[11]. Removal of apoptotic cells by 
macrophages seems to result in little or no 
production of inflammatory immune 
mediators by unstimulated macrophages 
[12]. On the contrary, necrosis is induced 
by external insults and is morphologically 
characterized by an increase in cell volume 
leading to the early rupture of the plasma 
membrane. Consequently, cytosolic, 
organelle, and nuclear components are 
spilled into the surrounding tissue [13]. 
Unlike apoptosis, necrosis is considered to 
be immunologically harmful at all times, 
because of the sudden release of so-called 
danger signals such as ATP or high 
mobility group box 1 (HMGB1), which 
elicit inflammation by activating toll like 
receptors (TLR) or the inflammasome in 
myeloid cells [14]. Besides, necrotic cells 
are able to act on fibroblasts to activate 
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NF-κB and induce the expression of genes 
that are involved in inflammatory 
responses [15].  
Classical activation of human macrophages 
is characterized by the production of 
superoxide (O2 -), TNF-α, IL-1β and IL-6, 
also termed the M1 macrophage phenotype 
[16]. In contrast, the cytokines IL-4, IL-13 
or IL-10 are usually produced by the M2 
phenotype [16, 17]. Since Virchow et al. 
observed the presence of leukocytes in 
human tumors in 1863, it seems accepted 
that macrophages are a major cell 
component infiltrating certain tumors [17]. 
High numbers of tumor-associated 
macrophages (TAMs) often predict a poor 
survival prognosis for patients with solid 
human tumors [18]. Moreover, TAMs 
promote cancer metastasis through several 
mechanisms, including promotion of 
angiogenesis, induction of tumor growth, 
and enhancement of tumor cell migration 
and invasion [19-21] while showing a 
similar molecular and functional profile, 
that is displayed by a polarized M2 
phenotype [17, 22]. Therefore, 
reprogramming a M2 macrophage toward a 
M1 type seems to be beneficial with regard 
to tumor therapy [23].  
Here, we investigate whether the 
polyphenol resveratrol enhances anti-tumor 
effects of the common chemotherapeutic 
oxaliplatin, with special regard to the 
induction of different modes of cell death. 
We also determine whether tumor cell 
death occurs in a potentially immunogenic 
fashion via stimulating macrophages 
towards the pro-inflammatory M1 
phenotype, In addition, we determine 
possible cytotoxic effects on non-
transformed cells. 
 
2 Materials and Methods 
 
2.1 Cell culture and materials 
 
Caco-2 cells were kept in DMEM, 
supplemented with 10 % FCS, 1 % 
penicillin/streptomycin, 1 % sodium 
pyruvate and 1 % nonessential amino 
acids. Human foreskin fibroblasts (HFF) 
were cultured in DMEM/Ham’s F-12 
medium supplemented with 10 % FCS and 
1 % penicillin/streptomycin. Both cell lines 
were maintained at 37 °C in an atmosphere 
of 95 % air and 5 % CO2. The cells were 
passaged weekly using Dulbecco´s PBS 
containing 0.1 % trypsin and 1 % EDTA. 
Cells were screened for possible 
contamination with mycoplasma at 
monthly intervals. Resveratrol (Sigma-
Aldrich, München, Germany) was 
dissolved in DMSO at a concentration of 
100 mM, oxaliplatin (Sigma-Aldrich) was 
dissolved in water at a concentration of 10 
mM. DMEM, DMEM/Ham’s F-12 
medium, DMSO, sodium pyruvate 
solution, penicillin and streptomycin stock 
solutions were all obtained from PAA 
Laboratories GmbH. When synergistic 
effects were analyzed, the cells were pre-
treated with Res for 24 h. 
 
2.2 Cell Proliferation Assay 
 
The effect of the test subtances on DNA 
synthesis of cells was assessed using the 
cell proliferation ELISA kit (Roche 
Diagnostics, Mannheim, Germany). This 
assay is a colorimetric immunoassay for 
quantification of cell proliferation based on 
the measurement of bromodeoxyuridine 
(BrdU) incorporation during DNA 
synthesis, and is a non-radioactive 
alternative to the [
3
H]-thymidine 
incorporation assay. Cells were grown in 
96-well culture dishes (10
3
 cells/well), 
incubated with Res and/or Ox for 24 h, and 
then labeled with BrdU for further four 
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hours. Incorporated BrdU was measured 
colorimetrically.  
 
2.3 Combination index (CI) 
 
To assess the drug interactions of Res and 
Ox, we used the combination-index (CI) 
method defined by median-effect analysis 
of Chou and Talalay [24]. The fractional 
inhibitory concentration was calculated by 
dividing the concentration of the drug in 
the combination at IC50 by the IC50 of the 
individual drug.  
 
 
In this equation, the sum of the dose of Res 
and the dose of Ox give 50% inhibition of 
cell growth. Cl < 1 indicates a synergistic 
effect; Cl = 1, additive effect; and Cl > 1, 
antagonistic effect [25].  
 
2.4 Determination of ATP level 
 
Caco-2 cells were grown in 96 well culture 
dishes (10
3
 cells/well) and allowed to grow 
overnight. Cell Viability Assay Kit 
(ApoSENSOR
TM
, BioVision, CA, USA) 
was used according to the manufacturer’s 
instructions following a 1-24 h exposure to 
the substances. The assay utilizes 
luciferase to catalyze the formation of light 
from ATP and luciferin, and the light can 
be measured using a luminometer. 
Decrease in ATP levels was determined by 
comparing the results with the levels of 
untreated cells (control).  
 
2.5 Determination of DNA 
Fragmentation 
 
Caco.2 cells were seeded in 96-well culture 
dishes; 24 h after plating, cells were 
stimulated with substances for 24 h. 
Cytoplasmic histone associated DNA 
fragments, as a marker of apoptosis, in 
control and treated cells were quantified 
using a commercially available ELISA kit 
(Roche Diagnostics). 
 
2.6 Caspase-3 activity Assay 
 
Caco-2 cells, grown in 6-well plates, were 
stimulated with substances at 80% 
confluency. Fluorometric immunosorbent 
enzyme assay (Roche Diagnostics) was 
used according to the manufacturer’s 
instructions. Subsequent to the test, protein 
concentrations were measured for adaption 
of caspase activity. 
 
2.7 SDS-polyacrylamide gel 
electrophoresis and immunoblot 
analysis 
 
Caco-2 cells were seeded in 80 cm
2
 flasks; 
24 h after plating, cells were incubated 
with substances for 6 or 24 hours. Western 
blot analysis were performed as described 
previously [26]. The blots were incubated 
overnight at 4°C in 5% skimmed milk with 
a 1:1000 dilution of primary antibodies for 
PARP (from Cell signaling, Berverly, MA) 
or survivin (from Santa Cruz 
Biotechnology, Heidelberg, Germany). 
The secondary, horseradish peroxidase-
conjugated, antibody (Santa Cruz 
Biotechnology) was diluted at 1:5000 and 
incubated with the membrane for another 
60 min in skimmed milk. After 
chemoluminescence reaction (ECL, 
Amersham pharmacia biotech, Wien, 
Austria), bands were detected after 
exposure to Hyperfilm-MP (Amersham 
International plc, Buckinghamshire, United 
Kingdom). Blots were reprobed with β-
actin antibody (Santa Cruz 
Biotechnologies).  
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2.8 Mitochondrial membrane 
potential (∆Ψm) analysis 
 
Caco-2 cells were seeded into cultivation 
flasks at a densitiy of 1 x 10
5
 cells/well and 
allowed to grow overnight. Cells were 
stained with JC-1, as a component of the 
JC-1 Mitochondrial membrane potential 
Assay Kit (Cayman Chemical Company, 
Ann Harbor, MI) following a 6 and 24 h 
exposure to the subtances. JC-1 is a 
lipophilic, cationic dye that can selectively 
enter into mitochondria and reversibly 
change color from green to red as the 
membrane potential increases. Changes in 
∆Ψm were finally assessed by 
microfluorimetry analysis using TECAN 
SpectraFluor Plus (TECAN Austria 
GmbH, Grödig, Austria) and indicated as 
changes of red/green ratio. 
 
2.8 Annexin-V FITC/PI double 
labeled flow cytometry 
 
To discriminate between apoptotic and 
necrotic cell subpopulations simultaneous 
staining with Annexin V-FITC and 
Propidium iodide was performed. Cells 
incubated with the drugs for 5 and 24 h 
were harvested with accutase for 30 min. 
After centrifugation, cells were 
resuspended in 100 μL binding buffer 
mixed with 5 μL Annexin V-FITC 
(ImmunoTools, Friesoythe, Germany) and 
5 µl PI and then incubated in dark for 10 
min at 4 ºC. Fluorescence was measured 
with a flow cytometer. 
 
2.9 Cytotoxicity 
 
Cytotoxicity was analyzed by measuring 
lactate dehydrogenase release using a 
commercially available kit (Cytotoxicity 
detection kit (LDH), Roche). For this, HFF 
were incubated with substances for 24 h. 
Triton X-100 (2%) was used as a positive 
control. After centrifugation at 250 x g for 
10 min, the supernatant was carefully 
removed and transferred into 
corresponding wells of an optically clear 
96-well flat bottom microplate. To 
determine the LDH activity in these 
supernatants, 100 µl Reaction mixture was 
added and the samples were incubated for 
up to 30 min. Finally, the absorbance of 
the samples was measured at 490 nm.  
 
2.10 Cell Isolation and Culture 
 
Human monocytes were isolated as 
described [27]. In brief, monocytes were 
isolated from buffy coats (DRK-
Blutspendedienst Baden-Württemberg-
Hessen, Institut für Transfusionsmedizin 
und Immunhämatologie, Frankfurt am 
Main, Frankfurt, Germany) using Ficoll-
Hypaque gradients (PAA Laboratories, 
Karlsruhe, Germany). Peripheral blood 
mononuclear cells were washed twice with 
phosphate-buffered saline (PBS) and were 
allowed to adhere to culture dishes 
(Primaria 3072, Becton Dickinson, Lincoln 
Park, NJ) for 1 h at 37°C. Nonadherent 
cells were removed. Monocytes were then 
differentiated into macrophages with 
RPMI 1640 containing 10% AB-positive 
human serum (PAA Laboratories) for 7 d 
or more.  
Purified platelets were resuspended in 
serum-free DMEM containing 1 % 
penicillin/streptomycin, 1 % sodium 
pyruvate and 1 % nonessential amino 
acids, seeded in 80 cm
2
 flasks and 
immediately treated with subtances. After 
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24 h, LDH release in the supernatant was 
analyzed as described above. 
 
2.11 Co-culture Experiments 
 
Primary human monocyte-derived 
macrophages were seeded in 80 cm
2
 flasks. 
After differentiation, supernatants of 
Res/Ox-treated tumor cells (conditioned 
medium) were added, and co-cultures were 
maintained for 24 h. After analysis of the 
cytokine pattern (see below), the 
conditioned macrophage 
medium/macrophage supernatant was 
further applied to Caco-2 cells, grown in 
96-well culture dishes (10
3
 cells/well) 
overnight, to investigate possible cell 
growth inhibitory and cytotoxic properties 
after 24h of treatment (see overview in 
Figure 5). Cell proliferation and 
cytotoxicity were measured as described 
elsewhere. 
 
2.12 Quantification of Cytokines 
 
Cytokine measurements were performed 
essentially as described previously [28]. To 
quantities cytokines in cell culture 
supernatants of macrophages, we 
performed FACS analysis using the BD 
Cytometric Bead Array System (CBA) 
Human Inflammation Kit to determine IL-
10, TNF-α, IL-8 and IL-1β. Samples were 
analyzed with the FACSCanto (BD 
Biosciences) flow cytometer and processed 
with BD Biosciences FCAP software.  
 
2.13 Statistics 
 
All statistical analyses were performed 
using GraphPad Instat 4.01 (San Diego, 
CA, USA). The data are expressed as 
means  SE of at least three independent 
experiments. Results were analyzed by a 
two-way ANOVA. A p value < 0.05 was 
considered to be significant. 
 
3 Results and Discussion 
  
 
3.1 Synergistic antiproliferative 
effects of Res and Ox on Caco-2 
cells 
 
Although chemotherapy still plays an 
important role in the treatment of most 
solid tumors, it can only contribute to 
overall patient’s survival with 
compromised quality of life. Moreover, 
chemotherapy is falling behind on the fight 
against cancer because of an increasing 
trend of chemoresistance and the 
recurrence of secondary tumors. In this 
context, the use of phytochemicals as 
important enhancers of chemotherapy or 
radiotherapy, predominantly by 
modulating intracellular cell signalling 
pathways, abrogating drug resistance and 
diminishing systemic toxicities is 
considered to be an alternative for the 
management of this dread disease [5]. 
Resveratrol represents one of the 
promising dietary phytochemicals with 
chemopreventive and chemotherapeutic 
potential (3,5,40 trihydroxystilbene) [29], 
which has first been isolated from the roots 
of white hellebore (Veratrum glandiflorum 
O. Loes), and was subsequently identified 
in various food sources including red wine, 
grapes, peanuts, mulberries, etc. and in 
more than 70 other plant species [30]. 
Resveratrol was already examined in 
various studies to determine possible 
chemosensitizing properties when 
combined with established cancer 
treatments [31]. Here, we explored the 
possible chemosensitizing capability of 
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resveratrol in a cell culture model of 
colorectal cancer, also by anaylzing 
possible effects on immune cells. Our first 
results quickly revealed Res-induced 
potentiation of cell growth inhibition 
mediated by oxaliplatin (Figure 1) (*** 
p<0.001), which was more-than-additive as 
indicated by combination index analysis 
(CI=0.51) (C).  
 
3.2 Apoptotic effects of Res/Ox-
treatment in Caco-2 cells 
 
These cell-growth inhibitory effects of 
Res/Ox were accompanied by different 
hallmarks of apoptosis. In Figure 2A, 
changes in the intracellular ATP/ADP 
ratio, as a useful indicator to distinguish 
between different modes of cell death and 
viability, were analyzed. Although, 
decreasing ATP and increasing ADP levels 
are generally found in apoptotic cells, cells 
will rather undergo necrosis when 
intracellular ATP levels fall below a 
critical threshold [32]. We could 
demonstrate that incubation with Res [50-
100 µM] and Ox [1 µM] resulted in a 
significant dose-, and partially time-
dependent reduction of intracellular ATP 
which reaches a maximum after 24 h (*** 
p<0.001). Staurosporine [0.5 µg/ml], a 
well-known inducer of apoptosis [33], was 
used as a positive control. As DNA 
cleavage is another hallmark for apoptosis, 
we further quantified histone-complexed 
DNA fragments in Caco-2 after 24 h of 
treatment. Res [50-100 µM], in contrast to 
Ox [1 µM], thereby led to an increase of 
cystoplasmic histone-associated DNA 
fragments, an effect which could be 
significantly enhanced, when the drugs 
were used in combination (Figure 2B) (***
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p<0.001 vs. Ox). Additionally, as shown in 
Figure 2C, the effector caspase-3, which is 
one of the key proteases in the apoptotic 
pathway, was also induced by Res [100 
µM]. This effect could be significantly 
enhanced by co-stimulation with Res and 
Ox (*** p<0.001), which is in agreement 
with the observed cleavage of PARP 
(Figure 2D) (*** p<0.001), a classical 
substrate for activated caspase-3. 
Proteolysis of PARP usually is an indicator 
for early apoptotic events. Further 
experiments could demonstrate that the 
intrinsic apoptotic pathway plays a major 
role in apoptosis-inducing properties of 
Res as shown in Figure 3A, where Res 
alone already significantly decreased the 
mitochondrial membrane (*** p<0.001). 
Here, Res-induced depolarization of the 
mitochondrial membrane potential could 
not be further enhanced after combinatorial 
treatment. Recently, the anti-apoptotic 
9                                       B. M. Kaminski et al.         Mol. Nutr. Food Res. (under review) 
 
protein survivin has been described as 
being selectively expressed at high levels 
in most human cancers and is related to 
clinical progression.[34, 35]. Survivin is a 
structurally unique member of the IAP 
(inhibitors of apoptosis proteins) family 
that is potentially involved in both control 
of cell division and inhibition of apoptosis 
[36]. Specifically, its anti-apoptotic 
function seems to be related to an ability to 
directly/indirectly inhibit caspases [37], 
although the precise role of survivin in the 
modulation of the caspase cascade has not 
been fully elucidated [38]. In addition, 
survivin overexpression is correlated with 
poor prognosis of carcinomas of the lung, 
breast, colon and esophagus [39-42]. Since 
inhibition of effector caspases by IAPs 
occurs at the core of the apoptotic 
machinery, therapeutic modulation of IAPs 
could target a key control point in cancer 
resistance [43]. Thus, survivin is at present 
validated as a cancer therapeutic target 
[34] and actually in our studies we 
observed reduced protein levels of survivin 
after 24 h of drug exposure, whereas this 
effect was more prominent when the cells 
were co-treated with Res and Ox (*** 
p<0.001). Interestingly, in contrast to 
previous studies [44], we have shown that 
Ox causes a slight induction of the protein. 
It is by now well established that several 
anti-cancer agents, such as quercetin, 
arsenite and cisplatin show an upregulation 
of survivin [45]. 
 
3.3 Shifting from apoptosis to 
necrosis with increasing 
concentrations of SFN/Ox 
 
Depending on the lethal stimulus, tumor 
cells may also die by necrosis which is 
characterized by swelling of the cell and 
the cytoplasma organells before the plasma 
membrane ruptures and the cellular content 
is shed into the intercellular space [46]. To 
discriminate between different modes of 
cell death, Caco-2 cells treated with Res 
[50-100 µM], Ox [1 µM] alone and in 
combination for 5 and 24 h, were analyzed 
by Annexin V-FITC/PI labelling and flow 
cytometry. The degree of apoptosis thereby 
was quantitatively expressed as a 
percentage of the Annexin V-FITC-
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positive but PI-negative cells, while 
necrosis or late apoptosis was 
quantitatively expressed as a percentage of 
PI-positive or Annexin V-FITC/PI double-
stained cells. Analysis after 5 h was chosen 
in order to differentiate between primary 
and secondary necrosis. Interestingly at 
this time point, Annexin V-FITC positive 
but also PI-positive cells could be 
measured indicating direct necrotizing 
effects of Res and Ox (Figure 4A-C). Even 
though the population of apoptotic cells in 
the co-treated cells were still significantly 
increased after 24 h (** p<0.01), overall 
apoptotic events seemed to decline, 
particularly in Res [50-100 µM]- as well as 
Ox [1 µM]-treated cells (Fig. 4D-F), 
compared to the 5 h-treatment. Rather, at 
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this time point, a distinct population of PI-
stained cells could be observed, so that a 
mixture of cells undergoing rapid primary 
as well as secondary necrosis/late 
apoptosis can be assumed (Figure 4D). 
Obviously, apoptotic effects seemed to 
reach a maximum after 5 h of treatment, 
which is replaced by a shift towards an 
increased population of necrotic cells after 
24 h. Noting the facts that many cancers 
have defective apoptosis machinery or 
aquire apoptosis resistance during therapy 
[47], or the finding that apoptosis may be 
reversed in cancer cells [48], it is 
reasonable to consider whether activating 
alternative cell death pathways, such as 
necrosis, may be another effective strategy 
for cancer therapy [49]. Unlike apoptosis, 
which is considered immunosuppressive, 
therapy-induced necrotic cell death 
initiates an immune response [13]. This 
inflammatory response may help to recruit 
cytotoxic immune cells to the tumor site, 
thereby increasing the efficacy of the 
chemotherapeutic drugs. Effects of Res 
and Ox on the cytokine profile as a result 
of the observed necrotic events were 
therefore investigated by co-culture 
experiments.  
 
3.4 Conditioned medium of treated 
Caco-2 cells causes an alteration 
of cytokine profile in human 
macrophages 
 
Human primary macrophages were 
incubated with conditioned medium of 
treated or control tumor cells for 24 h 
followed by a quantification of prodcution 
of the cytokines TNF-α, IL-10, IL-8 and 
IL-1β. As indicated in Figure 6, 
macrophages that were incubated with the 
supernatant of Res- or Ox-treated Caco-2- 
cells (see overview in Figure 5) released 
slightly elevated levels of the pro-
inflammatory cytokines TNF-α (A), IL-1β 
(B) and IL-8 (C). This effect was markedly 
counteracted when macrophages were 
incubated with the supernatant of Caco-2 
cells treated with Res and Ox in 
combination (* p<0.05 vs. Ox). 
Interestingly, even though co-culture of 
macrophages with Res/Ox-treated Caco-2 
cells significantly counteracted the release 
of IL-8 mediated by co-culture with Ox [1 
µM] (C) (* p<0.5), this combination still 
provoked a marked increase in IL-8 
production as compared to control 
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macrophages (*** p<0.001), similar to 
single drug exposure (*** p<0.001). Most 
importantly, release of the cytokine IL-10 
by macrophages from Ox-treated co-
cultures was increased, compared to 
control macrophages, an effect which 
could be significantly abolished when the 
Caco-2 cells were stimulated with Res and 
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Ox in combination (D) (* p<0.05). Thus, 
although tumor cells treated with a 
combination of Res and Ox did not elicit a 
strong production of pro-inflammatory 
mediators, production of 
immunosuppressive IL-10 was completely 
abolished. Considering the role of IL-10 in 
suppression of immunity against 
established tumors e.g. by inducing 
regulatory T cells [50, 51], these findings 
strengthen the rationale of using Ox in 
combination with Res for tumor therapy. 
 
3.5 Apoptotic/necrotic tumor cells 
enhanced macrophage 
cytotoxicity against vital tumor 
cells 
 
It has previously been shown that apoptotic 
tumor cells reduced macrophage 
cytotoxicity against vital tumor cells [52] 
and disrupting recognition of apoptotic 
cells by macrophages or dendritic cells in 
vivo induced tumor regression [53]. To 
investigate whether conditioned medium 
may further lead to tumor growth, we 
treated Caco-2 cells with the supernatant of 
co-cultured macrophages (for details see 
overview in Figure 5) and measured cell 
proliferation as well as LDH release after 
24 h of stimulation. As indicated in Figure 
6, cell growth inhibition (*** p<0.001) (E) 
as well as lysis (*** p<0.001) (F) of Caco-
2 cells were significantly enhanced, 
especially when the cells were treated with 
the supernatant of co-cultured 
macrophages with Res/Ox-treated Caco-2 
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cells. These findings correlate well with 
the observed effects of tumor cell 
supernatants on IL-10 production in 
macrophages, since IL-10 potently 
suppresses the cytotoxic potential of 
macrophages [54].  
 
3.6 Combinatorial treatment of Res 
and Ox failed to induce 
cytotoxicity in human foreskin 
fibroblasts (HFF) and human 
platelets  
 
Responding to the question whether Res 
and Ox, alone and in combination, cause 
severe toxicity to normal tissue cells, we 
treated human foreskin fibroblasts and 
human platelets with Res [50-100 µM], Ox 
[1 µM] alone and in combination and 
quantified LDH-release as a marker of 
direct cytotoxicity after 24 h (Figure 7). 
[55]. In healthy human fibroblasts, Res 
was found to inhibit cell growth in a dose-
dependent manner (B), an effect which was 
already reported for some HDAC 
inhibitors [56, 57]. However, in contrast to 
Caco-2 cells, growth inhibitory effects on 
fibroblasts were not further enhanced and 
no signs of cytotoxicity could be observed 
when Res was combined with oxaliplatin 
(A), indicating a selective toxicity towards 
the tumor cell line while inducing only 
growth arrest in normal fibroblasts. 
Additionally, neither Res or Ox alone nor 
their combination caused any signs of 
cytotoxicity in human platelets (C).  
 
4 Concluding remarks 
 
As discussed here, the immune response 
against dying tumor cells can play a major 
role in determining therapeutic success. If 
tumor cell death occurs in a potentially 
immunogenic fashion and if the immune 
system is capable of perceiving this 
immunogenicity, a potent innate and 
cognate immune response raised against 
dying cancer cells can contribute to the 
control and elimination of residual cancer 
cells. Our findings demonstrate for the first 
time that the polyphenol resveratrol is 
capable of amplifying Ox-induced cell 
growth inhibition in colon cancer cells 
supposedly via induction of different 
modes of cell death. As a result of the 
apoptotic and necrotic effects of resveratrol 
and oxaliplatin, immunosuppressive 
potential in macrophages is prevented, 
which renders them potently tumoricidal. 
Resveratrol might therefore not only be a 
promising candidate for chemoprevention, 
but also for chemotherapy options.  
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Abstract: 
Even though, conventional cancer therapies, comprising surgery and chemo- and 
radiotherapy, play an important role in the treatment of most solid tumours, successful 
therapeutic outcome is often limited due to high toxicity and related side-effects, as well as 
the development of multi-drug resistances. Therefore, there is need for new therapeutic 
strategies not only to obtain higher treatment efficacy, but also for the reduction of toxicity 
and adverse effects. Emerging evidence suggests that natural compounds with distinct 
anticarcinogenic activity, may be considered as potential agents for enhancing the therapeutic 
effects of common cancer treatments. By using the examples of resveratrol and sulforaphane 
this review will summarize the findings of recent investigations focusing this topic so far and 
the current knowledge of the molecular mechanisms by which these selected phytochemicals 
may potentiate the anti-tumor effects of different cancer therapies. 
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Introduction 
 
Despite a markedly improved 
understanding of the disease, the advent of 
modern technology and rationally targeted 
drugs over the past years, cancer remains 
the second leading cause of death in 
industrialized countries, with a total of 
1,529,560 new diagnoses and 569,490 
deaths being projected in 2010 in the US 
[1]. Current treatment options involve the 
combination of a variety of 
chemotherapeutic drugs, radiation and 
surgery. However, successful therapeutic 
outcome is often limited due to high 
toxicity as well as the development of 
multi-drug resistance. It is therefore of 
particular importance to investigate other 
drug combinations for the development of 
new therapeutic regimens obtaining higher 
efficacy, and lower side effects, which 
could significantly improve patient 
survival rate. Emerging evidence suggests 
that combining chemopreventive agents 
with chemotherapy or radiotherapy may 
lead to enhanced antitumor activity 
through synergistic action or compensation 
of inverse properties. Combination 
treatment may also decrease the systemic 
toxicity of chemotherapy, because lower 
doses of radiation or anticancer drugs 
could be used. Beside a multitude of 
synthetic substances, like non-steroidal 
anti-inflammatory drugs (NSAIDs) [2] or 
selective estrogen receptor modulators 
(SERMs) [3], also numerous 
phytochemicals have been identified to 
exhibit potent chemopreventive effects in 
different carcinogenesis models, while, at 
the same time showing low toxicity [4]. 
Recent studies could further demonstrate 
that several of these plant-derived 
compounds are also capable of enhancing 
the efficacy of chemotherapy and 
radiotherapy in various in vitro and in vivo 
cancer models, predominantly by 
modulating intracellular cell signaling 
pathways, abrogating drug resistance and 
diminishing systemic toxicities. These 
findings have also been excellently 
reviewed by Sarkar and Li [5, 6]. Here, in 
particular we would like to give an 
overview on recent studies focusing the 
chemosensitizing activities of resveratrol 
and sulforaphane, two other interesting 
chemopreventive candidates, also with 
regard to possible risks and cons of this 
treatment strategy.  
 
Resveratrol 
 
Resveratrol (RSV) (Figure 1) is a naturally 
occuring polyphenol present in red wine, 
peanuts and grapes [7, 8] which exhibits 
multiple chemopreventive effects in 
various carcinogenesis models [9, 10], 
comprising cell growth inhibition, 
induction of apoptosis and prevention of 
angiogenesis. This effect of resveratrol on 
multiple signal transduction pathways 
related to carcinogenesis has generated 
tremendous interest in evaluating its 
potential for use as a clinical 
chemopreventive and chemotherapeutic 
agent.  
Bioavailability: 
Pharmacokinetic studies in mice and rats 
suggest consistently that resveratrol is well 
absorbed and rapidly glucuronidated and 
sulphated both in the liver and intestinal 
epithelial cells [11]. After oral 
administration of C
14
-resveratrol to 
humans (25 mg/kg) measurement of total 
radioactivity also demonstrated high 
absorption (at least 70%) followed by rapid 
metabolisation of resveratrol in the liver by 
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phase-2 drug metabolizing enzymes. 
Compared to resveratrol, which has a half-
life of 8-14 min, these metabolites have a 
plasma half-life of about 9.2 h. The amount 
of free resveratrol in plasma and serum 
reached ~37 nmol/L (less than 2% of total 
resveratrol). The appearance of a new 
resveratrol peak 6 h after consumption 
suggests enteric recirculation of conjugated 
metabolites by reabsorption after intestinal 
hydrolysis. Overall recovery in urine and 
feces was 71-98% after oral administration 
[12]. In 2007, Boocock et al. [13] reported 
the first phase I dose-escalation 
pharmacokinetics in 40 healthy volunteers. 
The doses administered ranged from 0.5 up 
to 5 g of resveratrol, which did not cause 
any serious adverse effects. However, even 
after high-dose trans-resveratrol, the 
plasma level of free resveratrol did not 
exceed 2,4 µmol/L. In contrast, most 
mechanistic studies suggest that 
carcinogenesis-modulating effects of 
resveratrol require a sustained presence of 
5-100 µmol/L, which might raise doubts 
on the therapeutic relevance of resveratrol 
due to the discrepancy between the 
apparently low bioavailability in vivo and 
the biologically relevant concentrations 
used in in vitro studies [14]. However, 
contrary to all expectations, systemic and 
oral administration of resveratrol has been 
shown to inhibit the initiation and growth 
of tumors in a wide variety of rodent 
cancer models [15, 16] . To respond to the 
question whether the observed effects in in 
vitro and in vivo models are also 
conferrable and relevant for humans, 
several phase I and II clinical trials are 
currently in progress for oral resveratrol 
administration in humans for both 
prevention and treatment of different types 
of cancer (www.clinicaltrials.gov) .  
 
Sulforaphane 
 
Sulforaphane (SFN) (Figure 2) is a natural-
ly occurring isothiocyanate derived from 
cruciferous vegetables such as broccoli, 
cauliflower, cabbage and kale [17], which 
targets cancer initiation and progression 
both in vitro and in vivo, and further induc-
es antiproliferative and cytotoxic effects in 
cells that are already transformed [18].  
Bioavailability: 
Several pharmacokinetic studies in both 
rats and humans indicate, that dietary ab-
sorbed sulforaphane can be widely distri-
buted in the body, reach µM levels in the 
blood and is capable of reaching target 
tissues in an active form [19, 20]. After 
absorption, sulforaphane is predominantly 
metabolized via the mercapturic acid 
pathway, starting with glutathione (GSH) 
conjugation by glutathione-S-transferase 
[21] followed by generation of 
sulforaphane-cysteine (SFN-Cys) and 
sulforaphane-N-acetylcysteine [22]. 
Notably, the accumulation of sulforaphane 
in colonic tissue corresponded with 
decreased adenoma formation in mice 
supplemented with 300 or 600 ppm 
sulforaphane [23]. In human experiments, 
it has been shown that 75% of 
sulforaphane from broccoli is absorbed in 
the jejunum and a portion of that returns to 
the lumen of the jejunum as SFN-GSH 
[24]. When the metabolism 
 of glucoraphanin efficiently occurs, SFN-
NAC is the primary sulforaphane 
metabolite excreted in the urine [25, 26]. In 
rats, nearly 72% of a single oral dose of 
sulforaphane was recovered in the urine as 
NAC conjugates in 24 h [21], but only 
about 1% of the dose was detected in the 
second 24-h urine sample [27], indicating 
an extremely high bioavailability and a 
small inter-individual variation of 
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sulforaphane absorption and metabolism. 
Once sulforaphane is distributed, it can 
accumulate in tissues and be maintained to 
achieve the anti-tumor effects [22]. In a 
recent pilot study in human mammary 
tissue, a oral dose of broccoli sprout 
preparation containing 200 µmol 
sulforaphane 1 h prior to tissue removal 
showed mean accumulation of 1.45 ± 1.12 
pmol/mg tissue in the right breast and 2.00 
± 1.95 pmol/mg in the left breast [28].  
The consumption of isothiocyanates, such 
as sulforaphane is actually expected to rise 
due to the use of dietary supplements and 
public health initiatives promoting the con-
sumption of more fruits and vegetables. 
This together with its excellent 
bioavailability makes sulforaphane a po-
tent candidate for food-drug interactions, 
whereby these interactions may result in 
both positive and negative consequences 
regarding cancer therapy.  
 
Interactions of Resveratrol and 
Sulforaphane with 
chemotherapeutic drugs in 
different in vitro and in vivo tumor 
models 
 
Due to their wide range of biological and 
pharmacological effects, especially with 
regard to chemoprevention, and the lack of 
toxicity in animal and human models, 
resveratrol and sulforaphane were also 
examined for chemosensitizing properties 
when combined with established cancer 
treatments. Actually both, synergistic as 
well as antagonistic effects could be 
observed for different anticancer drugs in 
in vitro as well as several in vivo tumor 
models (Table 1), whereby some modes of 
action could already be identified.  
Modulation of cell signaling: 
It is well known that chemopreventive 
agents exert inhibitory effects on the 
carcinogenesis process through modulation 
of multiple signaling pathways, including 
nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-κB), Akt, 
mitogen-activated protein kinase (MAPK), 
p53, cyclooxygenase-2 (COX-2), NF-E2-
related factor-2 (Nrf-2) and many other 
molecules that are known to regulate cell 
cycle progression, apoptotis and cell 
survival and are frequently involved in the 
development of drug resistance and thus 
cancer treatment failure. 
NF-κB is an inducible and ubiquitously 
expressed transcription factor which 
regulates cell survival, inflammation and 
differentiation and thus plays a critical role 
in cancer development and progression 
[29]. Moreover it is well known, that many 
chemotherapeutic agents and radiation may 
induce NF-κB activity in different cancer 
cells, which is mainly associated with the 
development of drug resistance [30]. Both 
resveratrol and sulforaphane have been 
reported to directly target NF-κB signaling 
in various tumor models [22, 31]. 
Moreover, resveratrol-induced inhibition 
of NF-κB activity seems to be critical for 
enhancing the antitumor activities of tumor 
necrosis factor-related apoptosis-inducing 
ligand (TRAIL) and gemcitabine in 
melanoma and pancreatic cancer cells [32, 
33]. Similar effects were described for 
sulforaphane, since NF-κB blockage was 
essential for enhancing the therapeutic 
potential of TRAIL in in vitro and in vivo 
models of pancreatic and prostate cancer 
[34]. In salivary gland adenoid cystic car-
cinoma high (ACC-M) and low (ACC-2) 
metastatic cell lines, treatment with sulfo-
raphane and 5-fluorouracil (5-FU) led to 
synergistic inhibition of cell growth, which 
was accompanied by decreased expression 
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of nuclear p65 protein, a subunit of the NF-
κB transcription complex [35].  
Nrf-2 is a transcription factor which was 
originally identified to be a critical regula-
tor of intracellular antioxidants and phase 
II detoxification enzymes by the transcrip-
tional up regulation of many antioxidant 
response element (ARE)-containing genes, 
and thus defending cells against toxic and 
carcinogenic effects of many environmen-
tal insults. The efficacy of dietary or syn-
thetic Nrf-2-activators in chemoprevention 
could also be verified both in animal mod-
els and in human clinical trials [36]. Con-
versely, Wang and colleagues demonstrat-
ed, that stable over expression of Nrf-2 in 
different cancer tissues resulted in cell sur-
vival and enhanced resistance of cancer 
cells to chemotherapeutic agents including 
cisplatin, doxorubicin and etoposide and 
they further discussed the feasibility of 
using Nrf-2 inhibitors as adjuvants to che-
motherapeutic agents to maximize cancer 
cell death [37]. Actually, sulforaphane was 
reported to increase Nrf-2 and detoxifica-
tion enzyme levels in breast cancer cell 
lines with very low basal Nrf-2 levels, 
which was suggested to be associated with 
significant chemoresistance to cytotoxic 
drugs like doxorubicin and paclitaxel [38]. 
The Akt pathway is another signaling 
pathway which is often involved in drug 
resistance. Both resveratrol and 
sulforaphane inhibit Akt phosphorylation 
and thus activation, thereby sensitizing 
different tumor cells to drug induced 
apoptosis [34, 39, 40].  
Cell cycle effects: 
Since the efficacy of most 
chemotherapeutic drugs is dependent on 
specific cell cycle phases, drug 
combinations with cell cycle modulating 
compounds may lead to both synergistic as 
well as antagonistic effects. Investigations 
by Fulda et al. for example revealed, that 
pretreatment of different human cancer cell 
lines and primary tumor cells with 
resveratrol resulted in cell cycle arrest in 
the S phase and apoptosis induction 
preferentially out of S phase upon 
subsequent treatment with various 
anticancer drugs [41]. Similar effects were 
described by Duraj et al. in drug-sensitive 
and drug-resistant leukemia cells [42]. S 
phase arrest induced by resveratrol was 
also found in hepatoma22 transplanted to 
male BALB/c mice [43] and colon cancer 
cells [44], thus enhancing the anti-tumor 
effects of 5-FU, a S phase specific 
pyrimidin analog typically used in the 
treatment of colorectal-, pancreatic- and 
hepato-carcinoma patients [45].  Zoberi et 
al. reported an early S phase cell cycle 
checkpoint arrest in cervical tumor cells 
induced by resveratrol, which also resulted 
in enhanced tumor cell killing by ionizing 
radiation [46]. G1 phase arrest, induced by 
resveratrol-mediated down-regulation of 
the Cyclin D1/cdk4-complex, in turn 
potentiated doxorubicin-cytotoxicity in 
B16 melanoma cells [47]. Mao et al. [48] 
recently reported an increased percentage 
of cisplatin-treated bladder cancer cells 
arrested in G1, when cells were cotreated 
with resveratrol.  In constrast, antagonistic 
effects were reported in different cell 
systems when resveratrol was combined 
with paclitaxel, a mitotic inhibitor, which 
amongst others is approved for the 
treatment of ovarian, breast and lung 
cancer as well as HIV-associated Kaposi's 
sarcoma [49]. Fukui et al. found, that 
resveratrol strongly diminished the 
susceptibility of different breast cancer cell 
lines (MDA-MB-435s, MDA-MB-231 and 
SKBR-3) to paclitaxel-induced cell death 
in culture by inhibition of paclitaxel-
induced G2/M-phase arrest. Solely in 
MCF-7 cells this effects was not observed 
[50]. Similar effects were described by 
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Nicolini and Rigolio et al. who not only 
demonstrated, that resveratrol was able to 
reduce paclitaxel-induced apoptosis in the 
human neuroblastoma cell line SH-SY5Y 
by direct modulation of different pro- and 
antiapoptotic proteins, but further 
suggested, that the resveratrol-induced S-
phase block seems to prevent SH-SY5Y 
from entering into mitosis, the phase of the 
cell cycle in which paclitaxel exerts its 
core activity [51-53].   
Apoptosis: 
Both resveratrol and sulforaphane 
demonstrate potent apoptosis-inducing 
properties in various tumor models [10, 22, 
31]. Morevover, most of the sensitizing 
effects, described here, are predominantly 
mediated by modulating the cell death 
machinery (summarized in Table 1). Gill et 
al. for example reported, that pre-treatment 
with resveratrol sensitized prostate cancer 
cells predominantly to agents, that 
specifically target death receptors but not 
agents that initiate apoptosis through other 
mechanisms [39]. Resveratrol also altered 
the expression of IAPs and Bax, leading to 
increased caspase activation and apoptosis. 
Resveratrol was also found to inhibit cell 
growth and induced apoptosis in TRAIL-
resistant LNPCaP cells, while not effecting 
normal prostate epithelial cells. The 
expression of proapoptotic Bax, Bak, 
PUMA, Noxa, Bim, TRAIL-R1/DR4 and 
TRAIL-2/DR5 was upregulated, the 
expression of antiapoptotic Bcl-2, Bcl-xL, 
survivin and XIAP was downregulated on 
treatment with resveratrol [54]. By the 
way, similar observations could be found 
using sulforaphane, which was further 
confirmed in an orthotopic mouse model of 
prostate cancer [34]. In non-Hodgkin 
lymphoma, multiple myeloma and lung 
cancer lines, resveratrol significantly 
enhanced antiproliferative as well as 
apoptotic effects mediated by paclitaxel 
[55, 56]. Here, resveratrol was able to 
selectively down-regulate the expression of 
anti-apoptotic proteins such as Bcl-xL, 
Bcl-2 and myeloid cell differentiation 
factor-1 (Mcl-1) and to further upregulate 
both, pro-apoptotic proteins (Bax, Bid, 
apoptosis-protease activating factor-1 
(Apaf-1)) as well as specific cell cycle 
inhibitors (p21
waf1
, p27
kip1
).  
Most studies concerned with a possible 
sensitizing efficacy of sulforaphane are 
admittedly reported for interactions with 
TRAIL, a member of the TNF family of 
cytokines, which can induce apoptotic cell 
death in several in vitro and in vivo cancer 
models, while sparing most normal cells 
[57, 58].  Even though TRAIL is consi-
dered to be a novel promising anticancer 
agent, a multitude of primary tumors 
present a phenotype which is rather resis-
tant to TRAIL-induced apoptosis [59, 60] 
so there is need for new strategies to over-
come TRAIL-resistance. Sulforaphane was 
found to sensitize TRAIL-resistant human 
hepatoma [61], osteosarcoma [62] and lung 
carcinoma cell lines [40] but not peripheral 
blood mononuclear cells [62] to TRAIL-
induced apoptosis, primarily by inducing 
death receptors DR4 and DR5. Similar 
effects could be detected in a mouse model 
of prostate cancer [34]. In another mouse 
xenograft model, using highly treatment-
resistant tumor-initiating cells (TIC), 
which play a central role in the pathogene-
sis of different tumor entities, including 
pancreatic cancer, sulforaphane strongly 
blocked tumor growth and angiogenesis, 
while again combination with TRAIL leads 
to enhanced efficacy without obvious cyto-
toxicity in normal cells [63]. Moreover, we 
could recently demonstrate that sulfora-
phane, in addition to the reported synergis-
tic activities, in combination with exogen-
ous TRAIL also seems to be capable of 
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inducing endogenous TRAIL expression in 
colorectal cancer cells [64].  
We could further show that sulforaphane 
synergistically amplifies oxaliplatin-
induced cell growth inhibition in the 
colorectal cancer cell line Caco-2, which 
was accompanied by different hallmarks of 
apoptosis, whereby apparently both 
extrinsic as well as intrinsic pathways were 
involved. However, in contrast to known 
apoptosis inducers these apoptotic events 
were not very prominent and might only 
partly account for the observed cell growth 
inhibition. In fact, with rising 
concentrations of oxaliplatin not only an 
increase of apoptotic but also a distinct 
population of necrotic cells could be 
revealed [64]. Noting the facts, that many 
cancers exhibit defective apoptosis 
machineries or aquire apoptosis resistance 
during therapy [65], or the finding, that 
apoptosis may be reversed in cancer cells 
[66], it is reasonable to consider, whether 
activating alternative cell death pathways, 
such as necrosis, may be another effective 
strategy for cancer therapy [67]. However 
whether immunologic responses, typically 
associated with necrotic cell death might 
really be desirable in the context of cancer 
treatment or rather lead to further tumor 
growth or even overshooting inflammation 
resulting in autoimmunity remains to be 
elucidated.  
 
 
Abrogation of multidrug 
resistance 
 
A major obstacle to effective 
chemotherapy is the development of 
multidrug resistances (MDR), which can 
be generated by different mechanisms.  
By now, modulatory effects of resveratrol 
on most of these pathways could be 
reported in different cellular and animal 
models. In drug resistant human oral 
epidermoid carcinoma KB cells (KBv200) 
and acute myeloid leukemia cells, 
resveratrol was capable of reversing 
multidrug resistance by decreasing the 
expression levels of membrane efflux 
pumps, namely multidrug-resistance gene 
1 (MDR-1) and Multiple Drug Resistance 
protein 1 (MRP-1) [68, 69]. In human 
multidrug-resistant carcinoma KB-C2 cells 
inhibitory effects of resveratrol on P-
glycoprotein (MDR-1 gene product) 
resulted in increased intracellular 
accumulation of daunorubicin, a natural 
relative of doxorubicin [70].  In addition, 
more recent studies could demonstrate that 
resveratrol regulates activity and 
expression levels of different members of 
the cytochrom P450 superfamily of 
enzymes in vitro and in vivo, and thus is 
able to directly modulate intracellular drug 
metabolism and bioavailability of various 
drugs [71, 72]. Moreover, in multidrug-
resistant human non-small cell lung, breast 
and oral epidermoid cancer cells, 
resveratrol was reported to induce 
apopotosis by down-regulating the 
expression of anti-apoptotic proteins (Bcl-
2, Bcl-xL, survivin) [68, 73], whereby 
evidence suggests, that again resveratrol-
activated SIRT1 deacetylase might play a 
pivotal role in regulating the balance of 
multidrug-resistance and sensitivity [74]. 
Sulforaphane was also found to increase 
expression levels of multidrug resistance 
proteins 1 (MRP1) and 2 (MRP2) in differ-
ent human carcinoma cell lines [75, 76]. 
Owing to the major role of these mem-
brane transporters in elimination of drugs, 
comprising cytostatics, modulation of its 
expression may also lead to adverse effects 
or to changes in drug pharmacokinetics, 
possibly resulting in therapeutic resistance. 
On the other hand, Fimognari et al. re-
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ported, that sulforaphane was able to re-
verse resistance to doxorubicin in mouse 
fibroblasts transfected with a p53 (Ser220) 
mutation, which is typically found in dox-
orubicin-resistant phenotypes of different 
human cancers [77].  
 
Conclusion 
 
Resveratrol and sulforaphane definitely 
show promise for serving as potent agents 
for enhancing the therapeutic effects of 
chemotherapy or radiotherapy in cancer 
treatment. However, on the other hand this 
strategy might also negatively affect clas-
sical treatment regimens under certain cir-
cumstances. These converse findings might 
at least partly be due to discrepancies in 
drug concentrations, experimental settings, 
tumor models and treatment procedures 
used in the different studies, whereby 
overall regularities could not yet be de-
fined. Ahmad et al. for example could 
demonstrate, that contrary to the apoptosis-
inducing activity at relatively high 
concentrations of resveratrol (30-100µM), 
prior exposure to low concentrations of 
resveratrol (4-8µM) could create an 
intracellular milieu resistant to apoptosis 
induced by either H2O2 or anti-cancer 
drugs [78, 79], which could provide cancer 
cells with a survival advantage by 
impeding death execution signals. The 
relevance of the applied concentration was 
further confirmed by Chan et al. who could 
show that resveratrol synergistically 
promotes 5-FU-mediated apoptosis at 
higher concentrations, but counteracts 5-
FU-activity when used at lower 
concentrations in a cell culture model of 
colorectal cancers [80]. Another reason for 
different findings might be related to 
varying modes of treatment. In their most 
recent publication, Mao et al could 
demonstrate, that resveratrol effectively 
prevented tumor death induced by taxol 
(paclitaxel) in 5637 bladder cancer when 
the drugs were added simultaneously, but 
in turn, induced synergistic cytotoxicity, 
when cells were pre-treated prior to 
addition of taxol [48]. Also cell cycle 
modulatory effects frequently observed in 
the presence of phytochemicals seem to be 
critical for discriminating between 
synergistic or antagonistic effects when 
combined with cell cycle specific anti-
tumor drugs.  This should as well provide a 
cautionary note for the uncontrolled and 
non-critical use of biologically active food 
supplements in patients with established 
cancer who are already undergoing chemo- 
or radiotherapeutic treatment.  
However, the most important fact that 
should be noted about all of these studies is 
that the efficacy of most phytochemicals 
on anti-tumor therapies has been tested 
only in preclinical conditions, either in 
vitro or in vivo. Whether benefical or 
detrimental effects can be also seen in 
humans is largely unknown.  
Recently, a clincal trial of a formulation of 
resveratrol has been suspended due to 
safety concerns. In this phase 2 trial safety 
and activity of a resveratrol-based drug 
alone or in combination with the 
proteasome inhibitor bortezomib in 
patients multiple myeloma should be 
assessed 
(http://clinicaltrials.gov/ct2/show/NCT009
20556). The trial was halted when 5 out of 
24  patients developed a kidney condition 
called cast nephropathy. Interestingly, all 
patients who experienced kidney failure 
during the trial were being treated with 
only the resveratrol-based drug when their 
kidney problems developed. 
However, it is still uncertain whether the 
kidney failures were actually related to the 
resveratrol treatment, or were simply a 
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manifestation of the underlying myeloma 
since cast nephropathy is so commonly 
associated with multiple myeloma that it is 
even called “myeloma kidney” [81] 
Further mechanistic studies, in vivo animal 
models and most important human clinical 
trials are therefore needed to certify the 
safety and efficacy of dietary compounds 
in combination cancer therapies paving the 
way for eventually transferring this con-
cept to clinical applications.         
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Table 1 Possible interactions of Resveratrol and Sulforaphane with Chemo- and Radiotherapy in different in vitro and in vivo 
tumor models 
Resveratrol 
Tumor models/Major findings Targets/Proposed Mechanisms References 
Lung cancer 
 
RSV enhanced paclitaxel-induced apoptosis of lung 
cancer cells (A549, EBC-1, Lu65) 
 
RSV induces apoptosis in human multidrug-resistant non-
small cell lung cancer cell lines SPC-A-1/CDDP and in a 
nude mice xenograft model  
 
 
DNA Fragmentation ↑, caspases↑, p21WAF1↑ 
 
 
Cell Proliferation ↓, Apoptosis ↑, Tumor growth ↓, Cell Cycle Arrest, 
Survivin ↓ 
 
 
[56] 
 
 
[73] 
 
Breast cancer 
 
RSV attenuated efficacy of taxol in human breast cancer 
cells MDA-MB-435s, MDA-MB-231 and SKBR-3 cells 
and in a athymic nude mice xenograft model, but not in 
MCF-7 cells 
 
RSV augmented cytotoxicity of cisplatin in Ehrlich-acites-
bearing mice 
 
 
Paclitaxel-induced G2/M cell cycle arrest ↓, Paclitaxel-induced ROS 
accumulation ↓ 
 
 
 
Tumor size ↓, Serum CRP↓, TNF-α ↓, leucocytes ↓, malondialdehyde ↓ 
 
 
[50] 
 
 
 
 
[82] 
 
Prostate cancer 
 
RSV sensitized androgen independent prostate cancer PC-
3 and DU145 cells to death-receptor mediated apoptosis 
 
RSV enhanced the therapeutic potential of TRAIL in 
LNCaP cells 
  
 
 
 
Caspases ↑, PARP cleavage ↑, Nuclear condensation ↑, BAX ↑, Akt 
phosphorylation ↓ 
 
Bax ↑, Bak ↑, PUMA ↑, Noxa ↑, Bim ↑, TRAIL-R1/DR4 ↑, TRAIL-
R2/DR5 ↑, Bcl-2 ↓, Bcl-xL ↓, survivin ↓, XIAP ↓, ROS ↑ , 
mitochondrial membrane potential, release of mitochondrial proteins,  
caspase-3 ↑, caspase-9 ↑, apoptosis ↑ 
 
 
[39] 
 
 
[54] 
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Neuroblastoma 
 
RSV cooperated with anticancer agents VP16, 
doxorubicin, cytarabine (AraC), actinomycin D, taxol or 
methotrexate to induce apoptosis in SEHP neuroblastoma 
cells in a time-and dose-dependent manner 
 
RSV reduced paclitaxel-induced apoptosis in human 
neuroblastoma SH-SY5Y cells 
 
 
 
S-Phase arrest, p53-independent, Survivin ↓, Activation of caspase-3, -
8, -9 and PARP ↑ 
 
 
 
Caspase-7-activation, Poly-(ADP-ribose)-polymerase degradation, Raf-
1 phosphorylation, Bcl-2 phosphorylation, S-phase block prevents cells 
to enter mitosis 
 
 
[41] 
 
 
 
 
[51-53] 
 
 
Leukemia 
 
 
RSV inhibited H2O2-induced apoptosis in promyelocytic 
leukemia HL60 cells 
 
RSV inhibited H2O2-, vincristine-, daunorubicin- and C2-
induced apoptosis in human leukemia HL60 cells 
 
 
 
RSV sensitized sensitive (HL60) and resistant 
(HL60/VCR (Pg-positive)) leukemia cells to doxorubicin 
(DOX), cycloheximide (CHX), busulfan (BUS), 
gemcitabine (GEM) and paclitaxel (PTX)-induced 
apoptosis 
 
RSV reverses doxirubicin-resistance in acute myeloid 
leukemia cells 
 
RSV reduced H2O2-induced apoptosis in erythroleukemia 
 
 
 
Caspase-Activity ↓, DNA Fragmentation ↓, Cell proliferation ↑ 
 
 
Caspase Activation ↓, DNA Fragmentation ↓, cytochrome C 
translocation ↓, intracellular superoxide ↓, drug induced acidification ↓, 
activation of NADPH oxidase complex ↓ 
 
 
S-phase arrest, apoptosis ↑  
 
 
 
 
 
Cell growth arrest ↑, apoptosis ↑, MRP1 ↓ 
 
 
Leukotriene B4 ↓, Prostaglandine E2 ↓, 5-lipoxygenase ↓, 15-
 
 
 
[78] 
 
 
[79] 
 
 
 
 
[42] 
 
 
 
 
 
[69] 
 
 
[83] 
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K562 cells by inhibiting leukotriene B4 and prostaglandin 
E2 
lipoxygenase ↓, Prostaglandin H synthase ↓  
 
Skin cancer 
 
RSV sensitized melanoma cells (WM9, LU1205, LOX) to 
TRAIL induced apoptosis 
 
RSV reverses multidrug resistance against vincristine, 
adriamycin and paclitaxel in KBv200 cell lines 
 
RSV induced the accumulation of daunorubicin in KB-C2 
epidermoid cancer cells 
 
RSV inhibits the growth of a doxorubicin-resistant B16 
melanoma in vitro and in vivo and further potentiates 
doxorubicin-cytotoxicity in B16 melanoma cells 
 
 
STAT3 ↓, NF-κB ↓, JNK-c-Jun ↑, c-FLIP ↓, Bcl-XL ↓ 
 
 
Apoptotic cells ↑, Bcl-2 ↑, MDR-1 ↑ 
 
 
P-glycoprotein ↓ 
 
 
Cyclin D1/cdk4 ↓, p53↑, G1-phase-arrest, apoptosis ↑ 
 
 
[32] 
 
 
[68] 
 
 
[70] 
 
 
[47] 
Gastrointestinal cancers 
 
RSV sensitized cholangiocarcinoma cells (Mz-ChA-1, 
HuCC-T1, CCLP1, and SG231) to chemotherapeutic 
agents (5-FU, gemcitabine, or mitomycin C) and further 
potentiates 5-FU-cytotoxicity in an in vivo xenograft mod-
el using Mz-ChA-1 cells 
 
RSV enhanced antitumor activity of gemcitabine 
pancreatic cancer cells (AsPC-1, MIA-PaCa-2, Panc-1, 
Panc-28) and in an orthotopic mouse model of human 
pancreatic cancer 
 
RSV enhanced the anti-tumor effects of 5-FU in a 
transplantable murine hepatoma22 model and antagonized 
5-FU toxicity 
 
 
Cell proliferation ↓, Apoptosis ↑, Tumor size ↓, Cyp1b1 ↓ 
 
 
 
 
 
NF-κB activation ↓, bcl-2 ↓, bcl-xL ↓, COX-2 ↓, cyclin D1 ↓, MMP-9 ↓, 
VEGF ↓, cyclin D1 ↓, ICAM-1 ↓, survivin ↓ 
 
 
 
Tumor size ↓, survival time ↑, S-phase-arrest  
 
 
 
 
[72] 
 
 
 
 
 
[33] 
 
 
 
 
[43] 
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RSV and Res-Analogs potentiate 5-FU cytotoxicity in 
SW480, SW620 and HCT116 colon cancer cells 
 
RSV synergistically promotes 5-FU-mediated apoptosis at 
higher concentrations irrespective of p53 but inhibits 5-
FU-triggered apoptosis at lower concentrations in p53+/+ 
colorectal cancer cells (HCT-116) 
 
S-Phase-arrest, Cyclin A/cdk2-complex ↑, cell proliferation ↓ 
 
 
 
Caspase-6-activity ↑, p53, apoptosis ↑↓ 
 
 
[44] 
 
 
 
[80] 
 
Gynecologic cancers 
 
RSV enhanced γ-radiation-induced apoptosis and cell 
cycle arrest of Hela and SiHa cells  
 
RSV improved the effectiveness of cisplatin and 
doxorubicin in human gynecologic cancer cells (OVCAR-
3, Ishikawa) 
 
 
S-phase-arrest, COX1 activity ↓, cell growth ↓ 
 
 
Cell growth ↓ 
 
 
[46] 
 
 
[84] 
 
Multiple Myeloma  
 
RSV sensitized multiple myeloma (8226/S and 
8226/Dox40) cells and non-Hodgkin’s lymphoma (Raji 
and Ramos) cells to paclitaxel-induced apoptosis 
 
 
Bcl-xL ↓, myeloid cell differentiation factor (Mcl-1) ↓, formation of 
tBid, mitochondrial membrane depolarization ↑, cytosolic release of 
cytochrome c and Smac/DIABLO ↑, activation of caspase cascade ↑, 
PARP cleavage ↑ 
 
 
[55] 
 
Bladder cancer 
 
RSV prevented taxol- and vinblastine-induced cell death 
in 5637 bladder cancer cells, but enhanced the cytotoxicity 
of cisplatin 
 
 
Taxol, viniblastine: Cell viability ↑, colony formation ↑, PARP cleavage 
↓, Caspase-3-cleavage ↓, p-Bcl-2 ↓, p-Akt ↑, pERK ↑, pJNK ↓, p-p38 ↓, 
p-IκB ↑, NF-κB ↑, cyclin D1 ↑, Cyclin E ↑, S-phase-arrest 
Cisplatin: Cell viability ↓, G1-phase-arrest 
 
 
[85] 
Sulforaphane 
Tumor models/Topic Targets/Major findings References 
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Lung cancers 
 
SFN sensitized lung adenocarcinoma A549 cells to  
TRAIL-induced apoptosis  
 
In contrast to other isothiocyanates, SFN did not  sensitize 
non-small cell lung cancer cells to cisplatin-induced 
cytotoxicity  
 
SFN enhanced the expression of phase II detoxification 
enzymes in and lung (A549) cancer cells 
 
 
 
Caspase-3-activity ↑, PARP cleavage ↑, pp38 ↑, pJNK ↑, pERK ↓,  
pAkt ↓ 
 
Cell viability →, β-tubulin → 
 
 
 
MRP1 and MRP2 mRNA and protein levels ↑ 
 
 
[40] 
 
 
[86] 
 
 
 
[76] 
 
Gastrointestinal Cancers 
 
SFN potentiates oxaliplatin-induced anti-tumor-activities 
in the colorectal cancer cell line Caco-2 
 
 
SFN sensitized TRAIL-resistant hepatoma cells to 
TRAIL-induced apoptosis 
 
The combination of SFN and TRAIL blocked tumor 
growth and angiogenesis in vitro (AsPC-1, BxPc-3, Ca-
pan-1 and MIA-PaCa2) and in vivo using a mouse 
xenograft model (MIA-PaCa2) of pancreatic cancer 
without obvious cytotoxicity in skin fibroblasts 
 
SFN enhanced the expression of phase II detoxification 
enzymes in liver (HepG2) and colon (Caco-2) cancer cells 
 
 
Cell proliferation ↓, ATP levels ↓, DNA Fragmentation ↑, caspase-3-
activity ↑, PARP cleavage ↑, TRAIL ↑, caspase-8 cleavage ↑, 
mitochondrial membrane potential ↓, necrotic cells ↑ 
 
DR5 ↑, Caspase cleavage ↑, PARP cleavage ↑, ROS ↑, IAPs → 
 
 
NF-κB activity ↓, XIAP ↓, cIAP ↓, FLIP ↓, Cell viability ↓, 
clonogenicity ↓, Tumor size ↓, Caspase-activity ↑, apoptosis ↑ 
 
 
 
 
MRP1 and MRP2 protein levels ↑ 
 
 
[64] 
 
 
 
 
 
[61] 
 
 
[63] 
 
 
 
[76] 
 
 
Prostate cancer 
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SFN enhanced the therapeutic potential of TRAIL in vitro 
(PC-3 and LNCaP) and in vivo in a prostate cancer 
orthotopic mouse model  
 
In vitro: reactive oxygen species (ROS) ↑, mitochondrial membrane 
potential ↓, caspase-3 ↑, caspase-9 ↑, DR4 ↑, DR5 ↑, Bax ↑, Bak ↑, Bim 
↑, Noxa ↑, Bcl-2 ↓, Bcl-xL ↓,  Mcl-1 ↓ 
In vivo: TRAIL-R1/DR4 ↑,TRAIL-R2/DR5 ↑, Bax ↑, Bak ↑, NF-κB 
pathway ↓, 
P13K/AKT pathway ↓, MEK/ERK pathway ↓  
[34] 
 
Gynecological cancer 
 
Combination treatment with SFN and paclitaxel resulted 
in additive growth suppression in epithelial ovarian cancer 
cells 
 
 
 
Cell viability ↓  
 
 
 
[87] 
 
Other systems 
 
SFN and 5-FU synergistically inhibit cell growth of high 
(ACC-M) and low (ACC-2) metastatic cell lines of 
salivary gland adenoid cystic carcinoma  
 
SFN enhanced TRAIL-induced apoptosis in human 
osteosarcoma cells (Saos2, MG63) 
 
 
Combination of SFN and doxorubicin reversed 
doxorubicin-resistant phenotype in mouse fibroblasts with 
p53Ser220 mutation 
 
 
Cell growth ↓, NF-κB p65 expression ↓ 
 
 
 
Bid cleavage ↑, Caspase-8 ↑, Caspase-9 ↑, Caspase-10 ↑, Caspase-3 ↑, 
DR5 mRNA and protein levels ↑, p53-independent  
 
 
Apoptosis ↑ 
 
 
 
 
[35] 
 
 
 
[62] 
 
 
 
[77] 
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